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SUMMARY
Benzo(a)pyrene was metabolised by short-term organ cultures 
of human, rat or hamster lung and hamster or rat trachea to ethyl 
acetate-soluble and water-soluble metabolites. 7,8-Dihydro-7,8- 
dihydroxybenzo(a)pyrene (7,8-dihydrodiol), 9,10-dihydro-9,10- 
dihydroxybenzo(a)pyrene (9,10-dihydrodiol) and benzo(a)pyren-3-yl- 
hydrogen sulphate were identified as the prevalent ethyl acetate- 
soluble metabolites with little or no monohydroxybenzo(a)pyrenes 
or 4,5-dihydro-4,5-dihydroxybenzo(a)pyrene (4,5-dihydrodiol).
A large proportion of the water-soluble metabolites from short­
term cultures of lung or trachea from rats or hamsters consisted of 
glucuronide conjugates, the main ones being those of 3-hydroxybenzo 
(a)pyrene, 4,5-dihydrodiol and 1(3),9,10-trihydroxy-9,10-dihydrobenzo
(a)pyrene.
Similar ethyl acetate-soluble metabolites were detected 
following isolated rat lung perfusion with benzo(a)pyrene excepting 
that rather more monohydroxybenzo(a)pyrenesand quinones were produced.
These results were extended by studying the further metabolism 
of 3-hydroxybenzo(a)pyrene, 4,5-dihydrodiol, 7,8-dihydrodiol and 
9,10-dihydrodiol. The principle ethyl acetate-soluble products 
following cultures with dihydrodiols were further hydroxylated 
metabolites whereas the main product from 3-hydroxybenzo(a)pyrene 
was benzo(a)pyren-3-yl-sulphate. Both 7,8-dihydrodiol and 9,10- 
dihydrodiol (to a lesser extent) were metabolised to a material which 
was identified as 7,8,9,10-tetrahydro-7,8,9,10-tetrahydroxybenzo (a) 
pyrene. The main water-soluble metabolites from each of the four starting 
materials were identified as glucuronide conjugates and in all but the
case of 9,10-dihydrodiol.it appeared that the product was formed directly by 
conjugation of a hydroxyl group with uridine-diphosphate glucuronic 
acid. The major glucuronide conjugate from 9,10-dihydrodiol was 
identified as that of 1(3),9,10-trihydroxy-9,lO-dihydrobenzo(a) 
pyrene with little or no material conjugated directly.
Benzo(a)pyrene, 3-hydroxybenzo(a)pyrene, 4,5-dihydrodiol, 7,8- 
dihydrodiol, 9,10-dihydrodiol and 1(3),9,10-trihydroxy-9,10-dihydro 
benzo(a)pyrene bound with ligandin, aminoazodye binding protein A 
and liposomes. 9,10-Dihydrodiol and 1(3),9,10-trihydroxy-9,10- 
dihydroxybenzo(a)pyrene bound significantly less than other metabolites 
to aminoazodye binding protein A and liposomes.
DNA-benzo(a)pyrene adducts were investigated following isolated 
rat lung perfusion with benzo(a)pyrene. A single type of adduct was 
found and identified as that produced by the interaction of 7a, 88- 
dihydroxy-98, 108-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene (anti 
diol-epoxide) with the 2 amino group of guanine. The formation of 
this adduct was increased approximately 10-fold by pretreatment of 
animals with 3-methylcholanthrene.
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Chapter 1
An Introduction to Chemical Carcinogenesis
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Chapter 1
Historical Aspects- 
In 1775, over 200 years ago, the English physician Percival2 
Pott described a disease in chimney sweeps which is now recognised 
as cancer of the scrotum and correctly ascribed "its origin from a 
lodgement of soot in the rugae of the scrotum". (Pott, 1775). This 
is the earliest recorded causal connection between chemicals and 
cancer. Detailed epidemiological and experimental studies carried 
out in more modern times have confirmed Pott’s original observation, 
and also implicated many other natural and synthetic chemicals as 
cancer causing agents (Miller, 1970; Heidelberger, 1975). It is now 
recognised that up to 90% of human cancer is caused by chemicals to 
which man is exposed (Wynder and Hecht, 1976).
In 1876, Volkmann connected skin cancer with tar distilling, 
which was in later reports confirmed and also connected with other 
coal products such as pitch and asphalt (I.A.R.C., 1973). In a series 
of three lectures recorded in the British Medical Journal, Buitin des­
cribed other sites of cancer in chimney sweeps (caused by soot) and 
proposed that chimney sweeps in other countries did not get scrotal 
cancer because of protective clothing and frequent washing. This 
report, an early example of preventive measures, led to the tightening 
of control measures in the British industry, and eventually, to a 
lowering in incidence of scrotal cancer (Miller, 1970). Recent reports, 
however, suggest that the disease has not disappeared altogether 
(National Acad. Sci., 1972).
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Chemical mixtures, in this case coal tar, were first shown to 
cause cancer to laboratory rodents in the early part of this century 
(Yamigawa and Ichikawa 1915; Tsutsui 1918). It was some time later 
before experimental production of cancer with a pure chemical was 
achieved by Kennaway and Heiger in 1930 using 1, 2-5, 6-dibenz- 
anthracene (dibenz(ah)anthracene). This was the fruit of an analytical 
examination of the fractioned products from coal tar, which led 
ultimately to the identification of benzo(a)pyrene as a coal tar 
carcinogen. The characteristic fluorescent spectra of the carcinogenic 
polycyclic aromatic hydrocarbons (PAH) were a key factor in the 
identification of benzo(a)pyrene as a constituent of coal tar (Kennaway, 
1955). It had been recognised as early as 1928 by Heiger, working in 
Kennaway's laboratory, that the fluorescent spectra characteristic 
of coal tar was related to that of benz (a)anthracene. This was, 
however, found not to be carcinogenic when tested (Kennaway, 1955), 
but did lead to the synthesis and testing of 1, 2-5, 6-dibenzanthracene.
During the next decade from 1933-1942 many hundrech of poly­
cyclic aromatic hydrocarbons were synthesized and tested for
37lcJ
carcinogenicity by the research groups of Kennawayn Shear and Leiter. 
Almost complete agreement of results from these two principal groups 
formed the foundation of our knowledge of carcinogenic polycyclic 
hydrocarbons.
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The Diversity of Structure of Chemical Carcinogens
It became apparent during the 1930's that compounds other than 
polycyclic aromatic hydrocarbons were carcinogenic. Liver cancers 
were found to be caused in rats by o-aminoazotoluene (Yoshida, 1933)
82o
and methylaminoAbenzene (Kinoshita, 1936) and bladder cancers in dogs 
by 3~napthy1amine ( Heuper et al, 1938). It was thus apparent that 
cancer was caused by a great variety of chemicals, in a variety of 
species and at various sites. A sample of the great variety of 
chemical structures of carcinogenic chemicals is illustrated in Fig. 1.
These compounds are diverse both in their chemical structure 
and chemical reactivity. Relatively few of the carcinogens known 
are chemically reactive and those that are, tend to be experimental 
model compounds such as uracil mustard and 3“ propiolactone, chosen 
for examination because of their alkylating action (Miller, 1970; 
Weisburger and Williams, 1975).
However, reactive compounds expected to be carcinogenic are often 
found to be only weakly or non-carcinogenic, probably because they do 
not gain access to critical intracellular sites. The high reactivity 
of this type of chemical usually renders them unstable in the environ­
ment and thus it is probable that they are unimportant in the general 
aetiology of the disease (Miller, 1970). Specific cases, however, 
such as the alkylating drugs used in chemotherapy are exceptions to 
this rule (Weisburger and Williams, 1975).
The majority of chemical carcinogens are not chemically reactive 
and it is now widely believed that some kind of metabolic activation 
is required which generates an active intermediate (Miller, 1970;
Heidelberger, 1974) that, initiates the carcinogenic response. This 
type of carcinogen is known as a 'precarcinogen1.
figure 1.
The Diverse Nature of Chemical Carcinogens
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Metabolic Activation of Carcinogens
Our initial knowledge of the metabolic activation of carcinogens 
has stemmed from the work of the husband and wife team James and Eliza­
beth Miller. They, together with their co-workers, have outlined 
the metabolism and activation of a number of chemical carcinogens 
including carcinogenic azodyes, aromatic amines and recently, safrole 
and aflatoxin B^ (Miller, 1970; Lin et al, 1977). The enzymes involved 
in the metabolism of carcinogens to the 'active intermediate' (or 
ultimate carcinogens), are the self-same enzymes normally involved in 
the detoxification of xenobiotic compounds to more polar, excretable 
compounds. This process is necessary to prevent the inevitable 
accumulation of xenobiotics in biological materials.
The enzymes involved in drug metabolism
Most studies with foreign compounds have used the liver as the 
source of biological material because it is the most active metabolising 
organ. Xenobiotic metabolising enzymes or drug metabolising enzymes as 
they frequently are called, are, however, not confined to the liver.
Their distribution also depends on the substrate and chemical reaction 
involved (Aitio, 1973).
Drug metabolism has been classified into two sequential phases, 
activation and conjugation, both of which have been implicated in chemical 
carcinogenesis (Miller, 1970).
Microsomal mixed function oxidases
The first of these phases generally involves the group of micro­
somal haemoproteins called cytochrome P-450(s). These were initially 
discovered in the metabolism of steroids, but later recognised as 
being responsible for the general non-specific metabolism of drug 
substrates (Estabrook et al, 1963; Cooper et al, 1965).
- 5 -
Reduced pyridine nucleotide (NADPH) and magnesium ions are 
essential cofactors for catalytic activity of the ’mixed function oxidase’ 
(Gillette et al, 1957). Mixed function oxygenases are now known to 
catalyse a variety of oxidative reactions including aliphatic oxidation, 
aromatic oxidation, N-dealkylation, O-dealkylation, S-demethylation, 
deamination, desulphuration, N-oxidation, and N-hydroxylation (Goldstein 
et al, 1974).
The overall reaction which a drug can undergo may be summarized 
by the following equations
1. NADPH + cyto. R450 +H+--- ►cyto R450H2 + NADP+
2. CytoF450H2 + 0^---* ’’active oxygen complex"
3. "active oxygen complex" + drug— oxidised drug + cytoP450 + H^O
NADPH + 02 + drug + H+— >NADP+ + oxidised drug + H20 
Some microsomal mixed function oxidases have recently been purified 
(Levin et al, 1974). The complete enzyme complex consists of NADPH- 
cytochrome reductase, cytochrome P-450 and phosphatidylcholine (Ryan et al, 
1975, Vermilion & Coon, 1975). The cytochrome P-450component has been 
resolved into a number of different haemoproteins which possess slightly 
different carbon monoxide difference spectra and catalytic specificity. 
These different types of cytochrome are synthesized or ’induced’ in 
response to stimulation by pretreatment with certain drugs. The two 
cytochromes which have so far been best characterised are those cytochromes 
purified from liver microsomes prepared from rats pretreated with pheno- 
barbital or 3-methylcholanthrene (3MC). The latter cytochrome, 
cytochrome P448or^-450 has a slightly shifted carbon monoxide difference 
spectrum and is characteristic of enzyme induction with polycyclic 
hydrocarbons (Sladek and Mannering, 1966; Alvares et al, 1967).
- 6 -
Mixed function monoox^genasesare induced in many tissues by pre­
treatment of animals with drugs such as phenobarbitone or 3-MC.
Thus, cytochromeP-448 which is produced in response to pretreatment 
with 3-MC is more efficient at metabolising polycyclic hydrocarbons 
than either constitutive cytochrome P-450 or cytochromeP-450 from 
phenobarbitonepretreated animals. Benzo(a)pyrene hydroxylase 
(or aryl hydrocarbon hydroxylase) is induced in 3-MC pretreated 
animals. The extent to which benzo(a)pyrene hydroxylase is induced 
by 3-MC varies in inbred strains of mice. This variability in 
induction has been shown to be inherited by Mendelian genetic 
principles governed by a single 'Ah locus’ (Gielen et al, 1972;
Nebert et al, 1975). However, indueibility in humans is more 
complex and is controlled by a polygenic mechanism (Nebert et al, 
1975).
It is now thought that there are many varieties of cytochrome 
P-450, perhaps 6 or 7 in rat liver, with each one possibly induced by 
a different agent.
The microsomal mono-oxygenase system of the lung is essentially 
similar to that of the liver so far as is known, and contains 
similar components. It is possible, however, that the preponderance 
of cytochromes may be different (Remmer, 1975), the uninduced lung 
enzyme containing a relatively greater percentage of cytochrome P-448. 
A further discussion on phase 1 lung metabolism is included later in 
this chapter.
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Epoxide Hydratase
It is now known that the initial product of many reactions of the 
microsomal mixed function oxidases, is an epoxide (Jerina et al, 1970;
Selkirk et al, 1971; Grover et al, 1972). It is this type of intermediate 
that is postulated to be of biological significance in many toxic reactions 
(Jerina & Daly, 1974). However, two enzymes are present in the tissues 
which have the function of detoxifying these active intermediates, epoxide 
hydratase and glutathione transferase.
Epoxide hydratase is, in most species, a microsomal enzyme, probably 
in very close association with the mixed function oxidase (Oesch, 1973).
It is inducible by phenobarbitoneand 3-methylcholanthrene (Oesch, 1973;
Bresnick et al, 1977) but to a lesser extent than aryl hydrocarbon hydroxy­
lase. It is probable that the enzyme exists in one form with wide substrate
specificity (Oesch & Bentley, 1976) although recent evidence suggests different 
varieties of epoxide hydratase (Lu et al, 1977) . The enzyme is apparently
ubiquitous throughout the body with the highest activity in. the testis, although
it may not be inducible in tissues other than the liver (Oesch et al,1977).
Epoxide hydratase catalyses the hydration of arene and alkene oxides by the
addition of water to form trans dihydrodiols (Oesch, 1973) by a highly
stereospecific mechanism. (Oesch, 1973, Yang et al, 1977a). It is possible,
though not proven, that certain epoxides may be toxic because they are not
substrates for epoxide hydratase (Oesch, 1973; Sims et al, 1974).
Recently a number of assays have been developed using 'K region’ aryl
hydrocarbon epoxides as substrates for this enzyme (Bettencourt et al, 1977;
Leutz & Gelboin, 1975; Schmassmann et al, 1976; Jerina et al, 1976a). The
publication by Jerina et al was of particular interest in describing the
assay of liver microsomal epoxide hydratase using 11 oxides substrates including
3 benzo(a)pyrene oxides.
The epoxide hydratase of rat lung was recently characterised 
by Seidelgard et al (1977) and shown to be essentially similar to 
that of liver. 3,3,3-Trichloropropylene oxide and cyclohexene 
oxide were shown to inhibit the hydration j, of styrene oxide by lung 
epoxide hydratase, similarly to that which occurs with the liver 
enzyme.
Glutathione-S-transferase
Epoxide intermediates can undergo an alternative enzyme reaction,
conjugation . with glutathione. This is mediated via a family of
cytoplasmic enzymes (Grover, 1977; Fjellstedt et al, 1973), with 
overlapping substrate specificities. Glutathione is a short peptide 
derivative of cysteine, and is thought to be an intermediate in the
production of mercapturic acids which are the finai
metabolites.
Interest in glutathione-S-transferase in chemical carcinogenesis 
is centred around two aspects. The first is mainly concerned with 
hepatocarcinogenesis and concerns the fact that they collectively add 
up to 10% of soluble liver protein (Litwacket al 1971; Grover, 1977) 
and bind many types of components. It is thought that they have a 
protective role by binding toxic compounds. This is further discussed 
under protein binding. Glutathione-S-transferase B, or ligandin as 
it is better known, is most characterised in this respect.
The other aspect is their general catalytic activity towards 
reactive epoxides. Five different glutathione-transferases have been 
separated electrophoretically from human liver and 6 from rat liver. 
The enzymes from rat liver have been designated E, D, C, B, A and AA 
according to their electrophoretic mobility. A test of the substrate
- 9 -
specificity of these transferases showed they overlapped broadly 
(Grover, 1977).
The importance of glutathione conjugation in polycyclic hydro­
carbon metabolism is uncertain, but it is known that a number of arene 
oxides can form glutathione conjugates in liver microsomes or homo- 
genates including oxides of naphthalene, phenanthrene,benz(a)anthracene 
and benzo(a)pyrene (Sims and Grover, 1974; Hayakawa et al, 1975).
A number of assays have been developed using arene oxides of poly­
cyclic hydrocarbons (Sims & Grover, 1974; Hayakawa et al, 1975;
Nemoto and Gelboin, 1975).
Sims & Grover, using the K region arene oxide, benz(a)anthracene- 
5, 6-oxide, measured the relative activities of epoxide hydratase and 
glutathione transferase in lung and liver and came to the conclusion 
that glutathione conjugation may be relatively more important than 
epoxide hydratase. Glutathione-S-transferase was found to be induc­
ible in rat lung after exposure to cigarette smoke (Uotila et al,
1977).
Hayakawa et al (1975) showed that a purified glutathione-S-epoxide 
transferase from sheep liver could catalyse the transfer of gluta­
thione to a number of arene oxide substrates. Benzo(a)pyrene ,4,5- 
oxide was a good substrate, but benzo(a)pyrene 7,8 and 9,10-oxides 
were weakly catalysed to glutathione conjugates. Nemoto et al (1975) 
using purified A, B, C, E and AA glutathione-S-transferases from rat 
liver showed that benzo(a)pyrene 4, 5-oxide was a substrate for all 
five transferases but an alkyl epoxide, 1, 2-epoxy-3(p-nitrophenoxy) — 
propane was only a substrate for transferases A and E.
The glutathione-S-transferases are thus integrally involved in 
the metabolism of polycyclic hydrocarbons but the extent of involvement 
is unclear from the literature.
UDP - Glucuronyl Transferase
Conjugation with glucuronic acid is quantitatively the most 
important of the phase II reactions in most mammals (Dutton et al., 
1977). The enzyme(s) which catalyse this reaction are located at, or 
in close proximity to,the endoplasmic reticulum and require micro­
somal lipid to exhibit catalytic activity. It is probable that the 
enzyme(s) concerned are a closely related series of enzymes which 
exhibit a wide, overlapping substrate specificity, but it is also 
possible that there is only a small number, perhaps only one, the 
specificity of which is controlled by its membrane bound environment 
(Dutton et al., 1977).
The overall reaction that occurs in glucuronide conjugation may 
be summated as:
1. D-glucose-1-phosphate + Uridine triphosphate (UTP)
— >UDP - aD-glucose (UDPG)
2. UDPG +2NAD+ + H O  ^  UDP- ot-D-glucuronic acid (UDPGA)
1 UDP 
dehydrogenase
3. UDPGA + substrate --------i— ^ substrate - 3 -GA +UDP + H^O
glucuronyl
transferase
UDPGA is thus the active precursor for glucuronide synthesis. The 
glucuronides produced have a 3 configuration and are thus hydrolysed by
3 -glucuronidase.
Glucuronyl transferase is active in many tissues. Glucuronidation 
is high in liver, blood and gut but is also significant in lung, spleen, 
thymus and adrenal gland, with low or negligible levels in placenta.
The actual levels of glucuronyl transferase may be difficult to compare 
from tissue because of differing substrate specificities, although a
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tissue specific transferase has not been discovered (Dutton et al.,
1977). Aitio (1973) found that rat or guinea pig lung contained 
glucuronyl transferase activity towards p-nitrophenol and 4-methyl 
umbilliferone to the extent of 1/3 - 2/3 that of liver when expressed 
on a microsomal protein basis; total lung activity is about 10% of liver. 
Litterst et al. (1977) concluded that the UDP-glucuronyl transferase 
activity of liver, lung and kidney were essentially similar in catalysing 
UDP transfer to a range of substrates.
Pretreatment of rats with 3-methylcholanthrene caused marked increases 
in glucuronide production in isolated perfused liver, considered to be 
due to increased glucuronyl transferase activity rather than increase of 
precursor hydroxylated metabolites (Hamada & Gessner, 1975) . In other 
studies however, using isolated rat hepatocytes or isolated rat lung 
perfusion, increases in benzo(a)py.rene glucuronide conjugates caused 
by 3MC pretreatment, were thought to be primarily due to increased 
production of phase 1 precursors (Vadi et al., 1975; VhhMkangas et al., 
1977) . In another study increased water-soluble metabolites without an 
increase of glucuronyl transferase was observed in lung after prolonged 
exposure to cigarette smoke (Uotila et al., 1977).
Sulphuric Acid Ester Conjugates
Sulphate conjugates are produced in competition and addition to
glucuronides. In mammals, sulphuric acid ester conjugation proceeds
by a three step reaction which can be summarized as:
21. ATP + S0^ >APS (Adenosine 5-phosphosulphate) + pyrosulphate
2. APS + ATP »-PAPS (3r-phospho adenosine 5^-phosphosulphate) + ADP
3. PAPS + Acceptor >PAP + Sulphate acceptor.
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The enzymes responsible for this three step process are 
(1) ATP-sulphate adenylyl transferase, (2) ATP-adenylyl sulphate 
3^~phosphotransferase (APS-kinase) and (3) an appropriate sulpho- 
transferase.
A number of soluble sulphotransferases are present in rodent 
liver as soluble cytoplasmic enzymes which are capable of conjugating 
sulphates to phenols, alcohols, aromatic amines and nitro compounds. 
The enzymes involved in drug metabolism are similar, and may in some 
cases be the same as those enzymes which play an active part in the 
intermediary metabolism of steroids. A second group of sulphotrans­
ferases present in the endoplasmic reticulum and Golgi membranes 
have a role in the synthesis of sulphate sugars and glycoprotein 
synthesis, but have no role in drug metabolism. The exact number of 
sulphotransferases is unknown but it is evident they are multiple. 
Phenolic steroids, alcoholic steroids, single phenols and aromatic 
amines are all known to be conjugated via separate enzymes (Dodgson, 
1977).
Some sulphoconjugates are pharmacologically and toxicologically 
active. For example, some steroid sulphate conjugates possess pharma­
cological activity, and the sulphate conjugate ester of N-hydroxy 2- 
acetyl aminofluorene is believed to be the ultimate carcinogen of 
2-acetylaminof.luorene (Miller, 1970).
Interestingly, sulphoconjugates tend to be excreted via the urine 
whilst glucuronide conjugates tend to be biliary excreted. This is 
not rigid but depends to a great extent on the size of the molecule 
in question and its overall polarity. Species is also important, for 
example rats tend to excrete compounds with a molecular weight of 300
or over in the bile whilst an equivalent human figure is nearer 
500. This may be pertinent in sulphoconjugation of some polycyclic 
hydrocarbons which have molecular weights in the region of 300-500.
These are the principal enzymes involved in the metabolism 
of polycyclic hydrocarbons. Other reactions are known and may be 
important. Diaphorase and cytochrome P-450 reductase have been connected 
with phase-1 benzo (a)pyre'ne metabolism, whilst conjugation to other 
sugars and amino acids are important in the metabolism of some xeno- 
biotics, particularly in avian species. The principal routes of 
metabolism of polycyclic hydrocarbons are shown in Fig. 2.
The Xenobiotic Metabolism of Respiratory Tissues
Greater than 90% of most xenobiotic metabolism is carried out 
by the liver. This, however, is probably not the case with inhaled 
xenobiotics or compounds administered directly into the trachea 
such as is performed with benzo(a)pyrene to induce respiratory cancer 
in rodents. Thus, xenobiotic metabolism by respiratory tissues is 
likely to be of importance in the case of bronchial carcinoma 
associated with cigarette smoking.
Lung has mixed function oxidase activity which is catalysed by 
cytochrome P~450 similarly to that of liver. The constitutive enzyme 
however, may be more like the induced P"448 type of liver enzyme 
(Remmer, 1976). Lung microsomes which metabolise xenobiotics can be 
prepared in much the same way as from liver (Matsubara et al, 1974; 
Litterst et al, 1975). Aryl hydrocarbon hydroxylase of lung is 
inducible by interperitoneal administration of polycyclic hydrocarbons 
or phenobarbitone similarly to that of liver but requires a more prolonged 
administration of the inducer (Hook and Bend, 1975). Much more rapid
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induction occurs with exposure to inhaled materials such as smoke.
For example benzo(a)pyrene-hydroxylase was induced nearly 3-fold in
rat lung and 6-fold in hamster lung, 24h after a brief exposure to
the smoke of 3-5 cigarettes (Akin and Bennei; 1976;; Uotila et al,
197 7). Diet has also been shown to effect this enzyme (Paine and 
McLean, 1973).
Although lung contains only a small fraction of the amount of 
cytochrome P-450 of liver, the enzyme is in no way deficient in its 
ability to metabolise xenobiotics. Furthermore, for a wide variety 
of substrates the lung cytochromeP^450's of rat, rabbit and hamster 
have higher turnover numbers than the respective liver enzymes 
(Hook and Bend, 1975). Such diverse activitiesas aniline hydroxy­
lase; aminopyrine, benzphetamine and ethylmorphine-N-demethylases, 
N-hydroxylation and arylhydroxylation of a wide variety of aromatic 
hydrocarbons are mediated via lung cytochromeP-^450. Pulmonary 
monoamine oxygenase is also known to metabolise nitro compounds (Hook 
and Bend, 1975). It has been proposed that a defiency of super­
oxide dismutase (SOD) in lung, is contributory to the pulmonary 
toxicity of the herbicide ’paraquat’ (Montgomery, 1977).
Glutathione-S-transferase can be detected in lung using epoxide 
substrates (Oesch, 1973; Grover, 1974; Hook and Bend, 1975). However, 
the ratio of activation enzymes to glutathione transferase is increased 
such that it has been proposed that the relative deficiency of 
glutathione transferase is contributory to the sensitivity of the 
tissue to polycyclic hydrocarbons (Grover, 1974). Oesch et al (1977) using
benzo(a)pyrene 4,5-oxide as substrate,recently showed.that there was 18 
fold less glutathione transferase in lung than in liver of NMRI mice
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but only a 2 fold difference in epoxide hydratase. This may be 
important because of the known involvement of epoxide hydratase 
in the production of the proximate carcinogen of benzo(a)pyrene.
Mukhtar and Bresnick (1976) found that administration of phenobarbital 
to six different strains of mice at concentrations which induced liver 
glutathione transferase, failed to induce the pulmonary enzyme. However, 
the rat enzyme may be inducible under similar conditions (Hook and 
Bend, 1975). Pulmonary glutathione transferase is not inducible by 
interperitoneal (ip) injection of 3-methylcholanthrene (Hook and Bend, 
1975; Mokhtar and Bresnik, 1976) but is readily induced by cigarette 
smoke (Uotila et al, 1977).
Rat lung contains less than 10% of the UDP-gluc.urorryl transferase 
of rat liver (Aitio, 1973). The enzyme is inducible by ip administration 
of 3-methylcholanthrene but not by phenobarbitoneor cigarette smoke 
(Uotila, 1976; Uotila et al, 1976; Hook and Bend, 1975). There seems 
to be a great variation in the levels of pulmonary glucuronyl trans­
ferase and in at least one species (rabbits) the enzyme is not detectable 
with a number of substrates (Mimnaugh et al, 1975). However, since it 
is known that liver UDP-glucuronyl transferase has variable substrate 
specificity, caution must be exercised in concluding that this enzyme 
is absent from rabbit lung.
Recently, interest has developed in the metabolising capacity of 
bronchial (and tracheal) tissues since, in man,, these are the principal 
sites of cigarette related cancer. Metabolism was first indicated when 
it was shown that carcinogenic PAH bind to macromolecules in cultured 
hamster trachea and human bronchii (Kaufman et al, 1973; Harris et al, 
1974). Benzo(a)pyrene was thereafter shown to be metabolised to phenolic
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and dihydrodiol metabolites (Pal et al, 1975) and the nucleic acid 
binding attributed to the formation of diol-epoxide adducts (Grover et 
al, 1976; Weinstein et al, 1976; Jeffrey, et al, 1976). Yang et al 
(1977a)reportc.d the production of other benzo(a)pyrene metabolites via 
a stereospecific mechanism. Metabolic studies by Harris and co-workers 
have subsequently shown metabolism of other PAH and unrelated carcino­
gens by cultured human bronchus (Harris e't al, 1977 (a), (b) , .(c)).
Respiratory tissues contain many different cell types, the exact 
function of which is largely unknown (Wynder and Hecht, 1976). It is 
thus important to localise the source of xenobiotic metabolism in these 
tissues. It is possible that metabolism could occur in pulmonary 
alveolar macrophages (Autrup et al, 1978; Palmer et al, 1978) with 
subsequent transportation of active metabolites to critical sites in 
the surrounding tissue. Other evidence, however, indicates that the 
Clara cell of the bronchial epithelium is a more likely site of 
metabolism (Boyd, 1977).
Some examples of metabolic activation of precarcinogens to ultimate 
carcinogens
As polycyclic hydrocarbons are discussed later in more detail I 
shall not deal with them in this section but shall try to illustrate 
the diversity of the mechanisms through which an active species may 
be formed.
The aromatic amines and amides, illustrated by 2-Acetylaminofluorene
The critical metabolic activation of 2-acetylaminofluorene (AAF) 
is believed to be N-hydroxylation (Miller, 1970). Strong circumstantial 
evidence that this is important originates from the fact that AAF is 
carcinogenic to rats, mice and hamsters which N-hydroxylate AAF,
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but is not carcinogenic to guinea pigs which do not. Furthermore,
N-hydroxy-AAF is more carcinogenic to rats than the parent compound.
However, it is thought that the ultimate carcinogen of AAF is an 
N-sulphate ester produced by conjugation and thus rats 
which excrete larger amounts of the N-sulphate ester than do other 
species, are particularly highlysusceptible to the precarcinogen.
Further indirect evidence has been obtained by manipulating the sulpho- 
transferase activity of rats by various hormonal treatments, but 
direct evidence by administration of the pure ester has proved 
impossible, probably due to its short half-life. It is thought that 
the sulphate ester spontaneously breaks down to yield a reactive species 
responsible for the biological reaction, this being substantiated by 
the high levels of carcinogen binding to protein and nucleic acids 
(Miller, 197Q) and the types of protein or nucleic acid adducts so 
formed.
Aflatoxin
Aflatoxin is a highly hepatocarcinogenic fungal toxin produced 
by the mould Aspergillus Flavus (Lancaster et al, 1961; Wogan, 1973).
Its presence at high levels in contaminated food in developing African 
countries, together with the high rate of hepatocarcinoma in these 
countries, make it a pertinent medical problem. It has been proposed 
that an epoxide intermediate at the 8,9 position (previously denoted
and.
2,3-epoxide) is the reactive intermediate (Swenson et al, 1973, 1974)A evidence 
is rapidly accumulating to substantiate this case. Aflatoxin is metabolised 
to a number of intermediates, none of which is as carcinogenic or 
mutagenic as the parent compound (Garner, 1976). The key intermediate, 
the 8,9-oxide has yet to be synthesized due to its extreme reactivity,
FIGURE 3.
The Proposed Mechanisms of Activation of 2-Acetylaminofluorene 
and Aflatoxin B,
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After Miller, 1970; Lin et al, 1977; Martin and Garner, 1977
but specific inhibition of epoxide hydratase in an Ames test with 
aflatoxin did not reduce the number of mutations, indicating that 
the metabolite responsible is not a substrate for epoxide hydratase.
Various model compounds have been synthesized to imitate the proposed 
epoxide, and have shown varying degrees of reactivity and mutagenicity 
(Swenson et al, 1977; Coles et al, 1977). Recent strong evidence for 
the 8,9-oxide as the ultimate carcinogen, has been obtained with the 
analysis of the DNA adducts obtained from DNA exposed to metabolically 
activated aflatoxin B^ (Martin and Garner, 1977; Lin et al, 1977).
A diagram of the proposed activation is shown in Fig. 3.
These examples illustrate different metabolic pathways which
generate reactive species. They are in these and many other cases electro-
philic species capable of binding to biological macromolecules. The
enzymes involved are not always confined to those of the examples;
for example hydrolytic enzymes of gut bacteria are thought to play a
role in the activation of cycasin (methylazoxymethanol-g'-glucoside).
Binding of Carcinogens with Cellular Macromalecules
It is recognized that covalent interaction of mutagens with the
genetic material is causative in mutation of simple organisms (Miller 
and Miller, 1971). This relationship is much more difficult to 
determine in the case of nucleic acid binding by chemical carcinogens, 
because of the increased complexity. It has, however, been suggested 
recently that there is at least a 90% correlation between bacterial 
mutation and carcinogenicity (McCann et al, 1975). It is possible that 
the 10% difference (a minimum figure) is due to differences in the 
mechanisms of mutation and cancer.
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Prior to the realisation of enzymic activation of carcinogens, 
mechanisms were devised whereby carcinogens such as the polycyclic 
hydrocarbons, thought at that time to act directly, could moderate 
their biological response by direct action with cellular macromolecules. 
Arcos and Argos (19 74) described two theories prominent at this time, 
intercalation and adlination. Of these, intercalation was by far the 
most popular. The prerequisite for intercalation was a suitable 
molecular geometry to allow a molecule to insert between two base pairs 
of DNA, a particularly attractive hypothesis when considering polycyclic 
aromatic hydrocarbons. Intercalation is at present considered to be 
unimportant in chemical carcinogenesis because it is now known that 
many chemical carcinogens bind covalently to nucleic acids.
Binding to Proteins
The first observations of covalent binding by carcinogens was to 
protein in 1947 (Miller and Miller) but it was a further ten years 
before covalent binding to nucleic acids was observed (Miller, 1970) . 
Since that time covalent binding to macromolecules has been observed 
with many carcinogens (Miller, 1970).
Several researchers have attempted to analyse the proteins to 
which chemical carcinogens bind (Ketterer et al, 1967, Sorof and Young, 
1967). The difficulty with this approach is that although it is 
possible to isolate the proteins fairly readily, usually by electro­
phoretic techniques, the final preparation remains an unidentified 
protein. This leaves a problem in identifying the unknown protein from 
its physical characeristics such as molecular weight and amino acid 
composition because any enzymic activity is often lost due to the 
binding of the carcinogen.
The great bulk of published research of protein binding by 
carcinogens has been with the methylaminoazobenzenes and azocarcinogens.
A protein that binds azocarcinogens and methylaminoaspkenzeoej' was 
isolated by Sorof and Young (1967, 1973). It was found to have 
a molecular weight of 88,000 and is known as the "slow 5S protein".
Kettererfs group (Ketterer et al, 1967) have identified two 
further proteins that bind carcinogens in rat liver. The first of 
these is now known as ligandin, a dimer of molecular weight 45,000.
It can bind among other things, a number of carcinogens and steroids 
both covalently and noncovalently (Litwack, Ketterer and Arias, 1971). 
Ligandin has since been further characterised as a type of glutathione 
transferase (transferase B) (Smith et al, 1977). The large amount of 
ligandin present in rat liver^ approximately 4.5% of soluble protein, 
(Smith et al, 1977) has led to speculation that it has more than a 
catalytic function and which may be as a cushion, absorbing
reactive molecules (a property thought to be shared with the "slow 
5S protein"). Both these proteins are known to bind 3-methylcholanthrene.
Ketterer's group have also characterised a carcinogen binding- 
protein from rat liver which has a lower molecular weight than ligandin, 
approximately 14,000 but has similar binding characteristics, including 
covalent binding to 3-methylcholanthrene (Ketterer et al, 1976). This 
protein does not possess any glutathione transferase activity and 
can be fractionated by using isoelectric focusing into at least three 
components. It also interacts non-covalently with many xenobiotics 
(Ketterer et al, 1976). Mouse skin has also been found to possess a 
protein which binds 3-methylcholanthrene covalently.
An alternative function of an aminoazo dye-binding protein was 
proposed by Tokama and Terayama, 1973, who proposed that a protein which 
bound 3-methyl-4-dimethylaminazobenzene in rat liver was alcohol 
dehydrogenase. This protein showed similar physical properties to 
ligandin, slow H protein and alcohol dehydrogenase.
Binding of a variety of carcinogens including 7,12-dimethylbenz(a) 
anthracene (DMBA) was observed with nuclear proteins from carcinogen 
pretreated rats (Jungmann & Schweppe, 1972). Nuclear protein binding 
is of particular interest in chemical carcinogenesis because of its 
close proximity to the genetic material.
A lung specific protein has also been found that covalently binds 
the polycyclic hydrocarbons 3-methylcholanthrene and 7,12-dimethylbenz(a) 
anthracene (Toft and Spelsberg, 1972).
Covalent binding to proteins by carcinogens is thought to occur at 
nucleophilic centres, for example, ligandin is mainly bound at cysteinyl 
residues although histidine and serine may also be involved. It is 
not certain at the present time if protein binding is a random or a 
specific event.
Binding to Nucleic Acids
Covalent binding to nucleic acids has now been observed with many 
different types of carcinogens (Brookes and Lawley, 1964; Miller, 1971; 
Magee, 1977). The significance of carcinogen-induced damage to nucleic 
acids, particularly DNA, is the subject of much controversy, (Miller & 
Miller, 1971).
The most reactive site for attack of DNA by electrophilic agents is 
the N-7 position guanine but attack at 0-6, N-3, 2-^1^, and c-8 of the 
same base are known, together with: b-NH^, N-l, N-3 and N-7 of adenine;
N-l, N-3 and C-5 of cytosine and 0-4 and C-6 of thymine (Sarma 
et al, 1975). Binding of carcinogens to nucleic acid was thought, 
prior to 19.64, to occur only with direct acting carcinogens.
Brookes and Lawley, (1964) isolated DNA from the skin of mice 
treated with a series of polycyclic hydrocarbons of increasing 
carcinogenicity. Their findings that the amount of hydrocarbon 
bound to the DNA was proportional to the time of exposure and the 
carcinogenicity of the hydrocarbon was highly controversial when 
it was first published but has been well substantiated since 
with many types of chemical carcinogens (Sarma et al, 1975). Chemical 
carcinogens do not react randomly with DNA. Aromatic amines react 
primarily with C-8 of guanine (Sarma et al,i975)s and benzo(a)pyrene 
reacts mainly withl-NH^ of guanine. This is in contrast to direct acting 
alkylating agents which react 70-90% with N-7 of guanosine (Sarma 
et al, 1975). The specific sites alkylated may be of importance in 
carcinogenesis; for example it,, is now known that the repair of 0-6 
alkylguanine is slow in brain, but fast in liver whilst N-7 alkyl guanine 
is probably removed from all organs at the same rate (Magee, 1977) .
General Theories of Carcinogenesis 
There have been many theories relating to the mechanism by which 
carcinogenesis occurs. New theories have always been closely related 
to new medical and biological findings. They are principally concerned 
with 'initiation1 of cancer and may be subdivided into three groupings:
(i) Epigenetic Mechanisms
(ii) Theory of Somatic Mutation
(iii) Virus Theory
Theories relating to the virus mechanism are ancient and a logical 
progression from early medical thinking when it was realised that 
infective agents were responsible for the bulk of human disease.
The first virus theory was proposed at around the time Percival 
Pott was observing the connection between scrotal cancer and chimney 
sweeps but, of course, through lack of knowledge at that time, 
viruses were not specified.
Circumstantial evidence connected with the proliferative action 
of viruses on some tissues (1907) was the first direct specific 
connection between cancer and viruses. An alternative hypothesis put 
forward by Boveri in 1914 and 1929 suggested that a somatic mutation, 
a change in the genetic material, was the cause of cancer. Experimental 
demonstration of cancer by chemicals had indicated that viruses need 
not necessarily be involved. However, this did not also directly support 
a somatic mutational theory; there could also be an alteration in the 
expression of the genetic material caused by an 'epigenetic mechanism'.
The somatic mutation theory implies that there be a direct alteration 
in the genetic material, the DNA. A mutation by definition is a change 
in the phenotype characteristics of an organism. It would thus be 
implied from a theory of somatic mutation that chemicals which are 
carinogens would also be mutagens. Much early data on mutagens was 
collected with chemically reactive compounds such as alkylating agents; 
these materials could very obviously interact with the genetic material. 
Parallel developments with carcinogens, focused principally on chemically 
unreactive polynuclear hydrocarbons which are generally not mutagenic 'per 
and gave apparent discrepancy between carcinogenicity and mutagen­
icity (Burdette, 1955).
To account for the discrepancy and also to accommodate develop­
ments in biochemistry and physiology, a number of epigenetic mechanisms 
were proposed between 1947 and 1965.
The Millers in 1947, on finding that carcinogens were bound to 
liver proteins suggested a 'theory of protein deletion'. Although 
the theory remains to be disproven, the particular protein that was 
found experimentally was probably primarily concerned in detoxific­
ation (see Section 1.4).
Larianov (1956) proposed a trophic theory of cancer which 
explained cancer as a cell response to impaired metabolism and 
nutrition.
Polyaetiological theories of cancer have been proposed in which 
cells respond to a persistently harmful stimulus by uncontrolled 
proliferation (Arcos et al, 1968). Holley (l969) proposed a more 
sophisticated mechanism whereby surfaces are transformed by this 
effect, thereby stimulating a change in internal metabolism and 
initiating the neoplasm. It would be difficult to explain the action 
of non-carcinogenic irritants, many of which cause cell proliferation, 
by such a general mechanism.
More recently, theories of cancer have been closely associated 
with discoveries into the control of genetic material. The discovery 
of specific repressor proteins by Jacob and Monod (1961) led Pitot 
and Heidelberger (1963) to propose that damage of specific proteins 
involved in cellular control, could be a carcinogenic stimulus. Thus, 
an epigenetic mechanism would have a direct action on the phenotype.
Recent speculation has, in many cases, involved the presence 
of a repressed piece of genetic material, the 'oncogene'. The oncogene 
could be formed because of the presence of viral genetic material,
or of fractions of such material encompassed within the genome.
The discovery of reverse transcriptase enabled such a mechanism 
to be extended to RNA viruses. Various mechanisms, perhaps even 
a chemical carcinogen, could cause this oncogene to become de­
repressed and stimulate neoplasia. Comings (1973) also proposed 
a similar mechanism . in a theory of transforming factors.Mathematical 
models have also been used to speculate on the existence of onco­
genetic factors using observations on transformation (Rosen, 1977) .
It is now evident that the conclusion reached by Burdette 
(1955) is incorrect and that carcinogens are in most cases, also 
mutagens. This, of course, does not mean that carcinogenesis is 
caused by a somatic mutation but it does mean that a rather obvious 
mechanism has yet to be disproven. Evidence, however, is only 
circumstantial and as carcinogens are known to have many more effects 
than just damage to DNA, it would be unwarranted to proclaim somatic 
mutation as the carcinogenic mechanism even if there were a 100% 
correlation between carcinogens and mutagens (Miller, 1970). Never­
theless, it seems that many researchers are trying to prove such a 
link (Huberman, 1975; Huberman et al, 1976a.and Porten, 1976). To 
further develop this theory, it is necessary to know if a specific 
mutation is required for carcinogenesis, and this appears to be 
one of the next research targets (Huberman & Sachs, 1976; Huberman 
et al, 1976).
The use of cell lines in this type of study may help to elucidate 
a cell transforming mechanism. It however need not be the only 
mechanism by which all cancers are produced.
There may prove to be more than one mechanism of malignancy and each
mechanism may be complex. It is likely that there are a number of
changes which cells must undergo before they become neoplastic and once
so, there are immunosurveillance mechanisms which must be avoided for
continued growth. It must be remembered that a human being is made 
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up of 10 cells and a single cancer is, therefore, an extremely rare 
event.
Some facts about Chemical Carcinogenesis - The 2 Stage Mechanism
There are a number of common factors concerning chemical carcino­
genesis .
(i) Tumour formation requires time; the period between exposure 
and appearance of a tumour is known as the latency period.
(ii) Tumour formation is dose dependent; the greater the dose 
of a carcinogen to a series of animals, the greater the percentage 
of animals that will bear neoplasms, and the greater the number of 
tumours per animal. Increased doses can also shorten the latency 
period.
(iii) Tumour formation is dependent on duration of exposure, 
i.e. A given dose of a carinogen is generally more effective when spread 
over a long period of time.
(iv) Tumour formation depends on the rate of administration and 
the physical form which the carcinogen is administered. For example, 
one generally expects more tumours on the skin if a carcinogen is 
painted on to it than if it is fed in the diet.
(v) Different species have different susceptibilities to carcinogens. 
The molecular basis of this is concerned with a wide variety of factors, 
(vi) Genetic predisposition makes certain groups of individuals more
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susceptible to cancer. The molecular basis of this is not under­
stood. Kellerman et al. (1973) has suggested that the inducibility of 
aryl hydrocarbon hydroxylase in lymphocytes of patients with bro<nchio- 
genic carcinoma may be related to their susceptibility to this disease.
Many laboratories have, however, attempted to repeat the experiments 
of Kellerman and coworkers without success (McLemore et al, 1977;
Paigen et al, 1977). It seems that many factors other than susceptibility 
to carcinomas also effect the basal and induced levels of aryl hydro­
carbon hydroxylase in cultured human lymphocytes.
(viii) Tumour formation depends not only on the dosage to the initial 
carcinogen but also to exposure to promoters, chemicals which though not 
carcinogenic in themselves, potentiate the carcinogenicities of other 
compounds. Chemicals, viruses and ionising radiation can combine at 
individually non-carcinogenic levels to stimulate formation of tumours.
(Nat. Acad. Sci., 1972).
Many experiments have been performed using ’promoters', chemicals 
which modulate the carcinogenicity of other chemicals such as benzo(a) 
pyrene and these have given rise to further ideas on the mechanism of 
carcinogenesis. A complete carcinogen such as benzo(a)pyrene can 'initiate' an 
promote' carcinogenesis. Promoters do only the latter and therefore are 
used as tools when examining the initiating properties of other carcino­
gens. This has been useful in determining the active metabolites of 
polycyclic hydrocarbons.
Polycyclic hydrocarbon, skin carcinogenesis was the first system in 
which promoters were shown to be active, (Berenblum, 1941). The 
promotor in these experiments was croton oil, the active constituent 
of which is12-0-tetradecanoylphorbol-13-acetate (TPA) (Hecker, 1967;
Van Duuren, 1968).
Naturally occurring hormones can also promote carcinogenesis.
For example, 30-40% of human breast cancer, and a similar proportion 
of 3-methylchol.anthrene or 7,12-dimethylbenz(a)anthracene induced 
mammary tumours in rats and mice require prolactin and/or oestrogen for 
continued growth.
The mechanism of TPA skin promotion and hormone-promoted 
mammary carcinogenesis is not understood. Ornithine metabolism is 
integrally involved in both mechanisms and may prove to be deeply 
involved in the carcinogenic mechanism.
Pharmacological manipulation of carcinogenesis
This can be subdivided into two groups: those compounds that 
effect initiation and those that effect promotion.
Compounds that effect initiation do so by effecting the metabolism 
and disposition of a carcinogen, thus a compound that induces or 
reduces the drug-metabolising enzymes can also affect a compound's 
carcinogenicity. The overall effects on carcinogenicity are varied, 
for whilst it may be perceived that induced drug metabolising enzymes 
increase the amount of metabolism and can therefore increase the overall 
amount of active metabolite, carcinogenicity may be increased or 
reduced (Weisburger & Williams, 1975).
For example, pre-treatment of female rats with inducing levels of 
polycyclic hydrocarbons, reduces the number of mammary tumours when 
the animals are subsequently dosed with 7,12-dimethylbenz(a)anthracene 
(Huggins, et al, 1964; Dao, 1973)in this case, metabolism is increased in 
liver but probably not in mammary gland, thus reducing the number of 
tumours by redirecting the carcinogen away from the mammary gland. 
Another possible mechanism is that metabolism is rerouted such that
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the generation of the ultimate carcinogen is reduced.
Reduction of the drug-metabolising enzymes may be expected 
to reduce the amount of active metabolites of a carcinogen and 
therefore reduce carcinogenicity. This rationale has been investi­
gated by Wattenberg and co-workers using compounds that inhibit drug 
metabolism (for example butylated hydroxyanisole) and has yielded 
surprisingly encouraging results (Wattenberg and Leong,1970;
Wattenberg et al, 1976; Wattenberg, 1977). It may be possible in 
the future to manipulate human enzymes in this way to reduce the 
incidence of cancer.
The number of compounds known to effect the promotional stages 
of carcinogenesis is rapidly increasing. These include not only the 
chemicals and hormones previously described but also simple phenols 
and aliphatic alcohols with greater than 10 carbon atoms; both are 
constituents of cigarette smoke.
One of the most interesting types of chemicals under investigation 
at the present time are the vitamin A analogues. These compounds when 
dosed concurrenly with polycyclic hydrocarbon carcinogens to experi­
mental animals decrease the appearance of respiratory and mammary tumours, 
(Cone and Nettesheim, 1973; Sporn, 1978). Two recent publications showed 
that vitamin A deficiency increased the covalent binding of benzo(a) 
pyrene (Genta et al, 1974) but treatment with an excess of a vitamin A 
analogue had no effect on the metabolism of benzo(a)pyrene (Bornstein 
et al, 1978). These results are conflicting and, as yet, it is uncertain 
whether vitamin A effects initiation, promotion or both phases of 
carcinogenesis. Vitamin A has been suggested, on the basis of an 
epidemiological survey, to be beneficial to man in preventing lung
cancer (Bjelke, 1975). These are a few of the many factors which 
are known to effect chemical carcinogenesis.
Our environment is obviously of critical importance and in view 
of the gradual increase of most kinds of carcinogenesis throughout 
the western world, it would be wise to refrain from the introduction 
of new environmental contaminants until we are in a better position 
to judge their initiating and promoting effects on carcinogenesis. 
Failure to comply with this is likely to result in the introduction 
into our environment of compounds which, although not carcinogenic in 
their own right, increase the carcinogenicity of already existing 
pollutants.
Chapter 2
An Introduction to the Carcinogenicity of Benzo(a)pyrene
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Chapter 2
An Introduction to the Carcinogenicity of Benzo(a)pyrene 
Human Exposure to Benzo(a)pyrene
Benzo(a)pyrene is an extremely common environmental pollutant, 
produced by pyrolysis during combustion of organic fuels. (Nat. Acad. 
Science, 1972, I.A.R.C., 1973). it is one of a family of carcinogenic 
polycyclic hydrocarbons (Fig 4).. It is not the most potent polycyclic 
hydrocarbon carcinogen although those that are more potent are purely 
synthetic compounds and not environmental pollutants. There are 
three basic ways in which humans are exposed to benzo(a)pyrene,
(i) through contact with it as a general environmental pollutant,
(ii) by specific contamination, for example by inhalation of tobacco 
smoke or eating contaminated food and (iii) through occupational 
exposures.
(i) Epidemiological evidence has shown that persons residing 
in industrialized urban areas, risk an increased chance of contracting 
lung cancer (Royal College of Physicians, 1971, Nat. Acad. Science,
1972; Grimmer, 1977). Concomitant with this increased risk is an
increased contamination of air-borne particulate benzo(a)pyrene
3 .
typically 30 jig per 1,000 m in urban areas. Incineration of waste
(0.1-25 jdg benzo(a)pyrene per lb rubbish burnt) and the internal 
combustion engine (10-170 jig benzo(a)pyrene per gallon of fuel consumed) 
are probable contributing factors to this contamination (Nat. Acad. 
Sciences, 1972). There is a considerable controversy over the 
contribution made by benzo(a)pyrene in determining the tumourigenicity 
of some air borne contaminants, for example Grimmer (1977) has calculated 
that 5-10% of the tumour initiating properties of automobile exhaust
Some Common Polycyclic Hydrocarbon Carcinogens
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condensate is attributable to benzo(a)pyrene, whilst Pfeiffer 
(1977) claims a figure nearer to 100%.
(ii) Insurmountable epidemiological evidence now exists that 
implicates cigarette smoking in the aetiology of lung cancer (Royal 
College of Physicians, 1971, 1977; Wynder and Hecht, 1976; Doll and 
Peto, 1976). Since the polycyclic hydrocarbons are known to be 
associated with the bulk of the tumourigenicity of cigarette smoke 
and of these, benzo(a)pyrene is one of the most abundant, it there­
fore naturally comes under suspicion. Estimates of benzo(a)pyrene 
in cigarette smoke have ranged from 0.2 to 12.5 pg per 100 cigarettes 
(Nat. Acad. Sci, 1972). Cigarette smoke, however, is a complex 
mixture, probably containing as many as 2000-3000 chemical components. 
Therefore, to consider the carcinogenic potency of benzo(a)pyrene 
alone is a naive approach since apart from other known carcinogenic 
components in cigarette smoke, there are also known tumour promotors. 
Particularly important in this context is dodecane which has been 
shown to increase the carcinogenic potency of benzo(a)pyrene towards 
mouse skin about 1000-fold (I.A.R.C., 1973). This, together with 
other less powerful promoters and co-carcinogens such as phenol and 
other hydrocarbons, may well alter the carcinogenicity of benzo(a) 
pyrene in cigarette smoke. The presence of benzo(a)pyrene in human 
food originates from two sources: contamination during growth and 
production and contamination produced by cooking. Food contaminated 
with benzo(a)pyrene is probably more wide-spread than is actually 
appreciated. For example, fruit and vegetables grown in contaminated 
urban areas can predictably be shown to contain measurable benzo(a) 
pyrene; perhaps more surprising are the high concentrations of
benzo(a)pyrene often found in marine mussels (Dunn and Stich, 1976). 
However, the majority of benzo(a)pyrene consumed by humans, probably 
originates in cooking procedures. Particularly bad contamination 
is caused by charcoal broiling and smoking of food. These procedures 
have been shown to produce concentrations of 11.2^jg/Kg and 107 jug/Kg 
in charcoal broiled and smoked meat respectively (I.A.R.C., 1973).
It has been conclusively shown that the absolute concentration of 
benzo(a)pyrene depends on the type and duration of cooking and smoking.
(iii) The original observation by Pott (1775) was the first of 
a great number of observations relating to the industrial exposure 
of benzo(a)pyrene. However, although considerable numbers of persons 
are exposed to benzo(a)pyrene occupationally, in each case benzo(a) 
pyrene is in a mixture and, in consequence, the results are difficult 
to interpret. For example, a number of soots, tars and oils used 
in industry have been shown to contain benzo(a)pyrene and alsortcause 
skin cancer to exposed workers (Nat. Acad. Sci. 1972). In another 
case, the exposure of British gasworkers to airborne benzo(a)pyrene, 
it was possible to construct a dose response relationship with bronchio- 
genic carcinoma based on therrestimated exposure to benzo(a)pyrene 
(Nat. Acad. Sci, 1972).
However, the most important industrial exposure to benzo(a)pyrene 
may be in combination with other carcinogens. For example, cigarette 
smokers exposed to asbestos or uranium show a vastly increased risk 
of contracting lung cancer, as much as 90-fold, whilst non-smokers 
show only a marginally increased risk (Wynder and Hecht, 1976) .
The Carcinogenicity of Benzo(a)pyrene in Experimental Animals
Benzo (a)pyrene has been shown to cause cancer in animals of at • least *3
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species. These include all the common laboratory rodents, monkeys 
and representative avian and amphibian species (I.A.R.C., 1973).
Benzo(a)pyrene has also been shown to cause precancerous changes 
in humans (Cottini et al, 1939).
Benzo(a)pyrene is usually associated with lung, mammary and 
skin tumours, although the actual tumour type depends upon its route 
of administration. It is common that tumours arise at or near the 
site of administration although they can form at remote sites, for 
example, lung adenomas which are sometimes formed in mice which are 
painted with benzo(a)pyrene on their skins.
There exists a large variation in the susceptibility of different 
species and strains of animals to benzo(a)pyrene induced cancers.
In some strains of mice and rats, a single skin application can result 
in a large percentage of skin carcinomas whilst other strains of the 
same animals are refractory to identical exposures. Oral or skin 
administration of benzo(a)pyrene to adult animals, even at large doses, 
usually results in a low tumour incidence. To obtain a strong tumour 
response, it is necessary to use young animals and administer benzo- 
(a)pyrene repeatedly. An exception to this rule is the high 
susceptibility of pubertal female rats to mammary carcinogenesis 
after a single oral dosing with benzo(a)pyrene (Huggins and Yang, 1962 ) .
Benzo(a)pyrene is not usually a hepatocarcinogen to healthy 
liver tissue (I.A.R.C., 1973). However, in conjunction with other 
stressing factors such as partial hepatectomy or CCl^ administration, 
it does cause hepatocarcinoma (Falk, 1963). This is probably an 
indication that there are only subtle differences between liver and 
other tissues.
Repeated intratracheal administration of benzo(a)pyrene when 
coated on to inert particles has been shown to cause a high incidence 
of tracheal, bronchial and lung carcinomas in rats, hamsters and 
mice. Administration of benzo(a)pyrene by this route to Syrian 
hamsters, has been suggested by Saffiotti (1968) to be a suitable 
animal model for human bronchiogenic carcinoma. The Syrian Golden 
hamster is particularly suited because it is normally refractory 
to respiratory diseases and tumours. Rodent trachea, apart from 
an absence of Kultschitsky cells, is histologically very similar to 
human bronchus. Saffiotti’s model system utilizes weekly administra­
tion of 2 or 3 mg of benzo(a)pyrene coated on to an equal weight of 
ferric oxide particles which results in a high tumour response after 
10-15 weeks dosing. The particle size of the benzo(a)pyrene ferric 
oxide mixture is critical and to obtain a high tumour incidence needs 
to be 0.2-10pm. The ferric oxide is believed to mainly exert its 
co-carcinogenicity physically by retaining the benzo(a)pyrene for 
longer at the site of administration. However it may also function by 
its irritant effects causing cell proliferation and hyperplasia. Particles 
made of the materials such as carbon black and aluminium oxide are 
equally effective in inducing tracheal tumours whilst benzo(a)pyrene 
alone gives a very weak response (Wynder and Hecht, 1976) . Apart 
from a lack of small cell or oat cell carcinomas, the resultant tumours 
obtained by this method are similar to the human bronchiogenic 
carcinomas that are associated with cigarette smoking. The difference 
is possibly because human oat cell carcinomas arise from transformed 
Kultschitsky cells (Wynder and Hecht, 1976). Using Saffiotti’s method 
an attempt was made at the start of this work to investigate the
FIGURE 5. A typical Hamster tracheal carcinoma produced by Benzola;pyrene 
ferric oxide mixture
Benzo(a)pyrene-ferric oxide mixture was prepared by the addition 
of 2g benzo(a)pyrene in 100 mis acetone to an equal weight of ferric 
oxide particles (2-5pin»Pfizer Pharmaceuticals) suspended in 21. of 
rapidly vortexing water. The product was harvested by filtration and 
stored dry at -20 C until required. Tracheal tumours were induced 
after fifteen weekly intratracheal installations of 6 mg benzo(a)pyrene 
-ferric oxide mixture suspended in 0.2 ml 0.9% saline. The weak tumour 
response (only about 15% of animals developed tumours) may have been 
due to the fact that sonification was routinely used in the resuspension 
of the carcinogen. It is believed that this may reduce the overall 
carcinogenicity by aggregating the suspended particles thereby rendering 
them excretable via the muco-ciliary system.
protective effective of Rovimix (Roche Pharmaceuticals Ltd), a 
vitamin A analogue, on tumour incidence. Unfortunately, tumours 
were not induced in a sufficiently high enough incidence to allow 
any conclusions to be made from this experiment. However, a typical 
tracheal tumour, induced in a Syrian Golden hamster is illustrated 
in Fig 5. Failure to induce a high incidence of tumours was probably 
due to technical reasons associated with the administration of the 
benzo(a)pyrene but may also have been due to the source of hamsters 
whose genetic predisposition may have been different from those used! by 
the original investigators.
The tumour initiating activity of benzo(a)pyrene has also been 
well characterized using the two-stage mouse skin testing system 
(Berenblum, 1941). It has been shown that as little as 25 p g can 
initiate a 100% response when used in conjunction with promoting agents. 
Benzo(a)pyrene metabolites have always, until recently, shown less 
carcinogenicity than the parent hydrocarbon (I.A.R.C., 1973). Recently, 
however, 7,8-dihydro-7,8-dihydroxy-benzo(a)pyrene-9,10-epoxide and 
its precursor metabolites have been shown to be highly carcinogenic 
to mice.
Investigations into the Metabolism and Mode of Action of Benzo(a)pyrene
Since its discovery in 1933, benzo(a)pyrene has been the subject 
of intense metabolic investigation.
The first described benzo(a)pyrene metabolites, benzo(a)pyrene-X
and benzo(a)pyrene-F were found as biliary metabolites by Peacock
(1936) because of their strong fluorescence. These two products were
later resolved into four components X^, F^ and F^ by Weigert and
Mottram (1946). Although the identity of these first described benzo(a) 
pyrene metabolites is far from clear, comparison with more modern data 
suggests that F^ and F a r e  phenols, probably 9-hydroxybenzo(a)pyrene 
and 3-hydroxybenzo(a)pyrene respectively.
Falk et al 1963; Sims,1968;Arcos and Argus,1974). Other data provided 
by Harper(1957,1958a) and Falk et al(1962) has indicated that and
X^ were the sulphate and glucuronide conjugates of 3-hydroxybenzo(a) 
pyrene respectively. The biliary metabolites of benzo(a)pyrene 
have still to be resolved by modern technology to provide conclusive 
identification.
During the 1-940 fs and 1950’s a number of phenolic benzo (a) pyrene 
metabolites were tested for carcinogenicity (Berenblum and Schoental 
1943 ; Harper, 1957, 1959?) and because of the negative results obtained 
it was widely believed that the parent hydrocarbon was responsible 
for the carcinogenic effect. Polycyclic hydrocarbons including 
benzo(a)pyrene were also found to be non-mutagenic (Burdette, 1955) 
and therefore, to accommodate the known factors, many epigenetic 
theories of cancer were proposed around this time (Chapter 1).
Two key discoveries made in the early 1960's have proved crucial 
in the development of polycyclic hydrocarbon carcinogenesis research. 
The first of these was the discovery of the metabolic activation of 
a carcinogen, 2-acetaminofluorene by the Millers (Miller, 1970) and 
the second that polycyclic hydrocarbons bind to DNA (Brookes and 
Lawley, 1964). In light of the known relationship between DNA binding 
and mutagenesis, it therefore became plausible to speculate that 
carcinogesis may also involve interaction with DNA, perhaps mediated 
by a metabolite other than the initial compound. Boyland (1950) 
had proposed many years prior to the appearance of this data, that 
carcinogenic polycyclic hydrocarbons may be activated to epoxides 
and that these are the mediators of the biological effects. Thus, once 
the controversial data of Brookes and Lawley had adequate confirmation, 
interest was revived in epoxides. However, evidence for this kind
of metabolite was circumstantial and scarce. The strongest evidence 
was that of Boyland and Sims (see review Sims and Grover, 1974) who 
showed that a variety of polycyclic hydrocarbons are metabolised 
to phenols and trans-dihydrodiols, both of which could arise from 
epoxide precursors. In this type of investigation, Sims (1967, 1970) 
showed that benzo(a)pyrene phenols (principally 3-hydroxybenzo(a)pyrene),
7,8-dihydro-7,8-dihydroxybenzo(a)pyrene, (7,<S-dihydrodiol) and 9,10- 
dihydro -.-rr9,10-dihydroxy benzo (a)pyrene (9,10-dihydrodiol) were metabolites
of benzo(a)pyrene / produced by rat liver. Subsequently,.4,5-dihydro-4,5- 
dihydroxybenzo(a)pyrene . (4,5-dihydrodiol) was also shown to be
produced by rat and hamster livers (Wang et al, 1972;
Grover et al, 1973). These four principle ethyl acetate-soluble 
metabolites are shown in Fig 63.
The discovery of the NIH shift, a rearrangement associated with 
metabolism of aryl ring compounds was much stronger evidence for 
epoxides as intermediates (Guroff et al, 1967). The considerable 
circumstantial evidence, was finally confirmed with the isolation of 
naphthalene-1,2-epoxide from a hepatic microsomal incubate of naphthalene 
(Jerina et al, 1968).
Almost simultaneously to the isolation of an epoxide intermediate, 
evidence was produced which suggested that metabolism was obligatory 
for DNA binding of polycyclic hydrocarbons (Grover and Sims, 1968,
Gelboin, 1969).
The production of epoxide intermediates was soon shown to be a 
general metabolic route of polycyclic hydrocarbon metabolism by the 
detection of epoxides of dibenz(a,h)anthracene (Selkirk et al, 1971) 
benz(a)anthracene (Grover et al, 1971) and benzo(a)pyrene (Wang et 
al, 1972). The formation of K-region epoxides (those of benzo(a)
FIGURE 6(a).
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pyrene and benz(a)anthracene) was of even greater significance 
at the time of their discovery because of a generally accepted 
theory of polycyclic hydrocarbon carcinogenesis (Pullman and Pullman, 
1955). These authors had speculated, based on molecular orbital 
calculations, that the K-region was critical in allowing intercalation 
with DNA and therefore epoxide formation at that position fitted well 
with pre-conceived ideas of polycyclic hydrocarbon carcinogenesis. 
Unfortunately the problem did not prove as simple as was first thought 
because K-region epoxides, although highly mutagenic (Ames et al,
1972; Sims and Grover, 1974) were not very carcinogenic in animal 
tests (Boyland and Sims, 1967; Miller and Miller, 1967;
Sims and Grover, 1974). However, this was inconclusive because it 
was believed possible that the epoxides were too reactive to reach 
critical macromolecular targets.
Whilst evidence pointing towards epoxide involvement in chemical 
carcinogenesis of PAH has rapidly increased during the period 1967- 
1974, the possibilities of the involvement of other types of metabolites 
have also been considered (Heidelberger, 1975). Of the number of 
possibilities that have been suggested, the two most prominent are 
hydroxymethyl and radical formation. Hydroxymethyl metabolites are 
believed responsible for the adrenal necrotic action of 7,12-dimethy1- 
benz(a)anthracene (Boyland et al, 1965). Dipple et al (1968) 
speculated that they may also be responsible for the carcinogenicity 
and on such an hypothesis a number of methylated polycyclic aromatic 
hydrocarbon derivatives have been tested as carcinogens (Arcos and 
Argus, 1974; Newman, 1976). The results, however, do not confirm 
such a theory. Oxy-radicals, such as could be formed during metabolism
at C-6of benzo(a)pyrene, the most chemically reactive position, have 
also been investigated as possible proximate carcinogens. However, 
although metabolism at C-6 of benzo(a)pyrene can be detected by 
electron spin resonance (Nagata et al, 1974) the 6 position does not 
appear to be involved in microsome mediated DNA binding (Blackburn et al,
1976). Direct radical formation has also been implicated, for example 
with 3-methylcholanthrene (Cavalieri et al, 1975). However, the 
carcinogenicity of 3-methylcholanthrene is more adequately explained 
by the formation of "bay region" epoxides (King et al, 1977).
Recent investigations into the Metabolism and Carcinogenicity of 
Benzo(a)pyrene
The development of high pressure liquid chromatographic (h.p.l.c.) 
techniques suitable for the analysis of benzo(a)pyrene metabolites has 
enabled the positive identification of metabolites hitherto completely 
unknown or only suspected. This technique has been of particular use 
in the identification of benzo(a)pyrene-quinones, phenols, dihydrodiols 
and further metabolic products of dihydrodiols (Yang et al, 1977b, 1977e; 
Selkirk et al, 1974, 1976a). The technique has yet to be adopted for 
use with benzo(a)pyrene conjugates.
The metabolism of benzo(a)pyrene has been studied using many different 
in vitro systems. Apart from the many studies using liver microsomes, 
these include lung homogenates and microsomes (Grover, 1974; Hill and Shih,
1975) isolated perfused lung (Cohen and Moore, 1976; VHhHkengas et al,
1977; Bingham et al, 1976), short term organ cultures of respiratory 
tissues (Grover et al, 1976; Cohen and Moore, 1976) and colon (Autrup 
et al, 1977), and purified cytochromes (Wood et al, 1976b).
It has been clearly shown that intact cells,
because of the presence of functional conjugation enzymes, metabolise 
benzo(a)pyrene differently to microsomes (Selkirk et al, 1976b; Vadi 
et al, 1975). Thus the toxic metabolites in a microsome catalysed 
system need not be the same as those of intact cells (King et al, 1976; 
Selkirk 1977). These results indicate the necessity to study
the toxicity, covalent binding and metabolism of benzo(a)pyrene in intact 
tissues. The conjugated metabolites of benzo(a)pyrene produced 
in intact systems have proved difficult to identify, and in comparison 
with the many studied of the oxidative metabolic products, information 
is limited (Cohen et al, 1976; Cohen and Moore, 1977; Baird et al,
1977). Specific inducers of xenobiotic metabolism have also been shown 
to affect the pattern of benzo(a)pyrene metabolites produced (Rasmussen 
and Wang, 1974). Metabolic studies have shown many types of different 
metabolites. However, it was the development of Sephadex LH20 
chromatographic methods suitable for the analysis of polycyclic hydro­
carbon metabolites bound to DNA that was crucial for the most recent 
developments in polycyclic hydrocarbon carcinogenesis.
This methodology enabled Baird et al (1973) to conclusively prove 
that K-region epoxides of 7-methylbenz(a)anthracene were not involved 
in the covalent binding of the parent hydrocarbon to DNA of intact 
cells. Almost simultaneously, Borgen et al, (1973) found that 7,8- 
dihydrodiol was metabolised to a DNA bound moiety, 10 times more 
efficiently than its parent hydrocarbon. These two key pieces of 
information led Sims1 group to investigate the metabolism of 7,8- 
dihydrodiol and to investigate the possible formation of a diol-epoxide 
(Sims et al, 1974). Sims and his coworkers showed that the DNA 
products formed during cellular metabolism of benzo(a)pyrene and benz(a)
anthracene were similar to those formed when chemically synthesized diol-epox
7.8-dihydro-7, 8-dihydroxy benzo (a)pyrene “9 ,10-oxide (7,8-dihydrodioiL<-9 , 
10-epoxide) and 8,9-dihydro-8,9-dihydroxybenz(a)anthracene -10-11- 
oxide (8,9-dihydrodio1-10,11-epoxide) were reacted with DNA, (Sims
et al, 1974; Booth and Sims, 1974; Swaisland et al, 1974).
It was also shown that the metabolism of 7,8-dihydrodiol 
produced similar DNA products but the metabolism of 3-hydroxybenzo(a)pyrene,
4,5-dihydrodiol and 9,10-dihydrodiol did not. The theory that 
diol-epoxides were responsible for the biological activity of PAH 
was further substantiated when 7,8-dihydrodiol-9,10-epoxide and
8.9-dihydrodiol-10,11-epoxide were shown to be potent bacterial 
mutagens (Malaveille et al, 1975). It was also shown that the 
fluorescence spectrum of 7,8-dihydrodiol-9,10-epoxide when reacted 
with DNA was similar to a sjpectrum obtained from mouse skin DNA from 
animals previously painted with benzo(a)pyrene (Daudel et al, 1975).
These observations have been amply verified and extended by many 
other scientists since the publication of this original data.
Rulbert (1975) pointed out that there were two possible sterio- 
somers of 7,8-dihydrodiol-9,10-epoxide and that their chemical reactivity, 
based on the ease of formation of a carbonium ion, would be different . 
However, whilst his speculation that the syn isomer (7a,83~dihydroxy- 
9 3 » 103 epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene ) would be chemically
more reactive than the anti-isomer (7a , 83 -dihydroxy-9a , 10a -epoxy- 
7, 8, 9,10-tetrahydrobenzo(a)pyrene ) was correct (Yagi et al, 1975), 
the anti-isomer was, against his prediction, a potent bacterial and 
mammalian mutagen. (Huberman et al, 1976b;Newbold and Brookes, 1976;
Wood, et al. 1976a, 1976c; Marquardt et al, 1977a; Malaveille
et al, 1977). After an initial controversy it now appears that whilst
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the syn isomer is a more potent bacterial mutagen (to Salmonella 
typhimurium) (Wood, et ax s 1976a, 1976e» Malaville et al, 1977), 
the anti~isomer is much more efficient in causing mammalian cells to 
mutate (Huberman et al, 1976; Newbold and Brooks, 1976; Wood, 
et al, 1976e > Malaveille et al, 1977) and transform (Marquardt
et al, 1977).
Recent studies with liver microsomes from 3-methylcholanthrene 
pretreated rats have shown a remarkable degree of stereospecificity in 
the metabolism of benzo(a)pyrene. This results in the predominant 
production of an optical isomer of 7,8-dihydrodiol^-)7a , 86 -dihydro- 
7a , 86 dihydroxybenzo(a)pyreneJ (Yang et al, 1977c,e.Further metabolism 
of the (-)7,8-dihydrodiol was also shown to predominantly produce 
the (+) enantiomer of the anti diol-epoxide £(+)7a , 86 -dihydroxy- 
96 > 106 -epoxy-7, 8,9,10-tetrahydro-benzo(a)pyreneJ(Yang et al, 1976, 1977 
c, e, Thakker et al, 1977). Metabolism by liver microsomes from control 
or phenobarbitone pretreated rats was also shown to be much less 
stereospecific than metabolism microsomes from 3-methylcholanthrene 
treated rats (Thakker et al, 1977). The absolute type of diol-epoxide 
produced is of considerable importance since it has been shown that 
the four possible optical isomers vary in their ability to mutate 
bacterial and mammalian cells (Wood et al, 1976b).
7,8-Dihydrodiol is a potent tumour initiator (Chouroulinkov 
et al, 1976; Slaga et al, 1976) and complete carcinogen to mouse skin 
(Levin, al. 1976; Levin et al, 1977a),
and neonatal mice (Kapitulnik et al, 1977). The (-) enantiomer of
7,8-dihydrodiolwas also shown to be 5-10 fold more potent tumour 
initiator than the (+) enantiomer (Levin, et al, 1977b).
7.8-dihydiodiol-9,10-epoxide was a weak mouse skin tumour initiator 
(Levin, et al, 1977a; , Slaga et al, 1976) but a
potent carcinogen to neonatal mice (Kapitulnik et al, 1978).
The nature of the 7,8-dihydrodiol-9,10-epoxide — nucleic acid 
adducts has been elicudated by a number of laboratories. The main 
nucleic acid adduct is formed between the C-10 of 7,8Tdihydrodiol-
9,10-epoxide and the 2 ^ of guanine (Koreeda et al, 1976; Osborne 
et al, 1976; Weinstein et al, 1976), although attack can also occur 
at phosphodiester linkages (Koreeda et al, 1976; Gamper et al, 1977) 
and other purine and pyrimidine bases (Straub et al, 1977; Jennette 
et al, 1977), 8enzo(a)pyrene-RNA and benzo(a)pyrene-DNA adducts 
produced by benzo(a)pyrene in organ culture with bovine and human bronchal 
mucosa respectively hase also been identified as diol-epoxide adducts 
(Weinstein et al, 1976; Grover et al, 1976;' Yang et al, 1977a). The 
major RNA or DNA adduct obtained in cultured cells or tissues is usually 
due to anti 7,8-dihydrodiol-9,10-epoxide (Osborne et al, 1976; Weinstein 
et al, 19 76) but the syn isomer can also form adducts; the exact nature 
of those found in cell culture has been shown to depend on the time of 
exposure to benzo(a)pyrene (Baird and Diamond, 1977).
The considerable amount of data reviewed here that indicates
7.8-dihydrodiol-9,10-epoxide to be an ultimate carcinogen derived 
from benzo(a)pyrene is continually growing. Nevertheless, many 
experiments have been performed using other metabolites of benzo(a)pyrene.
Many mutagenicity and carcinogenicity trials have been carried out 
with benzo(a)pyrene metabolites other than 7,8-dihydrodiol derivatives. 
Simple arene oxide metabolites vary in their mutagenicity and carcino­
genicity. For example, whereas 4,5-epoxide, the K-region epoxide is 
highly mutagenic to bacterial and cultured mammalian cells (Ames et al,
1972, Wislocki et al, 1976), benzo(a)pyrene-7,8-epoxide and 
benzo(a)pyrene-9,10-epoxide, non K-region epoxides are only weakly 
mutagenic in the same systems (Wislocki et al, 1976). Benzo(a) 
pyrene-4,5-epoxide is, in common with other K-region arene oxides, a 
weak tumour initiator (Levin, Wood, Yagi, Dansette et al, 1976,
Sims & Grover, 1974; Slaga, . et al, 1976). Benzo(a)pyrene-9,10-epoxide 
was also found to be a weak tumour initiator but benzo(a)pyrene-7,8-epoxide, 
a precursor of 7,8dihydrodiol-9,10-epoxide, was highly carcinogenic 
(Slaga et al, 1976; Levin et 1976 '» Slaga
et al, 1977). The other benzo(a)pyrene-K-region epoxide, benzo(a) 
pyrene-11,12-epoxide is also a weak tumour initiator (Wislocki et al,
1977; Slaga et al, 1977).
All twelve possible benzo(a)pyrene-phenols have been tested 
for mutagenicity and carcinogenicity (Wislocki et al, 1977). Although 
some of the phenols had weak mutagenic activity, none had significant 
carcinogenicity except 2 and 11-hydroxy-benzo(a)pyrenes (Wislocki 
et al, 1977; Slaga et al, 1978) both of which have yet to be 
demonstrated as benzo(a)pyrene metabolites (Selkirk et al, 1976).
However, a precancerous condition, epidermal hyperplasia, was observed 
in mouse skin treated with 9~hydroxybenzo(a)pyrene (Bresnick 
et al, 1977). This is possibly related to the nucleic acid binding 
of this phenol, (King et al, 1976).
Two dihydrodiols other than the proximate carcingen 7,8-dihydrodiol 
have also been tested for biological activity. 4,5-Dihydrodiol was 
a very weak tumour initiator to mouse skin (Chouroulinkov et al,
1976) but 9,10-dihydrodiol was completely inactive. Two possible 
further metabolites of 9,10-dihydrodiol, the syn and anti isomers of
9,10-dihydrodio1-7,8-epoxide, have also been tested for biological 
activity. Both were found to be bacterial mutagens, especially the 
anti isomer (Malaveille et al, 1977) but were not active in transforming 
mammalian cells (Marquardt et al, 1977). These types of epoxides, 
however, are not major liver metabolites of 9,10-dihydrodiol (Booth 
and Sims, 1976; Thakker et al, 1978).
A number of benzo(a)pyrene-quinones are also known to be weak 
mutagens (Wislocki et al, 1977).
None of these metabolites show the complete spectrum of biological 
activity as exhibited by 7,8-dihydrodiol 9,10-epoxide and its 
dihydrodiol precursor. Thus the susceptibility of a particular tissue to 
benzo(a)pyrene induced carcinogenesis is probably dependent in part 
upon the inherent type of cytochrome p-450, which determines the 
benzo(a)pyrene metabolites produced (Wood et al, 1976b ; Bentley
et al, 1977) and the ability of the tissue to detoxify the proximate and 
ultimate carcinogenic forms via alternative metabolic routes. At 
present although a number of conjugated metabolites of benzo(a)pyrene 
have been discovered, (Nemoto and Gelboin, 1976; Cohen et al, 1976;
1977; Sims and Grover, 1974), data concerning their mutagenicity 
does not exist. However, it is known that hydrolysis of/^h/ - benzo(a) 
pyrene-3-glucuronide with (3-glucuronidase results in binding to DNA 
(Kinoshita and Gelboin, 1978).
The Bay Region theory of Polycyclic Hydrocarbon Carcinogenesis
A quantum mechanican model of polycyclic hydrocarbon carcinogenesis 
has been proposed by Jerina and co-workers (Jerina et al, 1976b;
Jerina and Daly, 1977). It is proposed that mutagenicity and carcino­
genicity is related to the ease at which carbonium ions form around a
'bay region.' The simplest bay region diol-epoxide, phenathrene- 
1,2-dihydrodiol- 3,4-epoxide is shown in Fig 6b* Thus 7,8-dihydrodiol-
9,10-epoxide, an ultimate carcinogen derived from benzo(a)pyrene is 
a bay region diol-epoxide (Fig 6b). Table 1 summarizes some of 
the evidence that has been presented ■that substantiates the 'bay region' 
theory with polycyclic hydrocarbons other than benzo(a)pyrene.
The Aims and Scope of the Present Investigations
Benzo(a)pyrene is the most likely cancer causing compound known 
in cigarette smoke responsible for the carcinogenicity of this mixture 
to man. It is therefore natural that its disposition should be studied 
in detail in the respiratory tissues of experimental animals which 
are also susceptible to this carcinogen. The aim of the present 
study was to investigate the metabolism and binding of benzo(a)pyrene 
in the lung, trachea and bronchus of laboratory rodents. It was 
hoped that such a study would give indications to why these tissues 
are susceptible to the carcinogenicity of this compound whilst other 
tissues, such as liver, are not.
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FIGURE 6(b).
Some Bay Region Diol-Epoxides
The simplest bay region diol-epoxide: Phenanthrene-l,2-dihydrodiol-3,4-epoxide
OH
OH
A carcinogen from benz (a)anthracene: Benzo(a)anthracene-3,4-dihydrodiol,1,2- 
epoxide
An ultimate carcinogen of benzo(a)pyrene: Benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide 
(7,8-dihydrodo-7,8-dihydroxybenzo(a)pyrene-9,10-oxide)
Chapter 3
Materials and Methods
Chapter 3 
Materials and Methods
Animals
Male wistar albino rats (from the University of Surrey colony), 
maintained on wood shavings or male Syrian golden hamsters (from
D. Roberts of Basingstoke, England) maintained on inert bedding 
(Tolsa bedding, Trouspacet, Spain) were used for all animal experiments. 
All animals were allowed food (Spillers No 1 Laboratory diet) and 
water ad lib and were maintained under conditions of constant temper­
ature (22°C), humidity (50%) and lighting (12 h cycle). Human lung 
samples were obtained from the Milford Chest Hospital , Milford with 
the co-operation of the consultant surgeon, Mr Meredith-Brown.
Tissue Preparations
To fully investigate the metabolism of benzo(a)pyrene, a wide 
variety of tissue preparations were employed.
(a) Liver Preparations: Liver metabolism of benzo(a)pyrene was used 
in the preparation of purified benzo(a)pyrene metabolites. Rat 
liver (5~20 g) was cut into small pieces and homogenised using a 
Potter-Elvej diem apparatus in 4 vol. of ice cold 0.1M Na phosphate 
buffer, pH 7.4. In some experiments the supernatant solution 
obtained after centrifugation at 15,000 g (20 min) was used directly. 
However, in most experiments microsomes were prepared by a subsequent 
centrifugation at 100,000 g (1 h) and used for experimentation.
(b) Lung Microsomal Preparations: Lung microsomes were prepared 
after an adaption of the method of Matsubara et al, 1974. Rodent lung 
was homogenised in ice cold 0.1M Na phosphate buffer, pH 7.4, using 
short bursts of a Polytron homogeniser.
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The resultant homogenate was centrifuged at 16,000 g (10 min) 
and 100,000 g (1 h) to prepare microsomes. In some experiments
the microsomes were used directly but in others they were resuspended
in a suitable quantity of buffer and recentrifuged C 100,000, 30 min)
before use.
(c) Isolated Lung Perfusion
Isolated lung perfusion was employed because it offers the 
benefits of an isolated system yet the lung remains intact and almost 
'in vivo'.' This technique has been used previously to study the 
metabolism of compounds of pharmacological (Junod,1972b; Law.et al,
1974 and Hawkins et al, 1977) and toxicological (McGouren et al,
1976; Bingham et al, 1976; Cohen and Moore, 1976; Vhhhkdngas et al,
1977) significance. It has been shown that isolated perfused lung 
metabolises many xenobiotics similarly to lung microsomes although 
some reactions, such as metabolism of imipramine do not proceed as 
well in isolated perfused lung (Hook and Bend , 1975). It can also 
be demonstrated that the isolated perfused lung retains a full 
complement of phase 2 drug metabolising enzymes, and substrates such 
as 4-methylumbilliferone can be shown to be metabolised to glucuronide 
conjungates (Aitio et al, 1976).
Constituents of cigarette smoke such as nicotine McGouren et al, 
1976) and benzo(a)pyrene (Bingham et al; Cohen and Moore, 1976; 
Vhhhnkangas et al, 1977) are metabolised by the isolated perfused lung. 
Cigarette smoking or pretreatment with 3-methylcholanthrene has been 
shown to induce isolated perfused lung metabolism (Cohen et al, 1977; 
Vhhhkangas et al, 1977).
The lungs of adult male hamsters (100-140 gr) and male rats
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(190-300 gr) were perfused essentially according to the method of 
J u n o d (1972a). Animals were anaesthetized by i.p administration of 
Na pentabarbitone, 60-100mglKg{0.2-0.4 mis of Nembutal, Abbot 
Laboratories or Sagatal, May and Baker Ltd). Surgery was started 
by opening each animal ventrally and performing a tracheotomy using 
a suitably large cannula to support the lungs. The abdomen was then 
opened and artificial respiration started with a constant pressure 
animal ventilator (C. E. Palmer Ltd, London) to mimic the natural 
breathing of the animal (12-18 cm positive pressure 30-45 cycles/ 
min). The diaphragm was then dissected away and the rib cage 
carefully opened. Care was exercised to prevent sharp surfaced from 
damaging the surfaces of the lung. The lungs were perfused with 
Krebs-Ringer bicarbonate (pH 7.4) containing 4% bovine serum albumin 
via a cannula attached into the pulmonary artery. This was tied into 
position with a single suture which also ligated the aorta. Perfusion 
was started immediately the cannula was tied into position. This was 
slow at first but speeded up as soon as a cut had been made in the
left ventricle to release pressure. The perfusion circuit was completed
with a cannula attached into the left ventricle. The lungs were then 
isolated from the rest of the animal and placed in the perfusion
chamber supported by the tracheotomy cannula (Fig. 7). A 5 min
equilibrium period was allowed during which time the perfusion rate 
was gradually increased to the final flow rate of 4-6 ml per min.
After this metabolism was started by the introduction of a fresh 
medium containing benzo(a)pyrene. The circulating water bath
was thermostated at 39-40°C which maintained the perfusion chamber at 
35-37°C. In all experiments medium was allowed to recycle through
Key to Figure 7:
A. Watson-Marlow variable peristaltic pump.
B. Animal Ventilator (C.F. Palmer Ltd, London)
C. Thermostated water bath.
D. Thermostat/water circulating pump.
E. Perfusion chamber.
F. Tracheal cannula (to and from ventilator).
G. 'In' cannula (connected into pulmonary artery).
H. 'Exit’ cannula (connected into left ventricle) draining 
into funnel.
(a)
FIGURE 7 
Lung Perfusion Apparatus
(a) Complete Apparatus
(b) Close up of perfused lung
the lungs to favour complete metabolism of benzo(a)pyrene to 
primary and secondary metabolites. The system was therefore not 
suitable for kinetic studies.
However, in an experiment performed to measure the elution of 
radioactivity, it was found that lungs absorbed administered r 3s7- 
benzo(a)pyrene for the first 2-5 min. After this period, excreted 
levels of radioactivity were approximately equivalent to the administered 
levels, suggesting very rapid kinetics.
The principal drawback of this technique was the rapid degenera­
tion of the lung tissue by oedema which occurred after 45-90 min of 
perfusion. It was necessary to terminate each experiment when this 
occurred. The addition of 10 mM glucose to the perfusion medium did 
not notably improve the maintenance of the lungs. A specific bio­
chemical monitoring of lung metabolism and function was not performed but 
it was observed that metabolism of benzo(a)pyrene was still proceeding 
in some experiments after 60 min perfusion.
(d) Short term organ cultures of lung, bronchus and trachea, it was not
thought practicable to prepare microsomes of, or perfuse rodent bronchus < 
trachea. Therefore to study benzo(a)pyrene metabolism of bronchus 
and trachea it was necessary to employ short-term organ culture, and 
for comparison, this was a]so adopted for lung studies. The technique 
also had an added advantage in that it easily adapted for use with 
human material.
Polycyclic hydrocarbon metabolism has been widely studied in 
organ cultures. For example, 3-methylcholanthrene metabolism and 
binding has been observed in organ cultures of mouse skin, lung and 
muscle (Lasnitzki et al, 1974) and benzo(a)pyrene metabolism in colon
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cultures (Autrup, Harris, Fugaro and Selkirk, 1977). The metabolism 
and binding of benzo(a)pyrene in human and animal tracheal and 
bronchial organ cultures has been very important evidence in the implic­
ation of 7,8-dihydrodiol-9,J0-epoxide as an ultimate carcinogen derived 
from benzo(a)pyrene (Pal et al, 1975; Grover et al, 1976; Weinstein 
et al, 1976; Jennette et al, 1976). Benzo(a)pyrene and other polycyclic 
hydrocarbons have also been observed to cause neoplastic changes in 
organ cultures (Defries and Franks, 1976) . The wide uses of organ 
culture are fully reviewed in a recent book (Balls and Monnickendam,
1976).
Organ culture was performed essentially as described by Kaufman et 
al (1972). Male rats (150-250 g) or hamsters (100-140 g) were 
anaesthetized as described previously, and then exsanguinated by severage 
of the inferior vena cava. The respiratory tract was then dissected 
away, cleared of tissue debris and washed in Dulbecco's phosphate 
buffered saline. Bronchial and tracheal tissues were cleared of any 
contaminating tissue and opened out via an incision along the membraneous 
surface. Lung tissue for culture was similarly isolated from any 
bronchial tissue and then cut into suitable sizes for culture; in most 
experiments a single fragment of lung weighing 180-220 was used.
Tissues were cultured in 5 or 10 mis of Leibovitz L15 medium 
containing 2 mM L-glutamine, 10% foetal calf serum (Biocult Laboratories, 
Scotland or Flow Laboratories, Scotland) and antibiotics (penicillin,
100 U/ml and streptomycin, 100 /ig/ml, both from Sigma Chemical Co). 
Absolute sterility was not maintained, but bacterial contamination was 
minimised by the use of sterilized solutions.- Cultures were incubated 
in most experiments for 16-18 h at 37°C in a shaking water bath (45-50 
oscillations/min). [~ ^H7-Henzo(a)pyrene or /""^H^-benzo (a)pyrene
metabolites were added to cultures for metabolism at concentrations 
of 0.4-3.0 /uM as described for individual experiments.
After 24 h culture, trachea, bronchii and small pieces of lung 
appeared histologically normal when stained with eosin and haematoxylin. 
However, larger lung fragments used in a few experiments exhibited 
darker staining nuclei after culture.
In a few instances, human tissue was obtained after pulmonectomy 
and cultured. Lung or bronchial tissue was obtained directly after 
surgery and transported within 1-2 h to the laboratory in ice cold 
phosphate buffered saline. Culture was performed similarly to that 
described for animal tissues. As the tissues were obtained from 
random patients it is likely that they exhibited a great variation 
in their ability to metabolise and covalently bind benzo(a)pyrene as 
found by others (Harris et al, 1976).
It is likely that the simplicity, adaptability and resemblance 
of organ culture to the in vivo situation will stimulate its use more 
frequently in future for studies on the metabolism of xenobiotics.
Synthesis and Purification of Benzo(a)pyrene and Benzo(a)pyrene
Metabolites
Benzo(a)pyrene was obtained from Aldrich Chemicals (99%) and 
used without further purification/ In a few preliminary experiments, 
benzo(a)pyrene of a lower purity (97%, Koch-Light Laboratories Ltd,
Colne, Bucks) was used.
/" s7 -Benzo(a)pyrene (specific activity, 5-25 Ci/mwole) was 
obtained from the Radiochemical Centre, Amersham, Bucks and purified 
by the method of De Pierre et al (1975) before use. A 3 s7 -Benzo(a) 
pyrene was dissolved in hexane (2-3 ml) and repeatedly extracted with 
0.25 M-NaOH in 40% ethanol-60% water (5 ml) until pure. The final 
product was 98% radiochemically pure when assessed by t.l.c 
(benzene: ethanol, 9:1 or 19: lv/v). The only significant radiochemical 
impurity chromatographed at the origin.
Unlabelled 3-hydroxybenzo(a)pyrene, 4,5-dihydrodiol, 7,8- 
dihydrodiol and 9,10-dihydrodiol were obtained by rat liver metabolism 
of benzo(a)pyrene essentially as described by Sims (1970) . Benzo(a) 
pyrene (2-5 mg, 8-20 jumoles) was incubated (37°C) with rat liver 
supernatant solution or microsomes (equivalent to 5-10 g of liver 
from rats pretreated with 3-methylcholanthrene, 20 mg/Kg) with cofactors 
(NADP+, 50-100 mg, 60-120 pinoles, Sigma Chemical Co.; glucose' 6- 
phosphate, 100-200 mg, 0.3-0.6 m/noles, Sigma Chemical Co.; MgCl^, 500 mg,
1.6 mmoles; glucose- 6-phosphate dehydrogenase, 50-100 jul, 14-28U, 
Boehringer Mannheim GMBH in 100 mis 0.1 M Na phosphate buffer, pH 7.4. 
Metabolism was allowed to proceed for 15-60 min before the resultant 
benzo(a)pyrene metabolites were extracted with 2 or 3 x 1 vol. of ethyl 
acetate. The extract was dried with anhydrous Na^ S0^,
evaporated to dryness and the resultant residue redissolved in a 
small quantity of ethyl acetate and applied to t.l.c. plates for 
chromatography. The t.l.c. plates were developed in benzene:ethanol,
9:1 or 19:1 v/v and the separated metabolites visualised by their 
fluorescence under u.v light (254 nm). Individual metabolite 
bands were immediately scraped from the t.l.c. plates and the individual 
metabolites eluted into 96% ethanol. Metabolites were identified from 
their chromatographic properties and comparison of their u.v spectra 
with those of authentic metabolites.
7,8,9,10-Tetrahydro-7,8,9,10-tetrahydroxybenzo(a)pyrene 
(tetrahydrotetrol) and 9,10-dihydroxybenzo(a)pyrene /l(3), 9,10-tri- 
hydroxy-9,10-dihydrobenzo(a)pyrene_/, (Thakker et al, 1978) were pre­
pared according to the method of Booth and Sims ,(1976) . T h e  lat'ter 
will be subsequently referred to as 1(3),9,10-trihydroxy-9,10-dihydro­
benzo (a)pyrene. 7,8-Dihydrodiol (approximately 50yg) or 9,10-dihydrodiol 
(approximately 50yg) previously prepared by metabolism of benzo(a)pyrene 
were incubated with liver microsomes essentially as described previously 
excepting that the microsomes were prepared and incubated (60 min) in 
0.1M Na-pyrophosphate, pH 8.0. The resultant metabolites were extracted 
and purified by t.l.c. (chloroform: methanol, 4:1 v/v) as previously 
described. To facilitate identification of the required unlabelled 
metabolites, a similar experiment was performed simultaneously using 
small quantities of /~^h/-7,8-dihydrodiol and /~^h/-9,10-dihydrodiol.
The tetrahydrotetrolsproduced by metabolism from 7,8-dihydrodiol or
9,10-dihydrodiol had similar u.v spectra to that described by Booth and 
Sims (1976). Tetrahydrotetrol from both sources also had similar
fluorescence excitation and emission spectra (see appendix).
1,(3),9,10-trihydroxy-9,10-dihydrobenzo(a)pyrene was only produced 
by metabolism of 9,10-dihydrodiol; its u.v. and fluorescence spectra 
(see appendix) showed it to be similar to the metabolite identified by 
Booth and Sims (1976) as 9,10-dihydrobenzo(a)pyrene.
3-Hydroxybenzo(a)pyrene and benzo(a)pyrene dihydrodiols were
mixed in suitable quantities and used routinely as t.l.c. markers
for most investigations of benzo(a)pyrene metabolism. 1(3),9,10-
Triol and tetrahydrotetrol were used sparingly when required. In some 
experiments, cis-benzo(a)pyrene-4,5-dihydrodiol (prepared by the
chemical method of Cook and Schoental, 1948) was used instead of
the metabolically prepared material. However, metabolically prepared
4,5-dihydrodiol and chemically prepared cis-4,5-dihydrodiol were
chromatographically indistinguishable in the t.l.c. systems used.
/"" 3H7-3-Hydroxybenzo(a)pyrena, ^*"^H7-4>5-dihydrodiol, /~^h7-7,8-dihydro
diol & C  3h7-9 ,10 -dihydrodiol /" 3h/-1 (3)', 9,10-trihydroxy, 9,10-dihydrobenzo (a) 
pyrene were prepared by rat liver metabolism of /~3H7-b enzo(a)pyrene 
(0.5-8 mCi) essentially as described previously for unlabelled 
metabolites. r * j  -Benzo(a)pyrene was diluted to a lower specific 
activity with unlabelled benzo(a)pyrene to enable the preparation of 
a reasonable mass of tritiated metabolites. All tritiated metabolites 
were purified by repeated t.l.c. until u.v and fluorescent spectral 
contaminants were removed. Typical purification procedures used for 
individual benzo(a)pyrene metabolites are outlines in Fig. 8. C W ~
Benzo(a)pyrene dihydrodiols were 98% and /~3h 7 3-hydroxybenzo (a) 
pyrene 96% radiochemically pure by t.l.c. after purification. H.p.l.c. 
analysis showed that the /"3H7~3-hydroxybenzo(a)pyrene prepared by
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these procedures contained approximately 10% /~"^H7-9-hydroxy- 
benzo(a)pyrene.
Purified metabolites were stored in the dark at -20°C until 
required for experiments and if necessary rechromatographed directly 
prior to use.
7-Hydroxybenzo(a)pyrene and 9-hydroxybenzo(a)pyrene were 
synthesized by acid hydrolysis of 7,8-dihydrodioland 9,10-dihydrodiol 
respectively as described by Waterfall and Sims (1972). Small 
quantities of 2M HC1 (10-20 ;ul) were added to the respective benzo(a) 
pyrene dihydrodiols dissolved in small quantities of ethanol (100- 
200 ul). The addition of acid was ceased when no further change in 
the fluorescence spectra of the solutions was observed. 7-Hydroxy 
benzo(a)pyrene and 9-hydroxybenzo(a)pyrene were purified from the 
hydrolysates by t.l.c. (benzene:ethanol, 19:1 v/v) similarly to that 
described for other metabolites. The u.v and fluorescent spectra 
(see appendix) of the purified metabolites compared favourably with 
those reported by others (Sims, 1968; Yagi et al, 1976).
The Use of /~^H7~benzo(a)pyrene and /~^H7~benzo(a)pyrene metabolites
in the determination of benzo(a)pyrene metabolism by tissues of the 
respiratory tract
2 ju.M-/~^H7-8enzo(a)pyrene was used for all metabolism studies 
of benzo(a)pyrene with respiratory tissues. This concentration was a 
compromise between the concentration likely to occur in the respiratory 
tract of smokers and that amount which could be reasonably determined 
by radiometry and fluorimetry.
f s7~® enzo(a)pyrene and r317 -metabolites were added to biological 
preparations dissolved in small quantities of acetone or ethanol. The
final concentration of organic solvent did not exceed 0.1% v/v f°r
3 3r a/-® enzo(a)pyrene and 0.3% v/v for Z"jh7 -metabolites. Metabolism was
allowed to proceed as described for individual experiments. Microsomal
incubates were terminated by the addition of cold ethyl acetate,
cultures by separation of cultured tissues from medium, and perfusions
by halting the flow of perfusate. Medium from all experiments was
immediately cooled on ice and analysed for benzo(a)pyrene metabolites.
Ethyl acetate-soluble benzo(a)pyrene metabolites. Ethyl acetate-
soluble metabolites were analysed essentially after the method of Sims
(1970).
Ethyl acetate-soluble benzo(a)pyrene metabolites were extracted 
by shaking the medium with 2 x 1  vol of ethyl acetate for a minimum of 
40 sec. The pooled ethyl acetate extracts were dried with anhydrous 
Na^SO^, rotary evaporated to dryness and the residues applied to
.nlica gel
commercially prepared aluminium backedAthin layer plates (Merck,
Darmstadt, W. Germany) for chromatography as described in individual 
experiments. Chromatographed benzo(a)pyrene metabolites were located from the
fluorescence of unlabelled marker metabolites.
For most experiments, extraction with 2.x vol. of ethyl acetate 
was quite sufficient to extract essentially all the benzo(a)pyrene 
metabolites. However, when water-soluble metabolites were being 
investigated, it was often necessary to reextract the medium at least 
once, and in some cases up to a total of six times to ensure the 
complete removal of ['^bj-benzo(a)pyrene. /"^Hj-benzo(a)pyrene 
metabolites were quantified by liquid scintillation counting of 5 mm 
cut sections of the t.l.c. plates or by use of a Bethold-Cambridge 
radiochromatogram scanner. In most cases, metabolites were quantified 
by both methods as the inherent low sensitivity of tritium radioscanning 
was complemented by the low resolution of the counting method. The. 
absolute amounts of metabolites produced were calculated from the 
amount of radioactivity cochromatographing with the marker metabolites. 
Water-soluble benzo(a)pyrene metabolites. Water-soluble benzo(a)pyrene 
metabolites were analysed by enzymic hydrolysis with specific enzymes 
and thereafter by similar methods to the ethyl acetate-soluble metabolites. 
Three specific enzymes were used,
(i) 3~glucuronidase (E.C. 3.2.1.31) (e^Helix Pom.atia, Sigma Chemical 
Co. Type H-l). This preparation contains traces of sulphatase 
activity.
(ii) Ketodase, a purified 3 -glucuronidase (ex bovine pancreas, Warner
Chilco ttl-abs, N.J., U.SA) • Excess of this enzyme did not hydrolyse 
benzo(a)pyren — 3-yl hydrogen sulphate (3-sulphate).
(iii) Aryl sulphatase (E.C. 3.1.6.1.)(ex Helix Pomatia, Sigma Chemical 
Co, Type H-l). This enzyme preparation contains 3-glucuronidase 
activity as an impurity, thus a 3-glucuronidase inhibitor, D-saccharic
acid l-*4 lactone (20 or 200 mM) was added to all incubations with 
this enzyme. Under these conditions aryl sulphatase hydrolysed 3-sulphate 
releasing 3-hydroxy benzo(a)pyrene but did not hydrolyse benzo(a)pyrene 
glucuronide conjugates. This enzyme preparation may also possess 
phosphatase activity, (Kao, J. personal communication).
Enzymic hydrolysis was carried out on ethyl acetate extracted 
medium from culture experiments; in some experiments, traces of ethyl 
acetate were removed by rotary evaporation. Enzymes were added to the •: 
culture medium in an equal volume of 0.1M Na acetate buffer, pH 5.0 
such that the final concentrations were: 3-glucuronidase, 110 Fishman 
Units per ml; Ketodase, 500-2000 U per ml, aryl sulphatase, 335-700 
U per ml. The hydrolyses were incubated for 1-2 h or 18 h at 37°C 
in darkened containers. Hydrolysates were extracted with 2 x 1  vol of 
ethyl acetate and analysed by tl.c. as previously described for ethyl 
acetate-soluble metabolites. In some cases, the high protein concentra­
tions in the hydrolysates caused ’gelling1 during ethyl acetate 
extraction. This was overcome by centrifugation or addition of 
further quantities of ethyl acetate.
Enzymic hydrolysis was also used to help ascertain the identity 
of purified benzo(a)pyrene metabolites. These, in small quantities 
of ethanol, were added to enzyme solutions in 0.1M Na acetate buffer, 
pH 5.0 and incubated as previously described.
Radioactivity and Spectroscopy Measurements
Liquid scintillation counting was performed using a Packard 
Tricarb (Model 3320) or an LKB Ultrabeta liquid scintillation spectro­
photometer. Most estimations were made using a scintillation 
cocktail of toluene: symperonic-NCP detergent (ICI), 2:1 v/v
containing .5 grams of P.P.O. (2,5-diphenyloxazole) and 0.5 g 
of dimethyl R0.P.QR (1,4-bis(2-(4-methyl-5-phenyl(oxazole)-benzene) 
per litre (Wood, English et al., 1976). Tissue samples were 
solubilized with Packard Soluene 350 according to the manufacturers 
instructions and counted in a similar scintillation cocktail from 
which the detergent was omitted. Calibration and quench correction 
was performed by internal standardisation.
Fluorescence spectra were obtained using a Perkin-Elmer MPF-3 
fluorescence spectrophotometer. Spectra were recorded in Merck 
fluorescence grade ethanol unless otherwise stated.
Uv spectra were recorded in 96% ethanol using a Pye-Unicam 
SP1800 spectrophotometer.
Chapter 4
3
Studies on the Metabolism of f  Hj-Benzo (a)pyrene 
by Rat, Hamster and Human Respiratory Tissue 
Preparations
Chapter 4
Metabolism of £  H7~Benzo(a)pyrene by Isolated Perfused Rodent Lungs
Rat and hamster lungs were perfused with 100 mis of recycled 
Krebs-Ringer bicarbonate, pH 7.4 as described in Chapter 3. Perfusion 
was continued for 45-160 min or until the lungs became oedematous.
In some experiments, medium (10 mis) was removed for determination 
of radioactivity and benzo(a)pyrene metabolites at prescribed intervals. 
Perfused lungs rapidly removed [" H7~benzo(a)pyrene from the medium 
during the first few minutes of perfusion (Fig 9). After approximately 
5 min the amounts removed from the medium slowed and eventually, after 
20-30 min perfusion, the levels entering and leaving the lungs were 
similar (Fig 11).
Isolated perfused rat or hamster lungs metabolised /~ H^- 
benzo(a)pyrene (2 yM) to ethyl acetate-soluble and water-soluble 
metabolites. The major ethyl acetate-soluble metabolites formed 
during perfusion were identified by cochromatography (benzene : ethanol 
9:1 or 19:1 v/v)as mono(3>hydro5ybenzo(a)pyrene, 9,10-dihydrodiol and 
a quinone, tentatively identified as benzo(a)pyrene-3,6-quinone by 
its red colouration. Smaller amounts of 4,5-dihydrodiol, 7,8-dihydrodiol 
and an unidentified metabolite (Y) were also produced (Fig 10). Thus, 
after 10-20 min perfusion, a steady state of metabolism was reached 
in which [  H^-benzo(a)pyrene was progressively metabolised to ethyl 
acetate-soluble (Fig 12) and water-soluble metabolites (Fig 11).
Qualitatively similar ethyl acetate-soluble metabolites were 
produced throughout perfusion. However, the proportion of monohydroxy- 
benzo(a)pyrene produced diminished, but was accompanied by a concomitant 
rise in benzo(a)pyrene-quinone and metabolite Y. The amounts of 
ethyl acetate-soluble metabolites produced (Figs 10, 12) are a composite
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FIGURE 9. Elution of radioactivity in the perfusate during the first few minutes 
of an isolated rat lung perfusion with [  benzo(a)pyrene. Data expressed 
as the percentage of radioactivity passing through the lungs.
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FIGURE 12. Cumulative production of ethyl acetate-soluble metabolites in the 
perfusate of an isolated rat lung perfused with 2 yM /" 3H/-benzo(a)pyrene. 
Metabolites were determined by t.l.c in benzene:ethanol (9:1, v/v) and liquid scin­
tillation counting. 3-hydroxybenzo (a) pyrene - O --------- O  ; 9,10-dihydro-
9,10-dihydroxybenzo(a)pyrene =®---•; 7,8-dihydro-7,8-dihydroxybenzo(a)pyrene =
A -----------------A  ; 4,5-dihydro-4,5-dihydroxybenzo(a)pyrene = X ------------------X
of their production and further metabolism into other ethyl acetate- 
soluble and water-soluble metabolites. In all of the experiments 
performed, medium was recycled; this favours secondary metabolism to 
polyhydroxylated or conjugated water-soluble metabolites.
Quinones are known metabolites of benzo(a)pyrene (Holder et al, 
1974; Selkirk et al, 1974), but in this case it is possible that 
they were produced by air oxidation of monohydroxybenzo(a)pyrenes 
rather than enzymically. Benzo(a)pyrene-quinones are not substrates
for glucuronide conjugation (Nemoto& Gelboin,1976‘) and thus for metabolism 
to water-soluble metabolites it is necessary that they be reduced to 
phenols as described recently (Lind et al, 1978).
Metabolite Y (Fig 10) fluoresced with a silver-grey colouration.
Its chromatographic and fluorescence properties suggest that it may have 
been 3,9-dihydroxy benzo (a) pyrene.. This is also consistent with its 
production in greater amounts during the later stages of perfusion.
The exact composition of the ‘ - monohydroxy benzo (a)pyrenes 
produced was not thoroughly investigated chromatographically. However, 
the fluorescence spectra of the mono hydroxybenzo(a)pyrenes when 
eluted into 96% ethanol closely resembled that of 3-hydroxybenzo (a) 
pyrene, suggesting that this was the principal component.
Hamster lungs produced significantly less ethyl acetate-soluble 
metabolites than rat lungs, although their capacity to convert 
benzo(a)pyrene to water-soluble products was comparable. To fully 
investigate hamster lung benzo(a)pyrene metabolism by perfusion it 
was necessary to pretreat hamsters with 3-methylcholanthrene (20 mg/
Kg in corn oil). This resulted in increased production of the ethyl 
acetate-soluble benzo(a)pyrene metabolites previously described but 
no observable increase in water-soluble metabolites. This result
suggests that in vivo, ethyl acetate-soluble metabolites are rapidly 
metabolised to water-soluble metabolites. It is possible that 
increases in binding of H^-benzo(a)pyrene to DNA in perfusions 
of lungs from 3-methylcholanthrene or cigarette smoke pretreated 
animals (Cohen et al, 1977; V&hSkangas et al, 1977; this thesis 
Chapter 6) is, in part, caused by ’desynchronisation1 of the activation 
and conjugation enzymes of drug metabolism.
The metabolism of /~5h7-Benzo(a)pyrene by short-term organ Cultures
of rat, hamster or human lung
Short-term organ cultures (16-18 h) of rat, hamster or human
lung metabolised /~^H7-benzo(a)pyrene to ethyl acetate-soluble and
water-soluble metabolites. T.l.c. analysis (using benzene ethanol 9:1 or 19:1
v/v)
showed that qualitatively similar ethyl acetate-soluble metabolites 
were produced by the three species. The major ethyl acetate soluble 
metabolites produced by hamster, rat or human lung culture cochromato­
graphed with 9,10-dihydrodiol, 7,8-dihydrodiol and metabolite Y (as 
found in perfused lungs). A major peak of radioactivity was also 
found which chromatographed at the origin in both t.l.c. systems.
Small amounts of radioactivity also cochromatographed with 4,5-dihydro- 
diol, monohydroxybenzo (a)pyrene and/or benzo(a)pyrene-quinones (Figs 
13, 18). The quantities of each metabolite(s) produced were dependent 
upon the incubation time and on the size and on’g m  of the lung 
fragment cultured (Fig 19).
Identification of Metabolite X
The major peak of radioactivity from /~^H~]— benzo(a)pyrene cultures 
with 0.5-lg of human lung, or whole lungs of rodents (0.5-lg) chromato­
graphed near to the origin in benzene:ethanol 9:1 or 19:lfv/vand was
associated with a bright blue fluorescence when viewed under u.v.
light (Fig 13, appendix 6). The bright blue fluorescence was not 
r-3 -robserved when H/-benzo(a)pyrene was incubated with smaller fragments 
of lung (150 mg) or with shorter incubations of large lung pieces, 
suggesting that it may be associated with a secondary metabolite 
of benzo(a)pyrene (X). The intensity and characteristics of the 
fluorescence excitation and emission spectra of metabolite X when 
eluted into 96% ethanol were suggestive of an intact aromatic structure, 
closely related to the parent hydrocarbon. As only small amounts of 
radioactivity cochromatographed with monohydrox.y benzo(a)pyrene, it 
seemed likely that metabolite X may be produced as a further product 
of a monohydroxy benzo (a) pyrene , probably 3-hydroxy benzo (a) pyrene •
This was confirmed when metabolite X was shown to be produced in lung 
cultures from metabolically prepared 3-hydroxybenzo(a)pyrene (G. Cohen, 
personal communication).
A comparison of the fluorescence spectral peaks of metabolite X 
(peaks at 416 and 439 nm) and 3-hydroxybenzo(a)pyrene (peaks at 434 
and 456 nm) showed that conversion of 3-hydroxybenzo(a)pyrene to 
metabolite X was associated with an hypsochromic shift. It was also 
shown that addition of alkali to metabolite X was not accompanied 
by the appearance of a phenolic ion type spectrum, characteristic of 
3-hydroxybenzo(a)pyrene and other monohydroxybenzo(a)pyrenes • Thus 
it was indicated that metabolite X was produced by metabolism, probably 
conjugation, at the hydroxyl group of 3-hydroxybenzo(a)pyrene - • The 
ethyl acetate-solubility of the metabolite suggested that the only 
likely conjugation group was sulphate. This was also indicated by 
the fluorescence spectra of metabolite X which closely resembled that
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FIGURE 13. Ethyl acetate-soluble metabolites from the medium after 18 h culture 
T W -b enzo(a)pyrene with (a) rat lung, (b) hamster lung and (c) human lung. The 
radioactive products were separated by t.l.c. in a mixture of benzene and ethanol 
(9:1 v/v) and quantified by liquid scintillation counting. SF indicates solvent 
front. Monohydroxy = Monohydroxybenzo(a)pyrene.
of a sulphate conjugate previously described by Harper (1958). The 
conversion of benzo(a)pyrene to the suspected metabolite, benzo(a) 
pyren — 3-yl-hydrogen-sulphate is shown in Fig 14. A series of 
experiments were therefore devised to establish the identity of 
metabolite X.
3 3a) The production of X from /~~ H7-3-hydroxy benzo(a)pyrene: H/-X
was found to be produced from benzo(a)pyrene by metabolism of H7-3-
hydroxy benzo(a)pyrene in lung and tracheal tissues (Cohen et al,
1976). The experiments are described in the following Chapter.
b) Chemical synthesis of Benzo(a)pyren^ 3-yl-Hydrogen Sulphate: 
Benzo(a)pyren-3-yl-hydrogen-sulphate (3-H-sulphate), the sulphate 
conjugate of 3-hydroxy benzo (a)pyrene , was chemically synthesized from 
3-hydroxybenzo(a)pyrene (prepared metabolically as described previously). 
3-Hydroxybenzo(a)pyrene was incubated with 0.3g chlorosulphonic acid
in 5 ml redistilled pyridine for 3 h at 37°C. The reaction was 
terminated with 20 ml of ice cold 1M KOH and the mixture extracted 
with 2 x 1  vol of ethyl acetate. 3-H-sulphate was purified by t.l.c.,
2 x benzene:ethanol, 4:1, v/v and 1 x ethyl acetate:hexane:acetic acid, 
75:20:5, v/v (Cohen et al, 1976). The final product chromatographed 
with an Rf of 0.15 (relative to benzo(a)pyrene) in the two chromatographic 
systems used for its purification, and near to the origin with benzene: 
ethanol, 9:1 or 19:1,v/v, similar to metabolite X. Chemically prepared 
3-H-sulphate exhibited almost identical fluorescence and emission specta 
to metabolite X (see appendix). As it proved impossible to obtain 
sufficient of metabolite X to measure its u.v. spectrum, the u.v. 
spectrum of chemically produced 3-H-sulphate was compared with the 
corrected fluorescence excitation spectrum of metabolite X.
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FIGURE 14. Formation of benzo(a)pyren -3-yl hydrogen sulphate (3-H-sulphate) 
from benzo(a)pyrene via 3-hydroxybenzo(a)pyrene.
2GG
370 40H
3G1
290
- 0.8
80
•100
240 2GO 280 300 3 GO 380
W ;iv('l('ii|;th  (nm )
FIGURE 15. U.v. spectra of 3-hydroxybenzo(a)pyrene (----- ) and synthetic benzo(a)
pyren-3-yl hydrogen sulphate (------ ) in 96% ethanol. The scale on the left hand
side and the insert refer to the synthetic metabolite.
Measurement of the corrected fluorescence spectrum of metabolite X:
The fluorescence spectrum of metabolite X was measured and corrected 
by the method of Bridges (1963 ), an adaptation of that of Parker 
(1953).
To obtain corrected fluorescence excitation spectra from the 
Perkin-Elmer LT-3 spectrofluorimeter used in these studies it was 
necessary to determine correction factors for the mercury lamp 
output and photomultiplier response over the wavelength range required 
(in this case, approximately 240-400 nm). The amount of light emitted 
from the mercury arc was determined by a chemical actinometer method. 
Potassium ferric oxalate undergoes stoichiometric photodecomposition 
by u.v. light, to potassium ferrous oxalate. Ferrous ions are simply 
determined colorimetrically after addition of phen anthroline monohydrate 
The exact procedure used for this detemination is described by Bridges 
(1963). Spectromultiplier response was calibrated from the indirect 
light using Rhodamine B to create a light scattering effect. Using 
these procedures, correction factors were determined at 10 nm intervals 
for the required range. These were then used to calculate the corrected 
fluorescence excitation spectra of metabolite X. The corrected 
fluorescence excitation spectrum of metabolite X was similar to the 
u.v. spectrum of chemically synthesized 3-H-sulphate (Fig 15). 
Furthermore, 3-H-sulphate synthesized from chemically-produced 3-hydroxy 
benzo(a)pyrene (obtained from N.I.H., Bethesda, Maryland, USA.) also 
had similar chromatographic and spectral properties to metabolite X, 
(Haws and Cohen, unpublished).
c)Acid and Enzymic hydrolysis of metabolite X : Harper (1958b)showed
that the sulphate conjugate of benzo(a)pyrene was hydrolysed by 
0.1M HC1, whereas the glucuronide conjugate required much stronger
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front.
acid for hydrolysis. Acid hydrolysis (0.1M HC1) of metabolically 
obtained X or 3-H-sulphate gave a product which cochromatographed 
(benzene:ethanol, 9:1, v/v) and had similar fluorescence excitation 
and emission spectra to 3-hydroxy benzo(a)pyrene (Cohen et al, 1976).
The identity of metabolite X as 3-H-sulphate was further confirmed 
by its hydrolysis with aryl sulphatase. [  H/-X was prepared from 
large scale cultures of [  ^ /-benzo (a) pyrene (2-200 pm) with large 
pieces of rat lung. It was then purified similarly to that described 
for other benzo(a)pyrene-metabolites using benzene:ethanol, 4:1,v/v 
and ethyl acetate:hexane:acetic acid, 70:20:5, v/v. The purified 
metabolite (40,000-60,000 cpm) was then incubated with aryl 
sulphatase containing 200 mM D-saccharic acid 1,4 lactone, ketodase 
and 0.1 Na acetate buffer, pH 5.0 only as previously described. When 
the hydrolysates were examined by t.l.c. (benzene:ethanol, 9:1, v/v),
92, 97 and 34% of the radioactivity from control, ketodase and aryl 
sulphatase incubations respectively, cochromatographed with metabolite 
X. The loss of radioactivity cochromatographing with metabolite X 
after aryl sulphatase incubation was associated with a concomitant 
increase in radioactivity cochromatographing with mono hydroxybenzo(a), 
pyrene (Fig 16). Similar hydrolysis with aryl sulphatase using un­
labelled X or 3-H-sulphate released a fluorescent product which when 
extracted from the t.l.c into 96% ethanol, exhibited the fluorescence 
spectral characteristics of 3-hydroxy benzo(a)pyrene. Incubation of X 
or 3-H-sulphate with ketodase did not release monohydroxybenzo(a)pyrene.
The 34% of radioactivity that remained after aryl sulphatase hydrolys 
of [ 3hJ~X may have been due to the presence of some other material 
than 3-H-sulphate or due to incomplete enzymic hydrolysis. This problem 
could not be resolved as it proved impractical to increase the concen-
trations of enzyme used for hydrolysis because of ’gelling' 
during extraction with ethyl acetate.
,nThe incorporation of into metabolite X: Additional proof that
metabolite X was a sulphate conjugate was obtained when it was produced 
by lung cultures in medium which contained [  sulphate.
Rat lungs (lg) were cultured essentially as described previously 
but in a medium containing unlabelled benzo(a)pyrene (20 u m) and
sodium sulphate (sp. act. 69.7 mCi/m.mole, Radiochemical Centre, 
Amersham, Bucks), 100 yCi per 10 mis. After 16 h culture, the ethyl 
acetate-soluble metabolites were extracted and chromatographed as 
previously described. A metabolite was found which cochromatographed 
and had similar fluorescence excitation and emission spectra to metabolite 
X, but when examined by liquid scintillation counting, was only associated 
with a very small number of counts. The low incorporation of radio­
activity was thought to be due to the final low specific activity of 
PhJ -sulphate in the Leibovitz L-15 - foetal calf serum medium which 
contains a high concentration of sulphate (- 2mM). To overcome this 
problem, the experiment was repeated using Dulbecco's phosphate buffered 
saline (normally used for washing the tissues prior to culture) as the 
culture medium. In this experiment, a significant amount of radioactivity 
was found to cochromatograph (benzene:ethanol, 9:1,v/v) with metabolite 
X. However, control incubations containing lungs, sodium sulphate
but no benzo(a)pyrene also incorporated radioactivity into a metabolite 
which chromatographed only slightly differently from metabolite X. In 
these control incubations, the incorporation of radioactivity was only 
40-50% of those which contained benzo(a)pyrene, and metabolite X could 
not be determined visually.or spectrofluorimetrically. The endogenous 
sulphate product and benzo (a)pyren-3-H-/”^ ^SJ/-sulphate 
conjugate were separated after a second experiment using Dulbecco’s
- 70 -
phosphate buffered saline in which the ethyl acetate-extractable 
metabolites were repeatedly chromatographed (4X) in one direction with 
benzene:ethanol, 9:1,v/v (Fig 17). In this experiment three peaks 
of phj activity were demonstrated after lung culture with 20 pM 
benzo(a)pyrene and sodium sulphate. The major of these, X,
(45-60% of the ethyl acetate soluble radioactivity) was associated 
with a product which cochromatographed and possessed the fluorescence 
excitation and emission spectra of metabolite X. A second peak of 
radioactivity, G,(8-ll% of the ethyl acetate soluble radioactivity) 
was associated with a characteristic fluorescent band which had 
benzo(a)pyrene related fluorescence excitation and emission spectra 
(see appendix). Attempts to identify G were unsuccessful, since although 
it was subsequently found as a product after [  ^ H/-benzo(a)pyrene 
experiments, it did not possess similar fluorescence spectra t o  those, of  l e n z © (& )
pyren-7-yl hydrogen sulphate or benzo(a)pyren-9-yl hydrogen sulphate.
The fluorescent products of G after acid hydrolysis were also unrecognis­
able although subsequent addition of alkali did show an observable 
phenolic ion fluorescence peak at 515 nm ( Ex 380 nm). Metabolite G 
is thus an unidentified benzo(a)pyrene sulphate conjugate. The 
remaining peak of /~^S]  activity was most probably an endogenous 
product as it was also demonstrated in the control incubations in which 
benzo(a)pyrene was omitted.
It was concluded from this series of experiments that metabolite 
X was indeed 3-H-sulphate. Benzo(a)pyrene-sulphate conjugates have 
previously been identified as 'in vivo1 products of benzo(a)pyrene 
metabolism (Harper, 1958b;Falk, 1963). This however, was the first 
identification of sulphate conjugates as an in vitro metabolite.
Recently Nemoto et al (1977) have measured the relative rates of 
sulphate conjugation of a number of benzo(a)pyrene derivatives by 
a soluble fraction of rat liver fortified with a PAPS generating 
system. Almost predictably, 3-hydroxy benzo (a)pyrene and other 
monohydroxybenzo(a)pyrenes were rapidly conjugated by this system.
These results have also demonstrated the competence of respiratory 
tissues in metabolising benzo(a)pyrene to sulphate conjugates.
The Effect of Species and Tissue size on Benzo(a)pyrene Metabolism by 
Cultured lung Tissue
In most further experiments, smaller lung pieces were cultured 
to overcome the histological damage observed with larger fragments.
This was also advantageous in being more comparable with bronchial and 
tracheal cultures in the disposition of benzo(a)pyrene after culture.
For example, after culture of lg rat lung with 2 y.M /"^H/-benzo(a) 
pyrene,54-60% of the radioactivity remained in the medium of which 
11-14% was ethyl acetate extractable whereas after 150 mg lung culture, 
25-82% remained in the medium of which 55-60% was ethyl acetate 
extractable. The latter figures compare favourably with rat or hamster 
tracheal cultures (111-124 mg) when 58-72% of the radioactivity remained 
in the medium and 22-50% was ethyl acetate-extractable.
The distribution of benzo(a)pyrene metabolites was also different 
when smaller weights of lung were cultured. 3-H-sulphate which was 
a major metabolite after lg cultures was a minor one if 200 mg were 
cultured, whereas production of monohydroxybenzo(a)pyrenes, quinones 
and most of all, dihydrodiols, was increased (Fig 18). This is more 
clearly illustrated by Fig 19 which shows the total amounts of products 
cochromatographing with 9,10-dihydrodiol and 3-H-sulphate (all
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A major proportion of the radioactivity chromatographing at the origin was associated 
with benzo(a)pyren-3-yl hydrogen sulphate.
radioactivity at the origin) after 16 h culture of 2 y,M /V- 
benzo(a)pyrene with varying weights of rat lung tissue. This difference 
presumably occurs because secondary metabolism is favoured in the 
larger lung culture. No qualitative differences were observed 
excepting that metabolite Y could not be observed when smaller tissue 
fragments were cultured. Metabolite Y was purified from large scale 
lung cultures and was found to possess similar fluorescence excitation 
and emission spectra to a suspected dihydroxybenzo (a) pyrene metabolite 
isolated from a preparative experiment using liver microsomes and 
-benzo(a)pyrene (Haws and Cohen, unpublished). The tentative 
identification of Y as a dihydroxybenzo(a)pyrene metabolite was further 
substantiated when ' Y 1 (purified from a liver experiment) was shown to 
possess a mass spectral peak of 286, characteristic of such a compound.
A quantitative difference was observed in the amount of ethyl 
acetate-extractable metbolites produced by rat and hamster lung 
cultures (Table 2). This was most marked in the metabolism of benzo(a) 
pyrene (2 p m) by 200 mg lung to benzo(a)pyrene-dihydrodiols, particularly
9,10-dihydrodiol. After .16 h culture, 6-12% of the ethyl acetate- 
soluble radioactivity cochromatographed with 9,10-dihydrodiol from 
hamster lung cultures whereas only .2-3% cochromatographed with 9,10- 
dihydrodiol from equivalent rat lung cultures. The known proximate 
carcinogen, 7,8-dihydrodiol was also found in hamster lung cultures 
(1-1.5%) to a greater extent than rat lung cultures (0.3-0.7%). The 
respective rates of synthesis of these two dihydrodiols are shown in 
Table 2• The reason for the larger amounts of dihydrodiols remaining 
in hamster lung cultures may be attributed to the relative rates of 
further metabolism in the two tissues.
Table 2
Rate of production of ethyl acetate-soluble metabolites during 18-24 
hour short-term organ culture
Tissue
Hamster trachea 
Hamster bronchi 
Hamster lungs* (200 mg) 
Rat trachea 
Rat bronchi
Rat lungs (150-250 mg)
p moles/g/min 
9,10-dihydrodiol 7,8-dihydrodiol
8.27 ± 3.9 
8.45 ± 2.91 
1.6 ± 0.5
1.59 ± 0.40 
2.29 ± 0.91 
1.1 ± 0.07
1.49 ± 0.14 
2.11 ± 0.83 
0.16 ± 0.05 
0.37 ± 0.11 
0.58 ± 0.22 
0.27 ± 0.07
All values represent mean ± S.E.M of 3 or 4 determinations. 9,10- 
dihydrodiol and 7,8-dihydrodiol were determined from the radioactivity 
cochromatographing with marker metabolites as determined by liquid 
scintillation counting as previously described. Tracheal and . •. . .
bronchial experiments were performed on all the material available 
from single animals whilst lung determinations were made using 150-250 
mgs of tissue, benzo(a)pyrene concentration = 2 pM except*
= 1 pM.
Studies on the metabolism of 9,10-dihydrodiol described in 
Chapter 5 showed it to be particularly resilient to further metabolism 
by hamster respiratory tissues.
benzo(a)pyrene, tissue size was also shown to be a major factor in 
determining the metabolite pattern; 3-H-sulphate was only a major 
metabolite when large (lg) portions of human lung were cultured. When 
smaller tissue weights were cultured (200 mg), a greater proportion 
of dihydrodiol metabolites were produced rather similarly to that 
observed with rat and hamster lung cultures.
The metabolites that accumulated within lung cultures were not 
fully investigated. However, in a single investigation, large pieces 
of lung were homogenized and extracted with ethyl acetate. The 
metabolites found were qualitatively similar to those found in the 
medium although quantitative differences may have existed.
Analysis of the Water-soluble Benzo(a)pyrene-metabolites produced by 
Cultured Hamster or Rat lung tissue
Metabolism of /~^H/-benzo(a)pyrene by rat and hamster lung cultures 
produced considerable quantities of non-ethyl acetate-extractable radip- 
active products (designated water-soluble metabolites, Table 3). 
Metabolism of /~^H/-benzo(a)pyrene to monohydroxybenzo(a)pyrene and 
quinones results in a 30% and 48% loss of tritium respectively (Osborne 
et al, 1975) and therefore is a major contributor to the formation of 
water-soluble radioactive products. However, this alone could not 
adequately explain the large quantity of water-soluble radioactivity 
found after some lung cultures, and it was presumed that polyhydroxylated 
or conjugated benzo(a)pyrene metabolites were being produced.
In similar experiments with cultured human
Table 3
The distribution of radioactivity from /~^H/-benzo(a)pyrene after 
rat and hamster lung culture after 18-hour culture
Percentage radioactivity, expressed as a fraction of initial radioactivity
Remaining associated with • Ethyl acetate Remaining in medium
tissue extractable after ethyl acetate
after culture extraction
Hamster ^ 34.0 ± 2.1 45.8 ± 1.9 20.0 ± 2.0
Rat <2> 25.6 ± 2.6 38.3 ± 4.6 36.4 ± 2.8
(1) Hamster lungs (180-200 mg, n = 4) cultured with 1 jj.m /V 
benzo(a)pyrene.
(2) Rat lungs (130-220 mg, n = 4) cultured with 2 /~^h/  benzo(a)
pyrene.
Figures are expressed as mean iS.E.M.
To investigate the possible presence of glucuronide conjugates,
3-glucuronidase was incubated with samples of the ethyl acetate- 
extracted medium remaining after hamster lung cultures. The samples 
were incubated with 3-glucuronidase and then extracted with ethyl 
acetate as described in Chapter 3. The extract was then chromato­
graphed in benzene:ethanol,9:1 v/v or 19:1,v/v. A typical t.l.c. 
pattern of ethyl acetate-soluble radioactive metabolites released by 
hydrolysis with 3-glucuronidase or acetate is shown in Fig 20 . The 
major radioactivity peak after 3-glucuronidase incubation cochromato­
graphed with monohydroxybenzo(a)pyrene ; smaller peaks also cochromato­
graphed with 7,8-dihydrodiol and 4,5-dihydrodiol. Radioactivity peaks 
that cochromatographed with quinones and the parent hydrocarbon were 
observed from hydrolyses with 3-glucuronidase or acetate buffer only.
The benzo(a)pyrene-quinone product probably consisted mainly of 
benzo(a)pyrene-3,6-quinone formed spontaneously from 3-hydroxybenzo(a)• 
pyrene or its conjugated matabolites. The pH (5.0) of the control and 
enzymic incubations may have assisted in the breakdown of the 3- 
hydroxybenzo(a)pyrene derivatives. The radioactivity that cochromato­
graphed with benzo(a)pyrene probably remained from incomplete extraction 
of the parent hydrocarbon during the first series of extractions, and 
in subsequent experiments extra ethyl acetate extractions were performed 
to overcome this problem. The absence of radioactivity cochromatographing 
with 9,10-dihydrodiol is in complete contrast to the ethyl acetate 
soluble radioactive metabolites produced by hamster lung culture 
(Fig 17). This reflects the inability of hamster lung to metabolise
9,10-dihydrodiol to water-soluble glucuronide conjugates. However, the 
radioactivity peak (Z) in Fig 20 may have been associated with a further
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FIGURE 20. Enzymic hydrolysis of water-soluble metabolites after short-term 
hamster lung culture witfyf 3H7“benzo(a)pyrene. Water-soluble metabolites after 
16 h short-term organ culture with [ 3H/-benzo(a)pyrene (2 yM) were hydrolysed
with 3-glucuronidase (— --- ) or acetate buffer (------ ). The ethyl acetate
extractable radioactivity from these hydrolyses was separated by t.l.c. in a mixture 
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metabolite of 9,10-dihydrodiol, 1(3),9,10-trihydro-9,10-dihydro 
benzo(a)pyrene (Thakker et al, 1978). Since this metabolite was not 
observed as an ethyl acetate-soluble metabolite it must, presumably, 
be conjugated to form a glucuronide extremely rapidly.
The glucuronide conjugates hydrolysed by 8-glucuronidase appear 
to be an inverse image of the ethyl acetate-soluble metabolites 
(Figs 18, 20) . The .absence or presence of small amounts of monohydroxy-* 
benzo(a)pyrene and 4,5-dihydrodiol produced as ethyl acetate-soluble 
metabolites, were mirrored by their appearance as conjugated metabolites. 
The observed metabolites were probably benzo(a)pyrene-glucuronides 
since although 8-glucuronidase contains traces of sulphatase activity, 
sulphate conjugates are unlikely as they would have been removed at 
the first ethyl acetate-extractions (Cohen et al, 1976; Nemoto et al, 
1977). Nemoto and Gelboin (1976) used rat liver microsomes fortified 
with UDP-glucuronic acid to measure the relative rates of glucuronide 
conjugation of a number of benzo(a)pyrene metabolites. They measured 
rapid rates of conjugation for metabolically produced monohydroxy- 
benzo(a)pyrenes, an intermediate rate of conjugation for 4,5-dihydrodiol, 
and slow rates of conjugation for 7,8 and 9,10-dihydrodiols which are 
all in agreement with the present study. Thus, the specificity of 
rat liver and hamster lung glucuronyl transferases are remarkably 
similar.
Unfortunately there was insufficient time to investigate the 
water-soluble radioactive products remaining from these organ cultures 
or other types of conjugates such as those of glutathione. However, 
other investigators have shown them to be produced from benzo(a)pyrene 
by perfused rodent lung (Smith,et al, 1978)
The Metabolism of [  3h7~Benzo (a)pyrene by Short:-term ' Cultures. of 
Rat and Hamster Bronchus and Trachea
Short-term organ cultures of rat or hamster bronchus and trachea 
metabolised /~^H/-benzo(a)pyrene (2 pH) to ethyl acetate-soluble and 
water-soluble metabolites. The major ethyl acetate-soluble radioactive 
products cochromatographed with 7,8-dihydrodiol and 9,10-dihydrodiol 
but little or no radioactivity cochromatographed with monohydroxybenzo(a) 
pyrene or 4,5-dihydrodiol. Table 2 shows the rate of production of 7,8- 
dihydrodiol and 9,10-dihydrodiol by cultures of single trachea and 
bronchii equivalent to one rat or hamster. The rates of production are 
similar in both tissues and thus, because of the technical difficulties 
associated with the bronchial cultures, further investigations were 
concentrated on tracheal metabolism.
The initial species differences observed in the rates of production 
of 7,8-dihydrodiol and 9,10-dihydrodiol by rat and hamster tracheal 
cultures (Table 2, Cohen and Moore, 1976) were confirmed using larger 
weights of rat and hamster tracheal tissue (111-126 mg) and benzo(a) 
pyrene (2 p m ) . These experiments also showed the production of smaller 
amounts of metabolites which cochromatographed with monohydrox)benzo(a) 
pyrene, 4,5-dihydrodiol and near to the origin in benzene:ethanol, 9:1 and 
19:1,v/v (Fig 21). The increased production of metabolites also 
enabled the positive identification of 7,8-dihydrodiol, 9,10-dihydrodiol 
and 3-H-sulphate from their characteristic fluorescence excitation and 
emission spectra when eluted into 96% ethanol.
The pattern of metabolites produced by the larger weights of 
cultured trachea was very similar to 200 mg lung cultures from the 
same species. The large amounts of 9,10-dihydrodiol produced by 
200 mg hamster lung cultures was also found with hamster tracheal cultures.
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This feature was reflected by the ratio of 9,10-dihydrodiol to
7.8-dihydrodiol, which was 8.6:1 for lung and 6.8:1 for trachea.
This excess of 9,10-dihydrodiol, a characteristic of hamster respiratory 
tissue metabolism of benzo(a)pyrene was not a feature when, the metabolism 
of £^w]-benzo(a)pyrene by adult hamster hepatocytes was examined,
(Jones and Moore, unpublished observations).
The species differences observed in the rates of production of
7.8- and 9,10-dihydrodiols previously observed using a single cultured 
trachea (Cohen and Moore, 1976) were accentuated when larger weights 
of trachea were cultured. The rates of production of 7,8-dihydrodiol 
were 0.37 and 0.74 (p moles/g trachea/min) for rat and hamster trachea 
respectively, and 0.44 and 5.0 for 9,10-dihydrodiol.
In addition to the identified metabolites, the radioactive peak 
chromatographing near to the origin was split into two,indicating 
there may be at least one unidentified product. It is also probable 
that at least part of the radioactivity chromatographing in the mono­
hydroxy benzo(a)pyrene region was associated with quinones since 3- 
hydroxybenzo(a)pyrene or any other monohydroxybenzo(a)pyrene could 
not be detected fluorimetrically. Benzo(a)pyrene-quinones may tend to 
accumulate in culture since they do not conjugate with glucuronic acid 
(Nemoto and Gelboin, 1976).
Mass and Kaufman (1979) recently described hamster tracheal 
experiments with benzo(a)pyrene similar to those described here except 
with the use of h.p.l.c. The pattern of ethyl acetate soluble metabolites 
obtained after 24 h culture was essentially the same as that described 
here except that these authors were also able to identify various 
benzo(a)pyrene-7,8,9,10-tetrahydrotetrols. These authors also describe
a method for the preparation of tracheal microsomes and compared 
their metabolism against that of the organ cultures. Tracheal 
microsomes produced much larger amounts of benzo(a)pyrene quinones 
(1,6-quinone, 3,6-quinone and 6,12-quinone) and monohydroxybenzo(a) 
pyrenes (3 and 9) than dihydrodiols. The discrepancy was attributed 
to the lack of conjugating enzymes in microsomes. Low levels of 
m o n o h y d r o xybenzo(a)pyrenes are a common occurrence when tissues or 
whole cells are incubated with benzo(a)pyrene, presumably because of 
their high rate of glucuronide conjugation (Vadi et al, 1975; Cohen 
and Moore, 1976; Cohen et al, 1976; DePierre and Ernster, 1978). The 
increased amounts of cultured trachea also produced measurable quantities 
of water-soluble benzo(a)pyrene metabolites (22-37% of the administerd 
radioactivity). It was necessary to use repeated extractions with 
ethyl acetate (up to 6 times as detailed in Chapter 3), to obtain a 
sufficiently low background of /~^H/-benzo(a)pyrene to allow successful 
analysis of the water-soluble metabolites by enzymic hydrolysis. 
Hydrolysis, with ketodase, aryl sulphatase and acetate buffer released 
34-41%, 34-35% and 4.0-4.5% of the water soluble radioactivity to ethyl 
acetate-extractable products respectively. These were then analysed by*', 
t.l.c. using benzene:ethanol, 9:1,v/v as previously described. The 
use of a t.l.c. radioscanner enabled more precise separation and location 
of the radioactive products than liquid scintillation counting (Fig 22) . 
There were at least five major radioactive bands released by ketodase 
and aryl sulphatase, and two with acetate buffer. The material 
associated with the radioactivity near the origin after ketodase treat­
ment (peak A) is unknown but probably contains polar polyhydroxylated 
metabolites (i.e. more polar than 7,8,9,10-tetrahydrotetrol) because 
chromatography in a more polar solvent (chloroform-methanol,.4:1 v/v) 
failed to elute It from the origin. Peak F, which chromatographs near
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to the origin after, hydrolysis with aryl sulphatase, was associated 
with a blue fluorescent material when observed under u.v. light.
This material, when eluted into 96$ ethanol, exhibited fluorescence 
excitation and emission spectra very similar to that described by 
Baird et al (1977) for the glucuronic acid conjugate of 3-hydroxy 
benzo(a)pyrene (see appendix). It is unlikely that any glucuronic acid 
conjugates remained in the ethyl acetate extracts after ketodase 
treatment, but the presence of other benzo(a)pyrene conjugates associated 
with protein ’carry over*, must be considered as a possibility.
Peaks B and G, from ketodase and aryl sulphatase hydrolyses respectively 
cochromatographed with 1(3),9,10-trihydroxy-9,10-dihydrobenzo(a)pyrene. This 
identity was confirmed from the ketodase hydrolysis when the material 
associated with peak B was examined fluorimetrically and found to 
exhibit the characteristic spectra of 1(3),9,10-tri-hydroxy-9,10-di­
hydro benzo(a)pyrene. The appearance of this material as a conjugated 
metabolite is in agreement with the route of metabolism of 9,10-dihydro- 
diol to 1(3),9,10-trihydroxy-9,10-dihydro benzo(a)pyrene-glucuronide 
found with purified A7- 9,10-dihydrodiol described in the following 
Chapter. The absence of 7,8-dihydrodiol as a glucuronide conjugate is 
in contrast with the findings with purified /~^h/-7,8-dihydrodiol.
This may have been because the low rate of glucuronide conjugation of
7,8-dihydrodiol (Nemoto and Gelboin, 1976) produced insufficient 
metabolite to enable detection or that further metabolism of 7,8- 
dihydrodiol formed ’in situ’ occurs by oxidative routes rather than 
conjugation. More sensitive detection methods such as h.p.l.c. are 
required to resolve this rather important point. However, material 
was detected that cochromatographed with 4,5-dihydrodiol from both. . 
ketodase (peak C) and aryl sulphatase (peak J) treatments.
Peaks D, K and M cochromatographed with monohydroxybenzo(a) 
pyrene and quinones. Much more radioactivity was released by 
ketodase that cochromatographed with monohydroxybenzo(a)pyrene 
than by aryl sulphatase or acetate buffer. The material that cochromato­
graphed with monohydroxybenzo(a)pyrene . after ketodase treatment (peak 
D) exhibited a fluorescence excitation and emission spectra (peaks 
at 271, (299), 310, 363, 380 and 400 nm, Em = 434 nm and 434, 456 nm,
Ex =380 nm respectively) which was almost identical to that of 
authentic 3-hydroxy benzo(a)pyrene. These, or other fluorescence 
spectra could not be detected when the material(s) associated with 
peaks . dand ^ from aryl sulphatase and acetate buffer treatments, 
were examined. This suggests that the radioactivity associated with 
these two peaks was associated with benzo(a)pyrene-quinones. The 
remaining peaks, E, L and N were roughly of equal size and were associated 
with small quantities of benzo(a)pyrene carried over from the initial 
incubation.
It was concluded from these results that the major water-soluble 
metabolites were the glucuronide conjugates of 3-hydrox>benzo (a)pyrene 
and 1(3),9,10-trihydroxy-9,10-dihydrobenzo(a)pyrene with smaller amount's 
of the glucuronide of 4,5-dihydrodiol. 34-41% of the water-soluble 
radioactive metabolites was identified as glucuronide conjugates. The 
major radioactive metabolite from the aryl sulphatase was also a glucuron­
ide conjugate and therefore 59-66% of the water-soluble radioactive 
products remain unidentified. As previously discussed for the water- 
soluble benzo(a)pyrene products produced by lung, a proportion of this 
is likely to be tritiated water released by the mechanic.sof the 
oxidative metabolism of benzo(a)pyrene to monohydroxybenzo(a)pyrenes and
quinones. This, however, is unlikely to account for all the 
remaining radioactivity and therefore, the presence of other products, 
particularly glutathione conjugates, is a possibility. Unfortunately, 
there was insufficient time and material to investigate this 
possibility.
Kinoshita and Gelboin (1978) have recently shown that hydrolysis of 
benzo(a)pyrene-3-glucuronide with B-glucuronidase, generates intermediates 
which covalently bind to DNA. Thus it is possible that the generation 
of benzo’(a)pyrene-3-glucuronide by lung and trachea as shown in these 
investigations may have some significance in the biological activity 
of benzo(a)pyrene. In the present investigations, protein binding by 
a similar mechanism as the DNA binding of Kinoshita and Gelboin's 
experiments, may be a factor contributing to the underestimation of 
glucuronide conjugation.
These results have shown that lung and trachea metabolise 
benzo(a)pyrene to a wide variety of oxidative and conjugated metabolites.
A summary of the identified metabolic products produced by lung and 
trachea is outlined in Fig 24.
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The Measurement of Induced Benzo(a)pyrene Metabolism by Short-term 
organ culture of Rat lung
Pretreatment of rats with 3-methylcholanthrene has been shown 
to induce the microsomal metabolism of benzo(a)pyrene (Nebert and 
Gelboin, 1969). This and cigarette smoke, have also been shown to 
increase the metabolism and covalent binding of /~^u/-benzo(a)pyrene 
when perfused into isolated rat lungs (Cohen et al, 1977; V^hakangas 
et al, 1977). 3-Methylcholanthrene pretreatment has also been shown 
to increase aryl hydrocarbon hydroxylase in hamster lung although in 
this case, the induced enzyme is believed to be more like uninduced 
liver P-450 rather than aP-448 type of enzyme (Burke and Prough, 1976).
It was of interest to demonstrate induction of benzo(a)pyrene 
metabolism in culture in order to ascertain if the previously observed 
metabolism was representative of control, or self-induced'benzo(a) 
pyrene metabolism. In order to investigate this possibility, lungs .from 
male hamsters pretreated for.3 days prior to sacrifice with 3-methyl- 
cholanthrene (20 mg/kg) were cultured (200 mg portions) with /V- 
benzo(a)pyrene and the resultant metabolism compared against that of 
control animals. Fig 23 shows the accumulative production of 9,10- 
dihydrodiol in cultures of lungs from 3-methylcholanthrene pretreated 
and control animals. An increased production of 9,10-dihydrodiol (and 
other benzo(a)pyrene metabolites) was only observed during the first few 
hours of culture in the pretreated lungs. The distribution of 
metabolites was also not significantly different between the control and 
pretreated animals. Thus, although induced benzo(a)pyrene metabolism 
was demonstrable in early stages of lung culture, factors concerned 
with the maintenance of the tissue in culture become overbearing after 
only a few hours. This could be for a variety of reasons, for example:
A '
Time, hr
FIGURE 23. Cumulative production of 9,10-dihydro-9,10-dihydroxybenzo(a)pyrene 
(9,10-dihydrodiol) from benzo(a)pyrene during short-term organ cultures of lung
(200 mg) from control ( a  a  ) and 3-methylcholanthrene pretreated hamsters (a----------------a)
Benzo(a)pyrene (2 pM) was cultured with lung samples for the times indicated and 
the amounts of 9,10-dihydro 9,10-dihydroxybenzo(a)pyrene determined by t.l.c.
(using benzene:ethanol, 9:1, v/v) and liquid scintillation counting. There were 
no significant differences in the amounts of water-soluble metabolites produced 
by control or 3-methylcholanthrene treated animals.
(i) product inhibition resulting from the production of a certain 
level of benzo(a)pyrene metabolites by control and 3-methylcholanthrene 
pretreated lungs,
(ii) cytochromeP-450 induction is marked by an even greater increase 
in water-soluble metabolites which was not thoroughly investigated,
(iii) the inherent mixed function oxidase of the control lung is 
rapidly induced by the concentrations of benzo(a)pyrene in culture,
(iv) the mixed function oxidases of control and induced lungs 
deteriorate in culture, similarly to that which occurs when many cells 
are cultured. This may be complicated because it may require a 
considerable time for metabolites to diffuse to the innermost parts of 
the tissue.
To investigate if factors (iii) or (iv) were important, the aryl 
hydrocarbon hydroxylase was determined in portions of lungs which had 
previously been cultured for various periods of time. The fluorescence 
method of Nebert and Gelboin (1968) was employed for this measurement. 
Although the assay as used was almost at its limits of sensitivity, 
induced benzo(a)pyrene metabolism was demonstrated in uncultured lungs 
and lungs cultured for short p e r i o d s  from pretreated rats. However, v 
lungs from both control and 3-methylcholanthrene pretreated rats that 
were cultured for longer periods of time(^ 6 hours) had little or no 
demonstrable benzo(a)pyrene metabolism. This result was later confirmed 
(Haws and Cohen, unpublished) using a more sensitive aryl hydrocarbon 
hydroxylase assay.
The results indicate that the culture methods used may underestimate 
the 'in vivo1 metabolism of benzo(a)pyrene. Therefore, quantitative 
estimations of the rate of production of metabolites in culture should 
be used only as a crude guide.
Discussion
These results h&ve demonstrated that /~^H/-benzo(a)pyrene is 
metabolised to a wide variety of ethyl acetate-soluble and water-soluble 
metabolites, these are summarized in Fig 24. The metabolites produced 
by.. /~^H/-benzo(a)pyrene by cultured and perfused lungs were qualitatively 
similar although there were some discrepancies in the ratio of individual 
metabolites produced by the different metabolising systems. It is 
probable that the observed differences were related to the conditions 
under which each study was made. For example, larger amounts of benzo(a) 
pyrene-quinones produced in perfused lungs may have been caused by 
excess non-enzymic air oxidation. Other differences such as the production 
of 3-11-sulphate were obviously related to the duration of incubation 
and size of cultured tissue.
The use of h.p.l.c. analysis would have enabled a much better 
resolution of benzo(a)pyrene metabolites had it been available. This 
would have been particularly useful in ascertaining if monohydroxy 
benzo(a)pyrene and 4,5-dihydrodiol were produced at low concentrations 
as ethyl acetate-soluble metabolites. It would also have enabled the 
analysis of different monohydroxy benzo(a)pyrenes more efficiently, 
than in the present study. If used in combination with enzymic hydrolysis, 
h.p.l.c. may have enabled the resolution of more conjugated metabolites.
It is possible that h.p.l.c. may have enabled the identification of the 
glucuronide conjugate of 7,8-dihydrodiol which was not clearly 
demonstrated by t.l.c.
The metabolising systems chosen for this study, perfusion and organ 
cultures have produced many diverse metabolites including important 
conjugates. These metabolites have also been of interest to other 
workers in view of the fact that it is possible they may reduce the
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effectiveness of benzo(a)pyrene as a carcinogen. Nemoto and 
Takayama (1977a) have demonstrated that the microsomal metabolism 
of benzo(a)pyrene can be modified by the addition of alternative 
cofactors required for conjugation with glucuronic acid which in fact 
occurs in vivo and in the'present metabolising systems. Thus, it 
is not surprising that glucuronides were detected in the organ culture 
system. It is possible that had they been investigated, glutathione 
conjugates would also have been detected as they recently were by Smith 
et al (1978) using perfused rabbit lung.
These experiments have shown the metabolism of benzo(a)pyrene to 
be very complex. In order to reduce this complexity, the metabolism 
of individual benzo(a)pyrene metabolites was investigated and is described 
in the following Chapter. These investigations, together with those 
of the following Chapter allowed much more satisfactory conclusions 
to be reached.
Chapter 5
Studies on the Metabolism of Purified Benzo(a)pyrene- 
metabolites by Short-term Organ Cultures of Respiratory
Tissues
Chapter 5
Preparation of /~3H/-benzo(a)pyrene metabolites
Purified /"^/-benzo (a)pyrene metabolites were prepared as 
described previously in Chapter 3.
The Metabolism of /~^Ij7-3-Hydroxybenzo(a)pyrene by Short-term Organ 
Cultures of Rat, Hamster and Human Respiratory Tissues
3-Hydroxybenzo(a)pyrene is the major monohydroxybenzo(a)pyrene 
produced from benzo(a)pyrene by metabolism in respiratory tissues. 
Monohydroxybenzo(a)pyrenes are believed to be produced by spontaneous 
breakdown of epoxide intermediates. In many cases, the precursor 
epoxides have been chemically synthesized and the breakdown steps 
observed. However, it appears that the precursor epoxide for 3- 
hydroxybenzo(a)pyrene, benzo(a)pyrene-2,3-epoxide, is extremely unstable 
and has yet to be synthesized. Indirect evidence that some 3-hydroxy- 
benzo(a)pyrene is produced via this intermediate has recently been dis­
closed by Yang et al (1977d). However, this route of metabolism may 
not entirely account for the large fraction of 3-hydroxybenzo(a)pyrene 
produced in most metabolising systems (generally 30-40% of total 
oxidative metabolism) and a proportion at least may be produced by 
direct insertion of a hydroxyl group.
Monohydroxybenzo(a)pyrenes have been shown to undergo extensive 
further metabolism to oxidative and conjugated metabolites. It 
has been claimed that further oxidative metabolism of 3-hydroxy­
benzo (a)pyrene can lead to DNA binding (Capdevila et al, 1975) but 
this may be due to the presence of 9-hydroxybenzo(a)pyrene as an 
impurity in the 3-hydroxybenzo(a)pyrene preparation. Most further 
metabolism of 3-hydroxybenzo(a)pyrene in intact cells and tissues occurs 
by glucuronidation or sulphation. Nemoto and Gelboin (1976), Nemoto
et al (1977) and Nemoto and Takayama (1977b) have shown that 
3-hydroxybenzo(a)pyrene (and other metabolically produced monohydroxy- 
benzo(a)pyrenes) are more rapidly conjugated to form glucuronidated 
or sulphated products than any other benzo(a)pyrene metabolites.
The Metabolism of /~^Ii/-3-Hydroxybenzofalnvrene by Rat, Hamster and 
Human Lung Cultures: Short.-term organ cultures of rat, hamster of 
human lung metabolised purified 3-hydroxybenzo(a)pyrene
(prepared metabolically from benzo(a)pyrene; contaminated with 
approximately 10% /"3H/-9-hydroxybenzo(a)pyrene' to <bthyr*acetate soluble 
and water-soluble metabolites. Figure 25 shows the ethyl acetate- 
soluble metabolite pattern from a lg lung culture of human lung (16 h) 
with /"3H/-3 -hydroxybenzo(a)pyrene. Similar metabolite patterns were 
obtained if similarly sized fragments of lung from rats or hamsters were 
cultured. The major radioactive peak, X, (62% of the ethyl acetate- 
soluble radioactivity) was associated with a product which cochromato­
graphed in three solvent mixtures (benzene:ethanol, 4:1, 9:1 and 19:1), 
and had similar fluorescence excitation and emission spectra to chemically 
prepared 3-H-sulphate. The amount of metabolism of 3-hydroxyberizo(a) 
pyrene was approximately proportional to the size of the tissue fragment 
cultured. For example, when larger tissue weights were used (Fig 25) 
very little of the radioactivity cochromatographed with the starting 
material whereas 61-69% of the ethyl acetate-soluble radioactivity 
cochromatographed with it after culture with 200 mg lung. The small 
amounts of radioactivity that did cochromatograph in the monohydroxy­
benzo (a)pyrene region after culture with large lung fragments, was 
probably mainly associated with benzo(a)pyrene-quinones as radioactivity 
did not precisely cochromatograph with carrier 3-hydroxybenzo(a)pyrene. .
- / / -
VA
Benzo(a)pyren -3-yl 3 - hydroxybenzo(a)pyrene
hydrogen sulphate
FIGURE 25. Ethyl acetate-soluble metabolites from the medium after 16 h culture 
of human lung (1 g) with [  3H7-3-hydroxybenzo(a)pyrene (0.2 yM) . The radioactive 
products were separated by t.I.e. in a mixture of benzene and ethanol (4:1, v/v) 
and quantified by liquid scintillation counting. SF indicates solvent front. ■
[ 3H7-3hydroxybenzo(a)pyrene and lung (------ ), A 3H/-3-hydroxybenzo(a)pyrene without
lung (------). Radioactivity is expressed as a fraction of the total radioactivity
on the t.l.c. plate.
Quinones may have been produced metabolically by the.cultured lung 
or by air oxidation. However, it is also possible that some benzo(a) 
pyrene-quinones may have been contaminants of the starting material 
as a result of their poor separation from 3-hydroxybenzo(a)pyrene in 
the t.l.c. systems, used for its purification, or, due to air oxidation 
during purification. Benzo(a)pyrene-quinones are effectively 
concentrated in culture because they cannot undergo glucuronide 
conjugation unless they are first reduced to phenols (Nemoto and Gelboin, 
1976; Lind et al,1978) .
Additional information confirming the identity of 3-H-sulphate was 
obtained when was cultured with rat lungs (I g) and 3-hydroxy
benzo(a)pyrene. The 3-H-sulphate obtained from this experiment was 
associated with /~33s/-radioactivity similarly to that described 
previously when it was found to be formed from benzo(a)pyrene by rat 
lung culture.
The theory that sulphation is a general route of monohydroxy­
benzo (a)pyrene metabolism was investigated using rat lung cultures. 7-
3
Hydroxybenzo(a)pyrene and 9-hydroxybenzo(a)pyrene (unlabelled and H- 
labelled) were prepared by acid hydrolyses of 7,8-dihydrodiol and 9,10-
3
dihydrodiol (unlabelled or H-labelled; prepared as described in 
Chapter 3) and used for similar experiments as those described herein 
with 3-hydroxjyLebzo(a)pyrene. 7-Hydroxybenzo(a)pyrene and 9-hydroxy­
benzo (a) pyrene were metabolised by rat lung cultures to benzo(a)pyren- 
7-yl-hydrogen sulphate and benzo(a)pyren-9-yl-hydrogen sulphate 
respectively ( Cohen et al, 1977a). /r3H/-Benzo(a)pyren-7-
y1-hydrogen sulphate and /~3H/-benzo(a)pyren-9-yl-hydrogen sulphate 
were hydrolysed by aryl sulphatase but not by ketodase to the respective
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monohydroxybenzo(a)pyrenes (Cohen et al, 1977a). The fluorescence 
excitation and emission spectra of these two sulphates were examined 
(appendix) and found to be dissimilar to the unidentified sulphated 
metabolite produced from benzo(a)pyrene (Chapter 4). The production 
of benzo(a)pyren-7-yl and 9-yl-hydrogen sulphates has recently been 
demonstrated by Nemoto et al (1977) from their respective monohydroxybenzo 
(a)pyrene precursors using a high speed supernatant fraction from rat 
liver portified with ATP and /"33s/-Na2S0^. However, their findings 
that benzo(a)pyrene dihydrodiols can form sulphate conjugates is not 
in agreement with any of the present studies using rat or hamster short­
term respiratory tissue cultures.
A much higher proportion of radioactivity remained in the medium 
(76-90%) after short-term organ cultures of 200 mg portions of hamster 
lung with /"3Il7-3-hydroxybenzo(a)pyrene (1 yM). However, as only 
approximately 16% of the total radioactivity was extractable by ethyl 
acetate, the major proportion of this radioactivity was associated with 
water-soluble products. The composition of the water-soluble products 
was examined by t.l.c. of the ethyl acetate extractable products aftei* 
hydrolysis with 8-glucuronidase or acetate buffer. A single radioactive 
peak, significantly larger than that of control incubations, was 
released by 8-glucuronidase which cochromatographed with monohydroxy­
benzo (a)pyrene, benzo(a)pyrene and benzo(a)pyrene quinones. The appearance 
of a small radioactive peak which cochromatographed with benzo(a) 
pyrene-quinones is in agreement with experiments previously discussed 
using benzo(a)pyrene in lung culture, and may be related to the instability 
of benzo(a)pyrene-3-0-glucuronide in acetate buffer. Insufficient radio­
activity remained after the experimental procedures described to enable 
further characterisation of the water-soluble radioactive material.
The Metabolism of [^\\]-3-Hydroxybenzo (a)pyrene by Rat and Hamster 
Tracheal Cultures: Short-term organ cultures of hamster or rat trachea
(44-52 and 121-167 mg respectively) metabolised H./-3-hydroxy- 
benzo(a)pyrene (1.0-3.0 yM) to ethyl acetate-soluble and water- 
soluble metabolites. Similar amounts of radioactivity remained in 
the medium (69.1-78.2%) to that remaining after short-term organ 
culture with 200 mg portions of lung tissue. However, a high proportion 
of the radioactivity was ethyl acetate extractable (25-45%) which was 
related to the smaller amounts of tissue. Analysis of the ethyl acetate- 
soluble radioactive products by t.l.c. using benzene:ethanol (9:1 or 
19:1, v/v) showed there to be two major bands of radioactivity 
(Fig 26). The material associated with the larger of these bands (65- 
87%) cochromatographed with 3-hydroxybenzo(a)pyrene . The material 
associated with the smaller of the radioactive bands (1-7%), cochromato­
graphed, and when eluted with 96% ethanol, exhibited the fluorescence 
excitation and emission spectra of 3-H-sulphate. Similar rates of 
production of 3-H-sulphate were observed from cultured hamster or rat 
trachea (3.7 and 2.9 p moles/min/g respectively). The only other ethyl 
acetate extractable radioactive material observed in these cultures was 
benzo(a)pyrene-3,6-quinone which was tentatively identified from its 
red colouration and chromatographic properties. However, similar 
amounts of this material were also produced in control cultures suggesting 
that it was a product of air oxidation rather than a metabolite.
Slightly more of the total radioactive material was metabolised 
to water-soluble metabolites by rat tracheal cultures (45.5 * 3.0%) than 
by hamster tracheal cultures (33.8 1 3.5%). However it could not be 
ascertained from these results whether this was because of a species
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FIGURE 26. Ethyl acetate-soluble metabolites from the culture medium after 16 h 
short-term organ culture of rat trachea (91-124 mg) with [  ^ WJ-3-hydroxybenzo (a) 
pyrene (2 yM) . The radioactive products were separated by t.l.c. in a mixture of 
benzene and ethanol (9:1, v/v) and quantified by liquid scintillation counting.
SF indicates solvent front. 3-hydroxy = 3-hydroxybenzo(a)pyrene.
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FIGURE 27. Enzymic hydrolysis of water-soluble metabolites after short-term 
hamster tracheal culture with /~ 3h /-3-hydroxybenzo (a)pyrene. The water-soluble
radioactive products after 16 h culture were hydrolysed with ketodase (------ )
or aryl sulphatase (------) and the ethyl acetate-soluble radioactive products
released separated by t.l.c. using benzene:ethanol (9:1, v/v). Ketodase released 
61% of the water-soluble products to ethyl acetate-soluble products. The 
radioactive ,band at the origin after aryl sulphatase treatment was associated with 
a blue fluorescent product which was identified as benzo(a)pyrene-3-0-glucuronide 
(Baird et al, 1977). SF indicates solvent front. 3-hydroxy =
3-hydroxybenzo(a)pyrene.
difference or due to the slightly differing weights of tissue used.
Hydrolysis of the water-soluble radioactivity remaining from rat 
or hamster tracheal cultures with ketodase, released approximately 61% 
to ethyl acetate extractable components, the majority of which 
cochromatographed with 3-hydroxybenzo(a)pyrene in benzene:ethanol,
9:1 or 19:1,v/v, Fig 27). Larger amounts of radioactivity which 
cochromatographed with 3-hydroxybenzo(a)pyrene were released from the 
water-soluble radioactivity of rat cultures than hamster cultures.
This reflected the larger weights of rat tissue used. The levels of 
benzo(a)pyrene-3-0-glucuronide were however, underestimated because a 
significant amount of radioactive material also cochromatographed with 
quinones, particularly from hamster experiments. Since benzo(a)pyrene- 
quinones would have been extracted during the first extractions, and as 
they are not substrates for UDP-glucuronyl transferase, it is probable that 
they arose spontaneously from benzo(a)pyrene-3-0-glucuronide during 
deconjugation. As expected, only very small amounts of radioactivity 
cochromatographed with 3-hydroxybenzo(a)pyrene or quinones after 
incubation of the rat or hamster water-soluble tracheal metabolites with 
aryl sulphatase. Instead, a large peak of radioactivity was found 
near the origin which was associated with a bright blue fluorescence 
when viewed under u.v. light (Fig 27). The material associated with this 
radioactivity was found to be much more polar than benzo(a)pyrene-sulphate 
conjugates as it could not be eluted from the origin even when 
chromatographed in chloroform:methanol, 4:1, v/v. When eluted into 
96% ethanol, this material exhibited fluorescence excitation and emission 
spectra which were very similar to that described by Baird et al (1977) 
for benzo(a)pyrene-3-0-glucuronide (appendix). It was concluded that the
high concentrations of protein in the aryl sulphatase incubates had 
interacted with the benzo(a)pyrene-3-0-glucuronide in such a way, 
as to render it ethyl acetate extractable.
The 39% of water-soluble radioactivity remaining after hydrolysis 
with ketodase was not investigated. However, a small proportion of this 
radioactivity would have been associated with /"^h Z - ^ O , resulting 
from the conversion of 3-hydroxybenzo(a)pyrene to quinones.
These results with cultured trachea and lung indicate the further 
hydroxylation of 3-hydroxybenzo(a)pyrene (and 7 and 9-hydroxybenzo(a) 
pyrenes) be relatively unimportant, whereas conjugation to glucuronide 
and sulphate are major routes of metabolism. However, small amounts of 
a suspected dihydroxybenzo(a)pyrene metabolite (Y) were produced from 
benzo(a)pyrene in 1 g lung cultures and rat lung perfusions (Chapter 4) 
in contrast to these results. This may be attributed to the fact that 
that the mono hydroxybenzo (a) pyrene precursors of the dihydroxy
metabolite, when produced from benzo(a)pyrene, are already present at the 
site of metabolism, the mixed function monooxygenases, immediately after 
synthesis. They are therefore more likely to undergo oxidative metabolism 
than a compound randomly approaching the microsomal membranes.
Further oxidative metabolism of a metabolica.lly prepared mono­
hydroxy benzo (a) pyrene mixture, containing both 3 and 9-hydroxybenzo(a) 
pyrene has been shown to cause binding to DNA (Capdevila et al, 1975).
The exact mechanism by which this is mediated is unknown but may be 
because of epoxidation at the 4-5 position of 9-hydroxybenzo(a)pyrene 
(King et al, 1976) or possibly an equivalent reaction
with 3-hydroxybenzo(a)pyrene.
An experiment performed to investigate the rat liver microsomal 
metabolism of 3-hydroxybenzo(a)pyrene illustrated the diversity with
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FIGURE 28. Thin layer radioscan of ethyl acetate-soluble radioactivity after 
incubation of [_ ^H7“3-hydroxybenzo(a)pyrene with (a) liver microsomes or (b) buffer 
only. The radioactive products were separated by t.l.c. in a mixture of benzene 
and ethanol (19:1, v/v). The three metabolites A, B and C are thought to be 
dihydroxy or trihydroxy products.
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which this molecule is oxidatively metabolised (Fig 28). Metabolite 
Y, suspected as being 3,9-dihydroxybenzo(a)pyrene was not observed 
as a product in this investigation. This may have been due to excess 
metabolism which resulted in many diverse polyhydroxylated metabolites 
being produced rather than simple dihydroxymetabolites. Alternatively 
'Y1 may not be 3,9-dihydroxybenzo(a)pyrene.
The readiness with which 3-hydroxybenzo(a)pyrene undergoes 
conjugation has been well demonstrated in these experiments. As it 
is known to be weakly mutagenic and cytotoxic (Glatt and Oesch, 1976; 
Wislocki et al, 1976), its conversion to conjugated metabolites is 
presumably beneficial. The net result, the fact that 3-hydroxybenzo(a) 
pyrene and other metabolically produced : monohydroxybenzo(a)pyrenes 
are non or only weakly carcinogenic (1AJIC., 1973; Kapitulnik et al, 1976; 
Wislocki et al, 1977; Slaga et al, 1978) may be related to the ease at 
which they undergo conjugation. However, as it is known that hydrolysis 
of benzo(a)pyrene-3-0-glucuronide by B-glucuronidase can cause binding 
with DNA, (Kinoshita and Gelboin, 1978) it is possible that hydrolysis 
of this and related compounds by enzymes of the gut flora may be involved 
in the formation of bowel cancers.
The Metabolism of 4,5-Dihydro-4,5-dihydroxybenzo(a)pyrene (4,5-Dihydrodiol) 
by Short-Term Organ Cultures of Hamster Respiratory Tissues
4,5-Dihydrodiol is produced from benzo(a)pyrene by the successive 
actions of microsomal mixed function oxidase and epoxide hydratase 
(Oesch, 1973). It has been shown to be produced in microsomal preparations 
derived from rat, monkey and human lung (Grover et al, 1974; Grover,
1974; Rasmussen and Wang, 1974; Hundley and Freudenthal, 1977).
Studies of the metabolism of benzo(a)pyrene by lung and tracheal 
cultures described in the previous Chapter showed that little or no
4.5-dihydrodiol was present as an ethyl acetate-soluble metabolite after 
culture. However, a radioactive material which cochromatographed with
4.5-dihydrodiol was identified after enzymic digestion with B-glucuronidase 
or ketodase of the water-soluble radioactive products from these cultures, 
suggesting that any 4,5-dihydrodiol produced is .rapidly conjugated to 
glucuronic acid. This phenomenon, together with the possibility that 4,5- 
dihydrodiol may be. further metabolised to more hydroxylated metabolites
by the mixed function oxidases, was investigated using purified /~3H/-
4.5-dihydrodiol (prepared as described previously) with short-term organ 
cultures of hamster lung and trachea. x
The lack of biological activity of 4,5-dihydrodiol when assessed 
by DNA binding (Sims et al, 1974) and mutagenicity (Malaveille et al,
1975; Wislocki et al, 1976) have made this metabolite uninteresting to 
most researchers. However, in at least one case, 4,5-dihydrodiol ;was 
a tumour initiator albeit less active than benzo(a)pyrene or 7,8- 
dihydrodiol (Chouroulinkov et al, 1976). The mechanism by which 
this metabolite could have operated to bring about this tumourigenic 
response is unknown. Metabolism to a bay region diol-epoxide, by a 
three step process, is possible. Alternatively, metabolism to a toxic 
11,12-epoxide intermediate may occur as suggested by Sims (1976). Studies 
of the glutathione conjugated produced by rat lung have indicated that 
metabolism of both olefinic and aromatic double bands of polycyclic 
hydrocarbon dihydrodiols may take place (Sims, 1976).
/~^H/-4,5-L)ihydrodiol (0.4-1.0 pM) was metabolised by short-term 
organ cultures of hamster lung (180-220 mg) or trachea (30-70 mg) 
to similar ethyl acetate-soluble and water-soluble metabolites (Moore et al, 
1977; Moore and Cohen, 1978). Significantly more radioactivity remained in th
medium after 4,5-dihydrodiol (1 PM) tracheal cultures (93.4 ±0.6%) 
than in lung cultures (65.7 ± 0.7%). 66.4(±3.9%) and 34.1% of the
radioactivity remaining in the medium was ethyl acetate-extractable 
after tracheal and lung cultures respectively.
Analysis of the ethyl acetate-extractable products by t.l.c. using 
benzene:ethanol, 4:l,v/v showed there to be two bands of radioactivity 
from tracheal or lung cultures. The larger of these bands cochromato­
graphed with the starvting material. When the material associated with 
this band was eluted into 96% ethanol it was shown to possess the 
fluorescence excitation and emission spectra of 4,5-dihydrodiol. The 
material associated with the smaller radioactive band (Rf = 0.26-0.32 
relative to benzo(a)pyrene) was, on the basis of its fluorescence 
excitation and emission spectra, similar from trachea or lung. The 
material was, however, produced more rapidly by trachea (10.7 1 1.8 
p mol/g/min) than lung (4.5 ± 0.9 p mol/g/min). The fluorescence 
excitation (peaks at 275, 284, 300, 310 and 325 nm) and emission spectra 
(370 and 380 nm) of the unknown material were compared against those of 
naphthalene, phenanthrene, chrysene and 4,5-dihydrodiol in order to help 
ascertain its identity. The spectra of the unknown metabolite resembled 
that of 4,5-dihydrodiol but was unrelated to those of .either napbtbaJene 
or phenanthrene. It was also not possible to observe a phenolate ion 
type spectrum in alkaline solution. This suggested that the material 
was not phenolic in nature, although as observed by Jerina et al {1976), all 
monohydroxybenzo(a)pyrenes do not exhibit distinct phenolic ion spectra.
It is possible that the smaller radioactive band was associated 
with two or more metabolites incompletely resolved by t.l.c. This was 
indicated by radioscans obtained from some experiments which showed the
- 96 -
smaller of the two bands split into two closely aligned peaks.
Further experiments were precluded because insufficient amounts of 
metabolite were available for analysis. It was concluded from the 
available data that the unidentified metabolite (s) was probably a
tetrahydrotetrahydroxybenzo(a)pyrene.
Smaller quantities of water-soluble radioactive metabolites were 
produced by short-term tracheal cultures (24.1 ± 3.5%) than short-term 
lung cultures (31.6 ± 1.8%). Most of the water-soluble radioactive 
material (81.0% from tracheal cultures and 86.0% from lung cultures) 
was hydrolysed by ketodase or 3-glucuronidase to an ethyl acetate- 
extractable product which chromatographed as a single radioactivity band 
when analysed by t.l.c. (benzene:ethanol, 4:1, v/v) Fig 29). The material 
associated with this band cochromatographed with, and exhibited the 
characteristic fluorescence spectra of, 4,5-dihydrodiol. Similar 
incubations of the water-soluble radioactive material with aryl sulphatase 
(containing 20 mM D-saccharic acid l->-4 lactone) or acetate buffer only, 
failed to release significant amounts of radioactivity to ethyl acetate- 
extractable product(s) (Fig 29).
These experiments using the water-soluble radioactivity from /~^h/-
4,5-dihydrodiol had extremely clear cut results. As 81% and 86% of 
the radioactivity were released by enzymic hydrolysis with 3-glucuronidase 
or ketodase, and almost none by the controls, it is possible to calculate 
the total amount of conjugate produced and from this, determine a rate 
of production. Thus benzo(a)pyrene-4,5-dihydrodiol-glucuronide was 
produced at the rate of 14.0 ± 1.8 p mol/min/g lung and 53.9 1 4.1 
p mol/min/g trachea. Unfortunately the high rate of glucuronide 
conjugation by trachea could not be reproduced using other benzo(a)pyrene
4 ,5  - dihydrodiol Benzo(a)pyrene
FIGURE 29. Radioscan of enzymic hydrolysis of water-soluble metabolites after 
short-term hamster tracheal culture with [  3H7-4,5-dihydro-4,5-dihydroxybenzo(a) 
pyrene (1 yM). The water-soluble radioactive products after 16 h culture were 
hydrolysed with buffer, aryl sulphatase or buffer only and the ethyl acetate- 
soluble products release separated by t.l.c. using benzene:ethanol (4:1, v/v).
SF indicates solvent front.
metabolites and remains an enigma. However, if the result is 
genuine rather than artifactual because of the round-about way in 
which the rates of glucuronidation were obtained, the glucuronide 
conjugation is surprisingly high in trachea.
These experiments agree with the observation of Nemoto and 
Gelboin (1976) that 4,5-dihydrodiol is metabolised to a glucuronide 
conjugate but fail to confirm the existence of a sulphate conjugate 
also claimed by these workers (Nemoto et al, 1977). The relative 
amounts of water-soluble metabolites (mainly benzo(a)pyrene-4,5-dihydrodiol 
-glucuronide) produced in these experiments was much greater than in 
equivalent experiments with 7,8 or 9,10-dihydrodiols, but not as 
great as that obtained with 3-hydroxybenzo(a)pyrene. Thus although it 
was not possible to directly compare the rates of conjugation of 
benzo(a)pyrene metabolites in the experiments, they do agree with an 
intermediate rate of glucuronide conjugation for 4,5-dihydrodiol such 
as was found by Nemoto and Gelboin (1976). This, in their experiments 
was also greater than the rates of conjugation of 7,8 or 9,10- 
dihydrodiols. A rapid rate of conjugation is probably the primary 
reason why 4,5-dihydrodiol was not observed as an ethyl acetate-soluble 
metabolite from benzo(a)pyrene in cultures. It is possibly a metabolic 
route of high significance if 4,5-dihydrodiol is at all carcinogenic 
as suggested by the results of Chouroulinkov et al (1976).
The ethyl acetate-soluble metabolites that were found to be 
produced by lung and trachea may have some role in benzo(a)pyrene 
induced carcinogenesis. It is possible for 4,5-dihydrodiol to be 
metabolised to bay-region diol-epoxide intermediates which may be 
responsible for the tumour-initiating properties, found by Chouroulinkov et 
al (l976).Alternatively, the tumourigenicity could be the result of an
entirely different mechanism such as found with other polycyclic 
hydrocarbons (Harvey and Dunne, 1978). However, whether, or if 
either route is operative is probably academic, because the metabolite’s 
contribution to the total carcinogenicity of benzo(a)pyrene is 
undoubtedly minimal.
The Metabolism of /~^H/-9,10-Dihydro-9,10-dihydroxybenzo(a)pyrene 
(9,10-dihydrodiol) by Short-term organ cultures of Rat and .Hamster 
respiratory tissues
. The initiation of this project approximately coincided with the 
major publication by Sims et al (1974) which implicated did-epoxides as 
ultimate carcinogens of benzo(a)pyrene. The data from the experiments 
of Sims and his collaborators (Sims et al, 1974; Malaveille et al, 1975; 
Daudel et al, 1975) strongly implicated 7,8-dihydrodiol-9,10-epoxide 
as an ultimate carcinogen of benzo(a)pyrene. However, data in one of 
these publications indicated that 9,10-dihydrodiol-7,8-epoxide, a vicinal 
diol-epoxide derived from 9,10-dihydrodiol, could form spectrofluori- 
metrically similar DNA adducts to those of benzo(a)pyrene or benzo(a) 
pyrene-7,8-dihydrodiol-9,10-epoxide (Daudel et al, 1975). This information 
was of special significance when the first studies of the metabolism 
of /^H^-benzo(a)pyrene by rodent respiratory tissue cultures were 
collated (Cohen and Moore, 1976). It was thought possible that as up to 
10-times more 9,10-dihydrodiol than 7,8-dihydrodiol remained in the 
medium after short-term tracheal cultures, the generation of 9,10- 
dihydrodiol- 7, 8-epoxide derived from this metabolite may be of importance 
even if this was a minor metabolic pathway.
Booth and Sims (1976) showed that 9,10-dihydrodiol was metabolised 
by rat liver microsomes differently from its 7,8 counterpart. They
tentatively identified its major metabolite as a catechol, 9,10- 
dihydroxybenzo(a)pyrene. Nevertheless, a product tentatively 
identified as 7,8,9,10-tetrahydro - 7,8,9,10-tetrahydroxybenzo(a) 
pyrene (7,8,9,10-tetrahydrotetrol) was also found as a 9,10-dihydrodiol 
metabolite, suggesting that at least a small amount of metabolism 
must proceed via a diol-epoxide pathway. As previously discussed, more 
recent data has shown that the major metabolite of 9,10-dihydrodiol is 
not 9,10-dihydroxybenzo(a)pyrene but a further hydroxylated metabolite,
1(3),9,10-trihydroxy-9,10-dihydrobenzo(a)pyrene (Thakker et al, 1978).
In the present investigations, /V-9 ,10-dihydrodiol was incubated 
with respiratory tissue cultures in order to ascertain if diolepoxide 
formation, or other metabolism took place.
The metabolism of r* H/-9 ,10-dihydrodiol by lung cultures: Initial
metabolic investigations using /V-9 ,10-dihydrodiol (prepared metabolically 
as described previously), showed it to be, in comparison with other 
benio(a)pyrene derivatives investigated, relatively resistant.to further 
metabolism, particularly by hamster respiratory tissues (Cohen and Moore, 
1977). After short-term organ culture (16 h) of 200 mg of hamster lung 
with fW- 9,10-dihydrodiol (1 pm), 55.3-57.0% of the radioactivity v 
remained in the medium of which 46-48% was ethyl acetate-extractable.
The majority of the ethyl acetate-soluble radioactive material (>96%) 
was identified by cochromatography (in benzene:ethanol, 4:1, v/v and 
chloroform methanol, 4:1, v/v) as the starting material. The only other 
ethyl acetate-soluble radioactive product observed, was associated with 
a minor peak of radioactivity (0.2-0.3% of the total) that chromatographed 
with an Rf characteristic of 7,8,9,10-tetrahydotetrol. The identity 
of the material associated with this radioactivity was confirmed by 
spectrofluorimetric analysis. Similar analyses failed to confirm the
presence of 1(3),9,10-trihydroxy-9,10-dihydrobenzo(a)pyrene. Neither
I
the minor peak of radioactivity nor the fluorescence spectra of 
7,8/9,10-tetrahydrotetrol could be determined in extracts from control 
incubations in which lung tissue was omitted.
Insufficient radioactivity remained in the medium (<8%) after 
ethyl acetate extraction for a definitive analysis of the water-soluble 
radioactivity by enzymic hydrolyses. Hpwever, small amounts of 
radioactivity were released by 8-glucuronidase to ethyl acetate 
extractable components. The use of larger tissue weights in organ 
cultures (500 mg-lg) did not substantially increase the amounts of 
water-soluble radioactivity to overcome this problem, and therefore, at 
the time of the investigation it was concluded that hamster lung 
metabolised 9,10-dihydrodiol somewhat differently from rat liver 
microsomes (Cohen and Moore, 1977). However at a later date, when it 
was apparent that 1(3),9,10-trihydroxy-9,10-dihydroxybenzo(a)pyrene 
produced by viable rat hepatocytes (Jones and Moore, unpublished data) 
or cultured rodent trachea (Moore and Cohen, 1978), is rapidly 
conjugated to glucuronic acid, a reexamination of the thin-layer 
chromatograms performed at the time of the investigation was made. In 
the light of the further information, it was realized that the small 
amounts of water-soluble radioactivity which were released to ethyl 
acetate-soluble radioactive products by 8-glucuronidase, chromatographed 
with an Rf similar to that of 1(3),9,10-trihydroxy-9>10-dihydroxybenzo 
(a)pyrene. The amounts of radioactivity which chromatographed in this 
region were greater than that chromatographing with the starting 
material, 9,10-dihydrodiol.
A similar experiment to the one previously described was performed
with 200 mg portions of rat lung tissue. After 16 h short-term organ
radioactivity remained in the medium than with hamster tissue (73.1 
and 70.7%). Of this, only 19.6% and 5% (of the initial radioactivity) 
were ethyl acetate-extractable, indicating that the bulk of the 
radioactivity (53% and 65%) had become metabolised to water-soluble 
products. Analysis of the ethyl acetate-soluble radioactivity by t.l.c. 
(benzene:ethanol, 4:1, v/v) showed a similar radioactivity profile 
to that obtained with hamster lung cultures; the bulk of the radioactivity 
cochromatographed with* the.starting material and small amounts 
cochromatographed with an Rf characteristic of 7,8,9,10-tetrahydrotetrol. 
Due to the much larger amounts of water-soluble radioactivity available, 
enzymic hydrolysis with 8-glucuronidase was more definitive in rat 
experiments, releasing 3,800 and 12,900 cpm peaks of radioactivity 
which chromatographed similarly to 1(3),9,10-trihydroxy-9,10-dihydro 
benzo(a)pyrene. However, interpretation was difficult since in these 
experiments almost as large peaks of radioactivity were released by 
acetate buffer only, suggesting that this glucuronide is susceptible to 
acid catalysed hydrolysis similar to that observed for the glucuronide 
conjugate of 3-hydroxybenzo(a)pyrene. In subsequent experiments using 
tracheal cultures, B-glucuorinidase was substituted for ketodase* which 
gave much higher levels of enzymic activity. Thus, in these experiments, 
control incubations released peaks of radioactivity which were much 
smaller in comparison to that released by ketodase.
The metabolism of f W - 9  ,10-dihydrodiol by tracheal cultures: Short-
10-dihydrodiol (1.0-2.0 similarly to lung tissues (200 mg) from 
the respective species. Its relative resistance to further metabolism
culture with [^vj-9,10-dihydrodiol (1 pm) a higher proportion of
term organ cultures of rat or hamster trachea metabolised
was illustrated by the fact that after short-term culture (16 h) of 
hamster tracheas (43.7-114 mg) with [ 9,10-dihydrodiol, 65.7-87.0% 
and 7.3-20.7% of the initial radioactivity remained in the medium 
associated with ethyl acetate-soluble and water-soluble products 
respectively.
Ethyl acetate-soluble products: The majority of the ethyl acetate-
soluble radioactivity (81.0-97.0%) was found to be associated with the 
starting material when analysed by t.l.c. and spectrofluorimetry.
Small amounts of a metabolite which cochromatographed with, and 
exhibited the fluorescence excitation and emission spectra of, 7,8,9,10- 
tetrahydrotetrol were observed after hamster tracheal cultures (Fig 
30). In some experiments 1(3),9,10-trihydroxy-9,10-dihydrobenzo(a) 
pyrene could not be detected. In contrast, rat tracheal cultures 
(122-138 mg) did not metabolise 9,10-dihydrodiol to detectable amounts 
of 7,8,9,10-tetrahydrotetrol, but small amounts of radioactivity were 
detected which chromatographed with 1(3),9,10-trihydroxy-9,10-dihydro 
benzo(a)pyrene.
Water-soluble products: Rat tracheal short-term organ cultures (122-138
mg) metabolised [^vj-9,10-dihydrodiol to water-soluble products far v 
more readily than equivalent hamster tracheal cultures. The water- 
soluble metabolites were, however, qualitatively similar in both - species. 
Incubation of ethyl acetate-extracted medium from tracheal cultures with 
ketodase released large amounts of.ethyl acetate-extractable radio-, 
activity, especially from rat derived material (Fig 31). Similar 
incubations with aryl sulphatase or acetate buffer only released much 
smaller amounts of ethyl acetate-extractable radioactivity. T.l.c. using 
chloroform:methanol (4:1, v/v) showed there to be a single radioactive
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FIGURE 30. Ethyl acetate-extractable metabolites from the medium after 
short-term hamster tracheal culture(16 h) with [  ^ H7~9,10-dihydro-9,10-dihydroxy■ 
benzo(a)pyrene (1.4 yM). The radioactive products were separated by t.l.c. in 
chloroform:methanol (4:1, v/v) and quantified by liquid scintillation counting. 
SF indicates solvent front. Tetrol = 7,8,9,10-tetrahydro-7,8,9,10-tetrahydroxy- 
benzo(a)pyrene. Triol = 1(3), 9 10-trihydroxy-9,10-dihydrobenzo(a)pyrene.
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FIGURE 31. Enzymic hydrolysis of water-soluble metabolites after short-term 
rat tracheal culture with [  3h_7-9,10-dihydro-9,10-dihydroxybenzo(a)pyrene 
(2.0 yM). The water-soluble radioactive products after 16 h culture were
hydrolysed with ketodase (------- ) or aryl sulphatase (------) and the ethyl
acetate-soluble products released separated by t.l.c. using chloroform: 
methanol (4:1, v/v). SF indicates solvent front. Triol = 1(3),9,10-tri- 
hydroxy-9,10-dihydrobenzo(a)pyrene.
material released from all these incubations which cochromatographed 
with and exhibited the fluorescence excitation and emission spectra 
of 1(3),9,10-trihydroxy-9,10-dihydrobenzo(a)pyrene when extracted into 
96% ethanol (see appendix). These results suggest that the major water- 
soluble metabolite of 9,10-dihydrodiol produced by rat and hamster 
tracheal cultures is a glucuronide conjugate of 1(3),9,10-trihydroxy
9.10-dihydrobertzo(a)pyrene. A sulphate conjugate was not suspected as
the amount of radioactivity released by aryl sulphatase was approximately 
the same as that released by buffer only. Furthermore, it is anticipated 
that such a sulphate conjugate would have been extracted by the first 
ethyl acetate extractions. The radioactivity released in these incuba­
tions reflected the general instability of the conjugate under the acidic 
conditions as previously discussed.
At least three possibilities can be put forward to explain the differenc 
be.tween the observed abilities of rat and hamster trachea to metabolise
9.10-dihydrodiol to the eventual glucuronide conjugate, (i) A deficiency 
in the production of 1(3),9,10-trihydroxy-9,10-dihydrobenzo(a)pyrene.
This could be due to the inherent cytochrome P.-450 specifity of hamster 
tissues. Thus if 9,10-dihydrodiol is involved in the carcinogenicity
of benzo(a)pyrene it is possible that the specificity of cytochrome 
P-450 present in a tissue may predispose it towards the carcinogenic 
action of benzo(a)pyrene. (ii) A second possibility is a deficiency 
in the conjugation of 1(3) ,9,10-trihydroxy-9,10-dihydrobenzo('a)pyrene 
to glucuronic acid, (iii) A third possibility, a membrane difference 
which does not permit the entrance of 9,10-dihydrodiol into hamster 
cells, is unlikely since the differences in metabolism of 9,10-dihydro 
diol can be observed with benzo(a)pyrene itself (see previous chapter).
In order to determine which of factors (i) or (ii) was important 
the metabolism of f\J-1(3), 9 ,10-trihydroxy-9,10-dihydrobenzo(a)pyrene 
was investigated using short-term hamster tracheal cultures. After 
16 h, hamster trachea (48-54 mg) metabolised /~^h /-1 (3),9,10-trihydroxy -
9,10-dihydroxybenzo(a)pyrene (1 yM) such that only 21% of the original 
radioactivity remained ethyl acetate-extractable in the medium whilst 
57% was water-soluble. The ethyl acetate-extractable material was 
shown to be associated with the starting material by t.l.c. using 
benzene:ethanol (4:1, v/v). Portions of the water-soluble radioactivity 
were incubated with ketodase, aryl sulphatase or buffer only. 86% of 
it was released to ethyl acetate soluble products by ketodase but 
only small amounts by the other two treatments. This ethyl acetate- 
extracted radioactivity was associated with a single radioactive band 
when t.l.c'd in chloroform .'methanol, 4:1, v/v, which cochromatographed 
with 1(3),9,10-trihydroxy-9,10-dihydrobenzo(a)pyrene. It was thus 
concluded that hamster trachea possesses the glucuronyl transferase 
necessary for the production of the glucuronide conjugate of 1 (.3),9,10- 
trihydroxy-9,10-dihydrobenzc(a)|yrene, and therefore, the difference must 
lit in the inability of the tissue to produce this material from its 
precursor dihydrodiol.
In summary, these results have shown that the basic route of 
metabolism of 9,10-dihydrodiol by hamster or rat respiratory tissue 
cultures is to 1(3),9,10-trihydroxy-9,10-dihydrobenzo(a)pyrene-glucuronide. 
There are however quantitative differences caused by deficiencies in the 
ability of hamster material to oxidatively metabolise 9,10-dihydrodiol 
at the 1 or 3 positions which causes a greater proportion of the material 
to be metabolised to a vicinal diol-epoxide. This indirect route of 
metabolism and glucuronidation agrees with the findings of Nemoto and
Gelboin (.1976) who could not detect direct glucuronide conjugates
of 9,10-dihydrodiol in a liver microsomal preparation which glucuronidated
other benzo(a)pyrene metabolites.
Recent investigations have led to the conclusion that the two 
possible vicinal diol-epoxides from 9,10-dihydrodiol, (90,lOa-dihydroxy 
7a , 8a -epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene and 90, lOa-dihydroxy- 
70, 80-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene) although mutagenic 
to some bacteria, are probably not important in the mutation and 
transformation of mammalian cells (Malaveille et al, 1977; Marquadt 
et al, 1977). Thus, although the carcinogenic potential of these two 
diol-epoxides remains to be determined, they-are not likely to be highly 
potent carcinogens, and therefore the observed differences in the two 
species' capacity to metabolise 9,10-dihydrodiol is probably less 
important than was originally thought.
The metabolism of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene (7,8-
dihydrodiol) by Short-term organ cultures of Rat and Hamster respiratory 
tissues
The evidence that 7,8-dihydrodiol is a proximate carcingen of 
benzo(a)pyrene is unequivocal and amply detailed in previous chapters.
It has recently been shown that the metabolism of benzo(a)pyrene 
and 7,8-dihydrodiol is highly stereospecific. Chemically synthesized 
racemic 7,8-dihydrodiol is metabolised to mixtures of syn (70, 8a- 
dihydrodoxy-90,100-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene) and anti 
(70, 8a-dihydrodroxy - 9a,10a-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene) diol- 
epoxides. Metabolism by liver microsomes from rats pretreated with 
3-methylcholanthrene is more selective than metabolism by control rat 
microsomes and results in almost total production of anti diol-epoxide
(Yang et al, 1976; Thakker et al, 1977). The metabolism of 
benzo(a)pyrene by microsomes from rats pretreated with 3-methyl- 
cholanthrene is similarly stereospecific and results in the production 
of optically active 7,8-dihydrodiol (the (— ) enantiomer, Yang et al, 
1976).
It was the aim of the present study to investigate the metabolism 
of A i / - 7  ,8-dihydrodiol in cultured rodent respiratory tissues in 
order to quantify the production of oxidative and conjugated metabolites.
The oxidative metabolites produced via diol-epoxide formation have 
been well characterised althougn alternative fates of epoxides have 
not been well investigated. Thus, conceivable glutathrone conjugates 
remain to be investigated (Sims, 1976). Conjugation of 7,8-dihydrodiol 
to glucuronide has been demonstrated by Nemoto and Gelboin (1976) 
using rat liver microsomes fortified with UDP-glucuronic acid. The 
rate of production of the conjugate was however considerably slower 
than that observed for metabolically produced monohydroxybenzo(a)pyrenes 
or 4,5-dihydrodiol. The same investigators also demonstrated the 
formation of a sulphate conjugate of 7,8-dihydrodiol by a rat liver . 
high speed supernatant preparation, suitably fortified with PAPS 
(phospho-adenyl-phospho-sulphate)(Nemoto et al, 1977).
Previous experiments with / ”^ h /-benzo(a)pyrene showed 7,8-dihydrodiol 
to be a metabolite produced by both lung and trachea. However, it 
was difficult to ascertain from the ethyl acetate-soluble products 
whether it was further metabolised to a diol-epoxide and thence to
7,8,9,10-tetrahydrotetrol, and, from the water-soluble enzymic 
hydrolysates, whether a glucuronide conjugate was produced. It was 
anticipated that the use of ]-7,8-dihydrodiol would sufficiently
reduce the number of different metabolites to enable the investigation 
of these routes of metabolism.
The metabolism of [^vj-7,8-dihydrodiol by lung cultures: Short-term
organ cultures of rat or hamster lung portions (200 mg) metabolised
7,8-dihydrodiol (1 yM) to ethyl acetate-soluble and water-soluble 
products. Unlike the experiments previously described with /"^h /-9,10 
dihydrodiol and rat or hamster respiratory tissues, hamster lungs were 
not deficient in converting /”^h/-7,8-dihydrodiol to water-soluble 
products. In fact, the situation was reversed in comparison with
9,10-dihydrodiol as demonstrated by the fact 13.0-14.6% and 22.4-31.6% 
of the total radioactivity was converted to water-soluble radioactive 
products by rat and hamster lung cultures respectively.
Analysis of the ethyl acetate-soluble radioactivity by t.l.c. 
in benzene:ethanol, 4:1,v/v or chloroform:methanol, 4:1,v/v showed 
that similar radioactive products were produced by hamster or rat lung 
cultures. Fig 2 shows a typical radioactivity profile, in this case 
from a hamster lung culture. Most of the ethyl acetate^soluble radio­
activity was associated with the starting material, 7,8-dihydrodiol 
on the basis of cochromatography and spectrofluorimetric analysis. A 
minor radioactivity peak (Fig 32) produced by rat and hamster lung 
cultures (Rf = 0.14 relative to benzo(a)pyrene'in benzene:ethanol,
(4:1,v/v) was associated with 7,8,9,10-tetrahydrotetrol. The exact 
nature of the 7,8,9,10-tetrahydrotetrol produced was not investigated but 
as it was spectrofluorimetrically indistinguishable from that produced 
by microsomes from the livers of 3-methylcholanthrene-pretreated rats, 
it is likely that the major constituents were 7,8,9,10-tetrahydro- 
7 a, 83, 93,10 a - tetrahydroxybenzo(a)pyrene (Yang et al, 1977c).
It has also been shown that approximately 30% of the metabolism of 
microsomes from control rats is directed towards the production of 
a trihydroxy-metabo1ite which would be expected to separate from
7,8,9,10-tetrahydrotetrol in the chromatographic systems employed 
(Thakker et al, 1977). As this metabolite was not observed, these 
results suggest that hamster lung cytochrome P-450 resembles that of 
rat liver after pretr.eatment of animals with 3-methylcholanthrene.
However, it is possible that a trihydroxy metabolite derived from 7,8- 
dihydrodiol would be rapidly conjugated to glucuronide like 1(3)-tri- 
hydroxy- 9, 10-dihydrobenzo (a) pyrene. This type of metabolite was not 
observed in enzymic deconjugations but as it would only have been 
produced in minute quantities, it may have been overlooked.
The water-soluble metabolites remaining after ethyl acetate extrac­
tion of the medium from lung cultures were divided up into approximately 
equal portions for enzymic hydrolysis with 3-glucuronidase or control 
incubation with acetate buffer only. It was necessary to pool the 
water-soluble metabolites from two cultures in order to obtain sufficient 
material for analysis. Little or no radioactivity was hydrolysed to 
ethyl acetate-soluble products after control incubations (Fig 33).
Enzymic hydrolysis, based on the amount of ethyl acetate-soluble radio­
activity released, was variable and complicated by problems encountered 
with ’gelling* of the ethyl acetate-extracted hydrolysate. However, 
when this did not occur, efficiency of extraction was as high as 91% 
suggesting that the bulk of the water-soluble radioactivity was associated 
with glucuronide or sulphate conjugates (Fig 33). Analysis of the 
ethyl acetate extracts by t.l.c. using benzene:ethanol, 4:1, v/v showed 
a major band of radioactive material that cochromatographed with 7,8- 
dihydrodiol and traces of other less polar radioactive products. These
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may have been present in the [\\]-7,8-dihydrodiol at the start of 
the experiment or produced from it during the incubations or work­
up procedures.
Sulphate conjugates are unlikely candidates as water-soluble metabolites 
because:-
(i) they are ethyl acetate-soluble (Nemoto et al, 1977)
(ii) they were not detected as metabolites of 7,8-dihydrodiol in 
more detailed investigations in rodent tracheal cultures and 
(iii) benzo(a)pyrene-dihydrodiol-sulphate conjugates were not detected 
in other investigations using respiratory tissues, (Mehta and Cohen, 
unpublished observation).
Thus, it was concluded that the bulk of water-soluble radioactivity 
was associated with the glucuronide conjugate of 7,8-dihydrodiol.
In similar incubations with 200 mg rat lung cultures, a large 
percentage of the water-soluble radioactivity was also associated with 
the glucuronide conjugate of 7,8-dihydrodiol.
Glutathione conjugates were not determined from rat or hamster 
lung cultures. However, they were probably not present in large amounts 
as up to 91% or the water-soluble radioactivity was found to be 
associated with glucuronide conjugates. A recovery of 91% is 
surprisingly high considering the high protein concentrations of the 
enzymic hydrolyses. It is probable that a large fraction of the 
unextracted radioactivity was also associated with glucuronide, but was 
not extracted because of insufficient hydrolysis or attachment to 
macromolecules.
These studies were performed using biologically synthesized
7,8-dihydrodiol which probably consisted almost entirely of the (—)
enantiomer as microsomes from 3-methylcholanthrene pretreated rats 
were employed in its synthesis. If the cytochrome P-450 of hamster or 
rat lung tissue differs in some way to that of microsomes from the 
pretreated rats, erroneous data could result from the use of this 
single stereoisomer. To investigate the stereospecificity of lung 
monooxygenases, further experiments are required using 7,8-dihydrodiol 
of exactly known configuration with analysis by h.p.I.e.
It is possible that the rate of glucuronide conjugation of (— ) 
7,8^-dihydrodiol could be different from that of the (+) isomer.
Variation of this sort is exhibited by 4,5-dihydrodiol isomers; the 
trans isomer is conjugated with glucuronide 4 times more rapidly than 
the cis isomer (Nemoto and Gelboin, 1976).
These stereospecificity differences could explain why the glucuronide 
conjugate of 7,8-dihydrodiol was observed from 7,8-dihydrodiol but 
not from benzo(a)pyrene. An alternative possibility is that the 7,8- 
dihydrodiol produced within the tissues on exposure to benzo(a)pyrene 
is metabolised differently from the same metabolite entering the tissues 
from the exterior. It is conceivable that newly synthesized 7,8-dihydro- 
diol positioned adjacent to cytochromeP-450 is more likely to undergo 
further oxidative metabolism than a similar metabolite randomly entering 
the cell.
The metabolism of /r3H7-7,8-dihydro^7,8-dihydroxybenzo(a)pyrene (7,8- 
dihydrodiol) by short-term organ cultures of rat and hamster trachea:
[ 3H7-7,8-dihydrodiol (0.75-1.3 um) was metabolised by short-term 
organ cultures of rat or hamster tracheas (46.6-86.4 mg) to ethyl 
acetate-soluble and water-soluble metabolites. Chromatography of the 
ethyl acetate-soluble radioactivity from these cultures in chloroform:
methanol, 4:1,v/v, resolved two radioactive products (Fig 34).
These two radioactive products were identified as unmetabolised 7,8- 
dihydrodiol and 7,8,9,10-tetrahydrotetrol on the basis of cochromatography 
and their fluorescence excitation and emission spectra when extracted 
into 96% ethanol (see appendix).
The rate of formation of 7,8,8,10-tetrahydrotetrol from 7,8?dihydro 
diol was 2.9 1 0.8 p mol/min/g of hamster trachea, approximately 10-12 
fold its production from 9,10-dihydrodiol by similar tissue (0.2-0.3 p 
mol/min/g). The. nature of the 7,8,9,10-tetrahydrotetrol was not 
investigated but chromatographed as a single band in the solvent systems 
used. The previous comments on the source of /"3h/-7,8-dihydrodiol apply 
equally well to tracheal tissues and it is possible therefore, that 
certain types of 7,8-dihydrodiol metabolites have been excluded.
When the metabolite(s) associated with the water-soluble radio­
activity remaining after hamster tracheal cultures (approximately 10- 
20% of the starting radioactivity) was incubated with ketodase it was 
found that up to 70% of the radioactivity was released to ethyl acetate- 
soluble material. Chromatography in chloroform:methanol, 4:1,v/v and 
benzene:ethanol, 9:1,v/v (Fig 35) showed that a product was releasedv 
which cochromatographed and exhibited the spectrofluorescent products 
of 7,8-dihydrodiol. Similar incubations with aryl sulphatase or acetate 
buffer released only small amounts of ethyl acetate extractable radio­
activity which exhibited no trace of 7,8-dihydrodiol (Fig 35).
Small amounts of radioactivity were present in ethyl acetate-extracts 
from ketodase incubations which chromatographed close to the origin.
This may have been associated with 7,8,9,10-tetrahydrotetrol but when 
the associated material was eluted into 96% ethanol and examined spectro-
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fluorimetrically, this could not be confirmed and it was concluded that 
this band of radioactivity was associated with material carried-over by 
proteins. It was possible to calculate a rough rate of conjugation for
7,8-dihydrodiol from some experiments based on the amount of water- 
soluble radioactivity released. The value obtained, 8.6 p mol/g/min 
is approximately 6-fold lower than the equivalent value for 4,5-dihydro- 
diol.
Sulphate conjugates -of 7,8-dihydrodiol were not found in the 
present experiments. Sulphate conjugation by tracheal cultures was low 
when benzo(a)pyrene or monohydroxybenzo(a)pyrenes were used, in part 
due to the smaller tissue weights employed, than in lung experiments.
The expected rate of sulphate conjugation of 7,8-dihydrodiol is low 
(if the reaction occurs at all) and this, combined with the small weights 
of tissue used will have formed undetectable amounts of product.
Glutathione conjugates arising from the production of diol-epoxides 
cannot be precluded as only 70% of the tracheal water-soluble products 
could be accounted for by glucuronide conjugates. However, considering 
the small amounts of water-soluble radioactivity available for
i
experimentation, the 70% recovery is, like the lung experiments, a high 
one. Thus it is likely that glutathione conjugates were not of major 
quantitative significance.
A similar experiment to these described with hamster tracheal 
metabolites was performed using water-soluble radioactivity remaining 
from rat tracheal cultures, / ^ h /-7,8-dihydrodiol was similarly released 
by ketodase suggesting that, as with hamster trachea, 7,8-dihydrodiol- 
glucuronide was a major water-soluble metabolite.
These experiments have demonstrated the ability of rodent trachea
to metabolise 7,8-dihydrodiol via two pathways. The first, further 
oxidative metabolism, leads to the production of 7,8-dihydrodiol-
9,10-epoxides, a species of ultimate carcinogen of benzo(a)pyrene.
The second pathway, glucuronide conjugation, produces metabolites which 
are likely to be true detoxification products.
A distinct difference was not observed in the production of 7,8,9, 
10-tetrahydrotetrol by rat anci hamster trachea. Thus, other factors must 
contribute to the differences in sensitivity of these two species to 
benzo(a)pyrene induced tracheal cancer.
These experiments with /"^h /-7,8-dihydrodiol have verified the 
production of the glucuronide conjugate of 7,8-dihydrodiol. Although this 
was not distinctly observed as a metabolite of benzo(a)pyrene, it is 
unlikely that this route of metabolism is conpletely absent from the 
further metabolism of 7,8-dihydrodiol produced 'in situ'. Therefore, 
it must be considered as an opposing reaction to the generation of-7,8- 
dihydrodiol-9,10-oxides. Thus, it is possible that this reaction plays 
a role in the predetermination of carcinogenesis. For example, it is 
possible that glucuronide conjugation may have been a major factor 
contributing to the variability of binding of /~^H/-benzo(a)pyrene to' 
human bronchial tissues (Harris et al, 1976). Experiments designed to 
investigate this possibility may be a fruitful area for future 
experimentation.
Discussion
These results have further illustrated that the metabolism of 
benzo(a)pyrene by rodent respiratory tissues is complex and results in 
the production of a wide range of ethyl acetate-soluble and water- 
soluble metabolites. The pathways that have been demonstrated with 
individual benzo(a)pyrene metabolites are outlined in Figure 36. The 
analytical problems that are associated with the resolution of these 
metabolites are considerable. The techniques used in the present study; 
i.e. the use of purified /~^H/-benzo(a)pyrene-metabolites, short-term 
organ culture, enzymic hydrolysis, spectrofluorimetry and t.l.c; 
have enabled the identification of a number of benzo(a)pyrene-metabolites 
in respiratory tissues which have a metabolising capacity that is only 
a small fraction of that found in liver.
Recent developments in analytical chemistry using h.p.l.c. now 
enable a much better•analysis of ethyl acetate-soluble metabolites of 
benzo(a)pyrene than the t.l.c. methods of the present work (Selkirk 
et al, 1974). However, such methods are not yet available which will 
separate water-soluble’ benzo(a)pyrene-metabolites and until such time 
that they do become available, enzymic hydrolysis is a most useful 
tool in identification of such metabolites. Undoubtedly, the present 
study would have been improved if the use of an h.p.l.c. had been 
available for synthetic and analytical purposes. However, it is possible 
that the use of an h.p.l.c. may have not been without difficulties. For 
example, the fluorescence of 3-H-suLphate when present on a t.l.c. plate 
and viewed under u.v light, was a considerably useful property which 
helped ascertain its identity. This property may never have been 
discovered if analysis had been by h.p.l.c.
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The use of an h.p.l.c. would have been particularly useful in 
analysis and identification of minor metabolites such as the 7,8,9,10- 
tetrahydrotetrols from 7,8 and 9,10-dihydrodiols. It is possible
dihydrodiol because of the t.l.c. methods used for its preparation; 
h.p.l.c. preparation of this metabolite would have ruled out this 
possibility.
The metabolism of individual benzo(a)pyrene metabolites has in 
general agreed with that of the parent hydrocarbon. It has been particu­
larly useful in demonstrating the further metabolism of these compounds 
to glucuronide and sulphate conjugates. However, a principal drawback 
with their use is the prevention of metabolism to glutathione conjugates 
as shown by others (Hook and Bend, 1975; Smith et al, 1978). These 
may have contributed to the 60% unidentified radioactive products 
that remained after enzymic • hydrolysis of benzo(a)pyrene water-soluble 
metabolites. However, since there were no simple epoxides in the further 
metabolising systems, they would not have been observed except as more 
complex metabolites.
A major objective of the present study was the comparison of hepatic 
and pulmonary metabolism of benzo (a)pyrene. This is important 
because differences may explain the lungs' sensitivity to benzo(a)pyrene. 
Hovever, when benzo(a)pyrene metabolism was studied in isolated viable 
rat and hamster hepatocytes (in collaboration with Dr C Jones ; Jones 
et al, 1978; Jones and Moore, unpublished data), there were no major 
qualitative differences in the products obtained from those of respiratory 
tissues. All the metabolic pathways found with respiratory tissues
that the preparation of /~^h /-9,10-dihydrodiol,used in the present
experiments, may have contained a very small
using benzo(a)pyrene or purified benzo(a)pyrene-metabolites were 
present in isolated hepatocytes. However, there were important 
quantiative differences. Benzo(a)pyrene metabolism was much more rapid 
in hepatocytes than in respiratory tissues and there was also bias 
towards certain routes of metabolism such as sulphate conjugation. 
Comparisons are not easy because of the widely-differing methodologies 
employed. Until a straightforward method for the separation and purifi­
cation of lung cell types becomes available, difficulties will remain. 
The culture technique used .resulted, in the production of many different 
metabolites and was obviously more representative of ’in vivo' 
metabolismthan microsomal preparations. These will only metabolise 
benzo(a)pyrene strictly according to the cofactors supplied (Nemoto 
and Takayama, 1977a). When the methodology becomes available to produce 
pure lung and tracheal cells, these will be suitable subjects for the 
study of benzo(a)pyrene metabolism. By studying kinetic aspects of the 
metabolism and comparison with refractory metabolising cells such as 
hepatocytes, insight may be further gained in the development of 
respiratory carcinomas. This kind of methodology will also be extremely 
useful in showing exactly which cells are responsible for the metabolic 
capacity of respiratory tissues.
These studies have shown that at least a proportion of the cells 
of trachea and lung give these organs a diverse metabolic capacity. 
Further experimentation is now required to show exactly which cells are 
responsible for the different routes of metabolism and the subsequent 
events in carcinogenesis. For example, are the cells that metabolise 
the carcinogen those that eventually become malignant or are activated 
species transported locally between cells? If so, are adjacent cells
deficient-in molecular repair mechanisms?
Further experimentation is necessary to answer these and other 
questions about carcinogenesis in the respiratory tract. Many 
techniques will be necessary to answer all the possible questions 
and organ culture and perfusion are likely to be among those used.
Chapter 6
Some Investigations of the Interactions 
of Benzo(a)pyrene with Tissue Components
Chapter 6
Some Investigations of the Interactions of Benzo(a)pyrene with 
Tissue Components
The study of the metabolism of polycyclic hydrocarbons is of 
prime importance in understanding their mechanisms of action. Many 
factors, however, modify the metabolism and disposition of foreign compounds 
in vivo, thus altering their potential toxicity. It is therefore important 
to study the way in which polycyclic hydrocarbons and their metabolites 
interact with tissue components. In vivo, foreign compounds are exposed 
to a wide variety of tissue components to which they may bind. In most 
cases, physical parameters such as lipophilicity and molecular size 
are important in regulating binding. However, in other cases, much more 
subtle factors can considerably alter binding characteristics, for example, 
relatively small changes in steric configurations of molecules can 
sometimes cause quite dras.tic differences in binding. This is particularly 
so with the binding of foreign compounds to proteins such as ligandin.
This protein is present at high concentrations, making up to 10% of the 
total soluble protein of liver. It may be one reason why this organ is 
normally refractory to polycyclic hydrocarbon induced carcinogenesis.' In 
this study binding observations made with whole lung pieces in culture, 
and hepatocytes in suspension, were compared with the binding of benzo(a) 
pyrene and its purified metabolites to pure proteins and lipids.
Studies on the Uptake and Excretion of /~^h/-Benzofa)pyrene and /~^H 1- 
Benzo(a)pyrene metabolites by cultured Hamster Lungs and isolated Rat 
Hepatocytes
At an early stage in the metabolic studies described in Chapters 
4 and 5, it was evident that the different benzo(a)pyrene derivatives
- 119 -
studied were taken up by cultured tissues to differing extents.
This was most marked in the culture experiments with 180-220 mg 
rodent lung tissue.. Table 4 summarises data from hamster lung culture 
experiments with [-^wj-benzo(a)pyrene and its metabolites previously 
described in Chapters 4 and 5. Because the individual metabolites 
differed widely in their further metabolism, results are not easily 
interpreted. In the cases of benzo(a)pyrene and dihydrodiols, a large 
fraction of the initial material remained unmetabolised after 16 hours 
and comparisons are therefore justifiable, but in the case of 3-hydroxy 
benzo(a)pyrene, where the bulk of the material was metabolised to its 
glucuronide conjugate after 16 hours, interpretation is more difficult.
In this case, it is likely that the equilibrium between the radioactivity 
in the tissue and medium is dominated by the large amount of polar 
glucuronide conjugate and therefore, only small amounts of radioactivity 
remained associated with the tissue.
Benzo(a)pyrene was the most lipophilic of the compounds investigated, 
and if this was the sole factor, it might be expected that this compound 
be taken up into the lung tissue to a greater extent than any of its 
metabolites, which was not the case. All three dihydrodiols were taken 
up to a greater extent than the benzo(a)pyrene, due obviously in some 
way to the presence of the two hydroxyl groups on the dihydrodiols.
These hydroxyl groups may function by facilitating solubilization of the 
benzo(a)pyrene dihydrodiols in aqueous medium, thereby reducing binding 
to serum proteins and association into polymers and increasing the 
availability to the tissue. The position of these hydroxyl groups is 
also important since a considerable difference was observed between the 
uptake of 7,8-dihydrodiol and the other two dihydrodiols. Since these
Table 4
Percentage Radioactivity remaining associated with hamster lung 
after culture with /"^IjZ-benzo(a)pyrene compounds
Percentage Radioactivity
34.0 ± 2.1
18.5 (12.1, 24.9)
40.5 ± 5.2 
52.4 ± 2.5 
41.3 ± 1.7
Results are expressed as the means and SEM values of the percentage of 
total radioactivity associated with hamster lung portions (200 ± 20 mg) 
after culture (16 h). Experiments were performed in quadruplicate 
except x which is the result from 2 determinations.
Metabolite 
Benzo(a)pyrene 
3-Hydroxybenzo(a)pyrene K 
4,5-Dihydrodiol 
7,8-Dihydrodiol 
9,10-Dihydrodio1
compounds contain the same groupings they are likely to possess 
similar lipophilicity, and this, therefore is unlikely to explain the 
difference in tissue uptake. It is unlikely that metabolism to tissue 
binding intermediates, such as diol-epoxides, could entirely account for 
the difference in uptake, and, therefore, another reason was sought.
The experiments from which these results were drawn were not 
ideally suited for the study of the uptake of benzo(a)pyrene and its 
metabolites because of the long incubation period needed for the
metabolism studies; conclusions must therefore be very guarded. The
/
results, however, were in basic agreement with observations of benzo(a) 
pyrene metabolism in isolated rat hepatocytes (Jones et al, 1978) in 
which a time course of metabolism showed a differential accumulation 
of metabolites inside and outside of cells. In this study rat hepato­
cytes obtained by the tissue slice method of Fry et al (1976) were 
resuspended (2 x 10^ cells/ml) in Leibovitz medium containing 10% 
foetal calf serum, 10% tryptose phosphate broth, penicillin ( l O O U / m l )  
and streptomycin (100 yg/ml), incubated with 80 yNj/'^Hy^-benzo(a)pyrene 
(introduced in a small volume of dimethyl formamide, not greater than 
0.2% of the total vol) at 37°C for periods up to 90 min. Metabolism • 
was terminated by cooling the cell preparations to 0°C, and the cells 
then immediately separated from the medium by low speed centrifugation 
and washing. The ethy1-acetate extractable metabolites associated 
with the cells and medium were then extracted by t.l.c. similarly to 
that described previously. Metabolism proceeded rapidly; it was 
easily detectable at 5 minutes, and by 90 minutes, only about 10% of 
the benzo(a)pyrene remained. Table 5 shows the relative p r o p o r t i o n s  
of different metabolites in the hepatocytes and medium at various
Table 5
The Distribution of Benzo(a)pyrene Metabolites formed by Rat 
Hepatocytes during Incubation
Metabolite 5 min
Cells 
50 min 90 min 5 min
Medium 
50 min 90 i
3-Hydroxybenzo(a)pyrene 94 77 86 6 23 14
4,5-Dihydrodiol 44 46 45 56 54 55
7,8-Dihydrodiol 60 46 50 40 54 50
9,10-Dihydrodiol 17 12 12 83 88 88
"Material at Origin" 47 30 26 53 70 74
[  ^ h/-Benzo(a)pyrene .(80yM) was incubated with isolated rat hepatocyte 
suspensions (2 x 10^ cells/ml). The cells and extracellular medium were 
separated by light centrifugation and extracted with ethyl acetate.
The ethyl acetate-soluble radioactive products were separated by t.l.c. 
(benzene:ethanol, 9.1 v/v) and quantified by liquid scintillation counting.
The percentages reflect the proportions found after totalling the amounts 
within the hepatocytes and in the extracellular medium. "Material at 
Origin" represents polar metabolites left at the origin after chromato­
graphy and includes 3-sulphate and 7,8,9,10-tetrahydro-7,8,9,10-tetrahydroxy 
benzo(a)pyrene.
times of incubation. It can clearly be seen that the metabolites 
are not equally retained inside the hepatocytes. Comparison of 
these results with those of the lung culture experiments (Table 4) 
shows some interesting parallels which suggest that benzo(a)pyrene 
metabolites may be adsorbed and retained similarly in lung tissue and 
hepatocytes. For example, 9,10-dihydrodiol is the dihydrodiol least 
easily taken up by cultured lung and most easily excreted by rat 
hepatocytes. Furthermore, 3-hydroxybenzo(a)pyrene which was observed 
to be rapidly adsorbed and metabolised by cultured lung, is not easily 
excreted out of hepatocytes. Indeed, the barrier for 3-hydroxybenzo(a) 
pyrene excreted in hepatocytes is so effective that after an initial 
efflux at the start of the incubation, almost no 3-hydroxybenzo(a)pyrene 
leaked from the cells for the remainder of the experiment. This may 
be because 3-hydroxybenzo(a)pyrene activates microsomal glucuronyl 
transferase of hepatocytes which is closely linked to the initial 
hydroxylating enzymes and therefore ' is removed more rapidly than it 
is produced.
It is unlikely that differences in the distribution of the dihydrodiols 
between hepatocytes and medium (Table 5) are because of metabolic orv 
lipophilic differences and therefore stereospecific factors are impli­
cated. In order to investigate the nature of this specificity, experiments 
using equilibrium dialysis were set up in collaboration with Drs 
Ketterer and Tipping of the Courtauld Institute, Middlesex Hospital,
London.
Studies on the Binding of Benzo (a)pyrene and Benzo(a)pyrene-
metabolites by Ligandin, Aminoazodye-binding protein A and Phospha­
tidylcholine bilayers
Miniature dialysis experiments were set up using the polytetra-
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fluoroethylene equilibrium dialysis apparatus previously described 
by Kettereret al, (1976) and Tipping et al, (1976) to investigate 
the binding of purified /^HZ-benzo(a)pyrene metabolites by ligandin 
(Litwack et al, 1971; Tipping et al, 1976), aminoazodye binding 
protein A (Ketterer et al, 1976) and unilamellar and multilamellar 
liposomes (Bangham et al, 1968; Brunner et al, 1976).
The apparatus consisted essentially of two similar polytetra- 
fluoroethylene shallow cylindrical chambers (each of volume approximately
0.3 ml) separated by a cellulose membrane made from well washed visking 
tubing preboiled in 1% (w/v) sodium carbonate. Experiments were 
started by the addition of the /"^H/^-benzo(a)pyrene or metabolites 
(in a small quantity of ethanol or dioxan; not more than 0.5% of the 
total) to the apparatus which had been previously filled with buffer 
(0.1M KC1, 0.5M Tris-HCl, pH 7.4) in one chamber, and buffer plus ligand 
in the other. The apparatus was then incubated until equilibrium was 
obtained (16-40h, 4°C) and radioactivity determined in both chambers.
A summary of the results from these experiments is shown in Table 6.
The recovery of radioactivity in the buffer solutions during these 
experiments was poor because of binding of the / ”^ h /-compounds to the 
polytetra-fluoroethylene cells and cellulose membranes. Up to 90% 
of the radioactivity associated with benzo(a)pyrene and 3-hydroxybenzo (a) 
pyrene, and 60% of that associated with dihydrodiols was lost in this 
manner. Since the concentration of benzo(a)pyrene-compounds was 
determined on both sides of the membrane, this recovery problem should 
not interfere with the interpretation of results, but it may explain 
the wide scatter. Apart from this effect of the apparatus, the only 
parameter influencing the even distribution of test compounds between 
the two chambers was the ligand examined.
Protein Binding:- Despite the difference in the number and position of 
the hydroxyl groups in the five benzo(a)pyrene metabolites examined, 
the binding to the ligandin was relatively even, there being only a 
three-fold difference between minimum and maximum binding ^ 1.2 ± 0.4 
to 4.3 ± 0.6 l.mol * for 1(3), 9-10-trihydroxy-9,lO-dihydrobenzo(a) 
pyrene and 3-hydroxybenzo(a)pyrene respectively). This contrasted with 
the results obtained with aminoazodye binding protein A (protein A), 
which exhibited a high binding affinity to 3-hydroxybenzo(a)pyrene and
4,5 and 7,8-dihydrodiols (2.1 ± 0.9 to 3.4 ± 0.3 l.mol *), similar to 
that observed with ligandin, but a weak binding affinity (11-30-fold 
less) for 9,10-dihydrodiol and 1(3),9,10-trihydroxy-9,10-dihydrobenzo(a) 
pyrene. Binding of benzo(a)pyrene to both ligands was of similar, inter­
mediate affinity (0.67 1 0.21 and 0.70 ± l.mol  ^ to ligandin and protein 
A respectively), probably because the total lack of hydroxy groups 
eliminates many of the interactions such as hydrogen bonding, partaken 
by the metabolites. It appears that hydroxyl groups at the 9,10 position 
of benzo(a)pyrene are orientated in such a way as to minimise binding 
to protein A.
Phospholipid Binding: The binding of a compound to phospholipid micelles
is governed by two factors, its lipophilicity, and its size and shape 
which allow it to interact in a specific manner. The compounds 
investigated have a range of both because the introduction of a hydroxyl 
group into the molecule is associated with a reduction in lipo­
philicity. The most lipophilic compound tested, benzo(a)pyrene,had 
relatively weak binding to lipid bilayers, 0.17 ± 0.1 and 0.12 1 0.4 1 mol 
of egg lecithin only (Bangham et al, 1968) and egg lecithin-cholesterol 
micelles (Brunner et ak, 1976) respectively. 3-Hydroxybenzo(a)pyrene 
and 4,5 and 7,8-dihydrodiols, on the other hand, had a much higher
binding to both types of lipid micelles (from 1.1 ± 0.3 to 3.0 ± 1.3
l.mol *). This discrepancy may have been caused by the ability of the 
hydroxylated compounds to orientate themselves in a specific way in the 
micelle membranes such that the hydroxylated end was on the outside 
interacting with the solvent. Benzo(a)pyrene would only tend to associate 
with the internal parts of the micelle membranes. 9,10-Dihydrodiol and 
1(3),9,10-trihydroxy-9,10-dihydrobenzo(a)pyrene were different from the 
other benzo(a)pyrene metabolites investigated, their affinities being 
very similar to that of benzo(a)pyrene (0.05 ± 0.3 to 0.3 ± 0.14 l.mol *) 
for the two types of micelles. In this case, it would appear that the 
orientation of the 9,10-dihydroxy groups does not allow any degree of 
specificity over and above that incurred with the parent hydrocarbon.
Ligandin and protein A are in greater abundance in rat hepatocytes
“8
than in any other cell, at concentrations up to3 x 10 moles/gram (1-2 
mg/gram liver (Ketterer et al, 1975)). Total phospholipid is however 
approximately 30 mg/gram liver or 3.8 x 10 5 moles (Davies et al, 1942) 
considerably more than ligandin. If the interaction of the metabolites 
with ligandin, protein A and phospholipid is on an equimolar basis, 
there is considerably more potential for binding to phospholipid than^ 
ligandin or protein A. However, whilst a molar basis of interaction 
with ligandin and protain A is expected, interaction with phospholipid is 
likely to be reduced by the number of pockets available in membranes 
which reduces the number of available sites. Both types of binding may 
be important in hepatocytes and lung and may be contributory to the factors 
involved in the uptake and clearance of berizo(a)pyrene metabolites. The 
ease at which 9, IQ-dihydrodiol exits from rat hepatocytes may be due to the 
low affinity of this dihydrodiolt to membranes and protein A within the
cell.
Ligandin has a two-fold protection for cells agains potentially 
toxic metabolites (Chapter 2, Smith et al, 1977). Firstly, detoxification 
by glutathione conjugation catalysed by its enzymic activity, and secondly 
by its wide binding activity (both covalently and noncovalently) of 
potentially toxic compounds. It is thought that this binding action plays 
a role in the prevention of hepatocarcinogenesis by binding aminoazo-dyes 
andpolycyclic hydrocarbons such as 3-methylcholanthrene in liver. This 
investigation has shown that benzo(a)pyrene and its metabolites are non­
covalently bound by ligandin and protein A in a way that could affect 
their disposition in tissues. It is possible that the weak affinity of 
9,10-dihydrodiol .for lipid bilayers and protein A may contribute to its 
lack of carcinogenicity (Chouroulinkov et al, 1976) by strongly favouring 
its excretion.
The adsorption of different benzo(a)pyrene-metabolites by ligandin and 
protein A has shown some interesting specificities. Useful and interesting 
experimentation could be performed in future to see if an ultimate 
carcinogen of benzo(a)pyrene, 7,8-dihydrodiol-9,10-epoxide, interacts 
covalently with these proteins and by doing so, offers protection to cells. 
If this were so, then a deficiency of these proteins in bronchial 
epithelial cells may be an underlying factor in their susceptibility to 
cigarette smoke induced cancer.
These experiments may have given an answer to an interesting difference 
in the disposition of very similar benzo(a)pyrene metabolites for which 
no other explanation is satisfactory. In future, similar investigations 
may throw light upon mechanism of tissue specificity of various carcinogens. 
Studies on the Covalent Binding of Benzo(a)pyrene to Tissue Macromolecules
Covalent binding to tissue macromolecules is presumably the way in
which carcinogenic polycyclic hydrocarbons exert their toxicity.
It has been assumed by many to be directed towards the nucleic acids 
(DNA) involved in replication of the genome but to date, a definitive 
experiment to prove this has yet to be performed. It is not certain 
if the metabolites involved in the binding of benzo(a)pyrene to nucleic 
acids are the same as those involved in binding to protein. Since 
administration of different, though related, hydrocarbons, can result 
in more than one toxic reaction believed to be mediated by different 
metabolites, there appears to be some degree of specificity. For example, 
the adrenal necrotic action and carcinogenicity of 7,12-dimethylbenz(a) 
anthracene may be mediated by different metabolites (Boyland et al,
1965; Moschel.et al, 1977). However, although it is possible to argue 
that active metabolites may have preferences for particular types of macro­
molecules (Hulbert, 1975), it is inconceivable to argue that reaction 
will be confined to either nucleic acids or proteins. A measure of total 
covalent binding in a particular tissue is therfore of value in ascertaining 
the relative toxicity of a compound, albeit not as sophisticated as measuring 
DNA or protein binding. The experiments described herein are of two types, 
a measure of the total covalent binding for the reason described and 
secondly, a qualitative assessment of the DNA-bound metabolite.
Investigations of the Covalent Binding of [^^J-Benzo(a)pyrene and [^vj- 
benzo(a)pyrene metabolites during short-term organ culture of hamster lung:
Total covalent binding was determined in 180-220 mg hamster lung 
portions remaining after short-term organ culture, using the sequential 
extraction method of Siekovitz (1952).
Lung samples were homogenized in 0.9% saline (approximately 3 mis) 
and an equal vol of 1M perchloric acid added. The precipitated protein 
was sedimented by centrifugation and washed with 2 x 3  mis 0.5M perchloric
acid, 2 x 5  mis 96% ethanol, 2 x 5  mis diethyl ether-ethanol-chloroform 
(2:2:1) and 4 x 5  mis acetone. The final acetone wash was checked for 
the presence of radioactivity but in all cases, only background counts 
were obtained. As the lung samples were primarily used for metabolism 
studies, the spceific activity of the /"'“’h /-benzo (a) pyrene compounds was 
relatively low, which resulted in low levels of covalent binding. This 
factor may be responsible for some of the scatter of the results. The 
results are shown in Table 7 .
A difference is shown in the covalent binding of individual /V-
benzo(a)pyrene metabolites to hamster lung macromolecules. Because of
the low specific activity, and the inherent low metabolism of lung
tissue, no claim can be made to the absolute accuracy of these determinations.
Nevertheless, the results are in agreement with what is expected from the
known facts of these metabolites. Determinations of covalent binding were
made using tissue cultured with each benzo(a)pyrene compound at 37°C
and 0°C. Cultures at the latter temperature did not metabolise benzo(a)
pyrene compounds and were used as controls. Binding in 0°C cultures was
attributed to background and was subtracted from the values obtained at
37°C to obtain a value for metabolically catalysed binding. The compound
which exhibited the greatest covalent binding when expressed in this
manner was 7,8-dihydrodiol (Table 7 ). The binding of this compound
high ly
was almost double that of the next most„bound metabolite, 9,10-dihydrodiol. 
This compound was fractionally higher in its binding than benzo(a)pyrene, 
suggesting that in this system at least, substantial binding occurs. This 
relatively high-level of 9,10-dihydrodidLbinding may have been because 
the'hamster lung possesses low levels of enzymic activity necessary for 
complete detoxification of 9,10-dihydrodiol to conjugated products (Chapter
V
Table 7
Covalent binding of Benzo(a)pyrene and its metabolites during short-
term organ cultures of hamster lung
Compound Covalent Binding (p mol/lung)
37°C 0°C Mean diffc
Benzo(a)pyrene 1200 ± 123 66,126 1104
7,8-Dihydrodiol 2796 ± 179 418,820 2177
9,10-Dihydrodio1 2018. ± 286 534,810 1346
3-Hydroxybenzo(a)pyrene 1573, 1952 814 849
4,5-Dihydrodiol 1303, 1606 1073 382
Covalent binding was determined after 16 hours organ culture at 37°C 
or 0°C with 1 yM concentrations of the respective /~^u/-benzo(a)pyrene 
compound. Results are expressed as the mean and SEM of 4 determinations 
or as individual results. The mean difference is the difference between 
the binding at 37°C and 0°C.
Covalent binding of benzo(a)pyrene compounds was determined in 
portions of hamster lung (200 ± 20 mg) by an exhaustive extraction method 
(Seikovitz, 1952) after short-term organ culture (16 h). Determinations 
were made after incubations at 37°C and 0°C. Results are expressed as 
the mean and SEM of 4 determinations or as individual results. The • 
mean difference is that difference between binding at 37°C and 0°C.
5). This could have resulted in the production of significant amounts 
of 9,10 dihydrodiol-7,8-epoxide, which was responsible for the observed 
binding. A similar determination made on tissues remaining after rat 
lung culture gave values of 2340 and 1354 p moles/gram lung for 7,8- 
dihydrodiol and 9,10-dihydrodiol respectively, suggesting that the high 
binding of 9,10-dihydrodiol is not specific to hamster lung. 9,10- 
dihydrodioL-7^8-epoxide has been found to be a potent bacterial mutagen 
but is not active in transforming mammalian cells (Malavielle et al, 1977; 
Marquardt et al, 1977). Much information suggests that 9,10-dihydrodiol is 
not a proximate carcinogen and does not therefore give rise to significant 
amounts of DNA products. Therefore, it is likely that the observed 9,10- 
dihydrodiol binding was principally with proteins, perhaps of the ligandin 
type. However, if this excess of 9,10-dihydrodiol covalent binding is 
only associated with respiratory tissue metabolism, it could be another 
factor in the tissue's susceptibility. The other metabolites investigated 
4,5-dihydrodiol and 3-hydroxybenzo(a)pyrene, bound less than the parent 
hydrocarbon.
The exact nature of the covalently bound products is unknown, but a 
proportion at least is likely to be similar to that found in other tissues. 
Thus, some of the 7,8-dihydrodiol was in all likelihood metabolised and 
bound to guanine adducts (Chapter 2). Although a further investigation 
of 7,8-dihydrodiol binding is necessary to reveal if the high covalent 
binding was due to a specific.nucleic acid directed attack or a more 
general attack to all macromolecules, it is likely that a large proportion 
of the observed binding was to protein. It is unfortunate that benzo(a) 
pyrene protein ligands have not been well characterized since this binding 
could well be important. Recent investigations of protein binding by
other carcinogens have shown diversity in the types of protein attached 
in susceptible tissues. For example 3-methylcholanthrene is bound to 
at least 5 separate proteins in mouse mammary gland (Dickens and Sorof,
1977) and aflatoxin to at least eight proteins in liver cytosol 
(Maini'gi and Sorof, 1977) . Since the mechanism of chemical carcinogenesis 
is not understood, it seems unwise to ignore this protein involvement 
which may yet provide a key to carcinogenesis.
An Investigation of the Nature of Benzo(a)pyrene-DNA adducts formed during 
Isolated Rat Lung Perfusions
A considerable volume of evidence has now accumulated to suggest 
that nucleophilic attack of metabolically formed 7,8-dihydrodiol-9,10- 
epoxide causes most of the benzo(a)pyrene-DNA binding observed in intact 
cells and tissues. One or both of the two possible isomers of this 
compound 7a,88 -dihydroxy-9a, ioa -epoxy-7,8,9,10 tetrahydrobenzo(a) 
pyrene (syn) and 7a,8B-dihydroxy-98, 108-epoxy-7,8,9,10-tetrahydrobenzo(a) 
pyrene (anti) have been detected via their d-guanosine adducts in the DNA of 
human and bovine bronchus, mouse skin and various cell cultures (Chapter 2). 
Rodent lung has been shown in these investigations (Chapters 4 and 5) to 
metabolise benzo(a)pyrene similarly to human lung (unpublished observations) 
and therefore, because of this and its susceptibility to benzo(a)pyrene 
induced lung tumours, is a useful model system. Thus, the covalently bound 
benzo(a)pyrene-DNA adducts were of great interest in these tissues. Rat 
lung perfusions were chosen for this study because of their uniqueness 
in offering a metabolising system which is completely intact yet 
isolated. Furthermore, in at least two cases, those of imipramine
and chlorocyclizine, it has been shown that isolated perfused lungs 
metabolised differently from lung microsomal preparations. Thus, it was
considered that covalent binding of benzo(a)pyrene in isolated lung 
perfusions would reflect the pattern found in the lungs of human smokers.
Lungs from control of 3-me.thylcholanthrene pretreated (20 mg/Kg) 
male rats weighing 175-230 g were perfused with Krebs-Ringer bicarbonate 
containing 4% bovine serum albumin (w/v), 10 mm glucose essentially as 
described in Chapter 3. After 5 min equilibriation, 0.5-0.7 mCi of 
/~^H/-benzo(a)pyrene was introduced into the perfusion. It had been
benzo(a)pyrene via the trachea and it was therefore introduced via the . 
medium. Lungs were perfused for 45-55 min with 40 mis of recycled medium. 
Perfusion appeared to proceed well until after about 45 min when fluid 
in the lungs accumulated rapidly and ventilation ceased. At the termination 
of the experiment as judged by the visual appearance of the lungs, the 
lungs were disconnected from the apparatus and carefully homogenised in 
10 or 20 mis of sodium p-aminosalicylate. Samples were taken of the 
homogenate to ensure that adequate /~^H/-benzo(a)pyrene had perfused 
into the tissue before proceeding with the extraction of lung DNA, according 
to the method of Diamond et al, 1967.
One tenth of a volume of 10% sodium dodecyl sulphate was added to the 
homogenate which was then extracted with an equal volume of phenol :m*-cresol 
:8-hydroxyquinoline:water (500:70:0.5:55) for approximately 30 minutes.
The mixture was separated into two phases by centrifugation (10 min
9,000 g, 4°C), the top layer carefully removed, and DNA precipitated by 
the addition of equal volume of cold ethoxyethanol. This was then 
redissolved in 0.0015M Na phosphate, 0.15M NaCl buffer, pH 7.0 and 
subjected to 15-30 min incubation with ribonuclease (Worthington 
Biochemicals, 50 pg/ml). DNA was then re-extracted with phenol mix and
hoped, but proved technically impossible to administer
reprecipitated-withethoxyethanol as previously described. Carbohydrate 
was removed from the DNA by dissolving the precipitate into 1.25M 
potassium phosphate and extracting with an equal volume of methoxyethanol. 
Finally, pure DNA was precipitated from the upper phase by the addition of 
I vol 1% cetyl trimethylammonium bromide. The precipitate was then 
washed repeatedly, twice with 2% sodium acetate in 70% ethanol, 70% 
ethanol, 96% ethanol, ethanol:diethyl ether 3:1 and diethyl ether before 
drying under a stream of nitrogen. The radioactivity associated with 
the DNA was estimated by liquid scintillation counting of soluene 350 
digested samples.
The lung DNA from control rat lung perfusions was found to be 
associated with only a small amount of radioactivity. DNA from lung 
perfusions of male rats treated for 3 days prior to sacrifice with 
3-methylcholanthrene (20 mg/kg) was associated with much larger amounts 
of radioactivity (10,000-50,000 dpm per lung). The nature of covalently 
bound radioactivity was investigated in collaboration with Dr. H King and Dr. 
P Brookes of the Institute of Cancer Research, Pollards Wood, Buckingham­
shire.
Samples of DNA from control and 3-methylcholanthrene pretreated rat 
lung perfusions were progressively hydrolysed to nucleosides by sequential 
enzymic digestion essentially as described by Baird and Brookes, 1973.
The DNA (0.5 - 4 mg) in 4 mis 0.1M Tris-HCl buffer (pH 7.5) was hydrolysed 
for 6-16 h (37°C) with 0.5 mg DNA-ase (ex beef pancreas, Boehringer Corp, 
(London) Ltd, 100 units/ml).• The mixture was further hydrolysed by 
incubation for 24-48 h (37°C) with snake venom phosphodiesterase (ex 
crotalus admenanteous, Boehringer Corp. (London) Ltd, 200 yl in 1 ml 
of 0,5M Tris-HCl buffer, pH 9.0). Hydrolysis to nucleosides was completed
by incubation for a further 48 h with 50 yl alkaline phosphatase 
(ex E. Coli, Sigma Chemical Co, type III). A clear preparation, suitable 
for hplc analysis was ontained after removal of protein and unhydrolysed 
DNA by passage through a short (approximately 10 cm) sephadex.LH20 
chromatography column. Hplc was carried out as previously described by 
King et al, 1977 using a Waters Associates apparatus fitted with a 250 
x 4.5 mm Partisil column and a 100 x 4.6 mm Partisil pre-rcolumn,eluted 
with a 30-100% linear methanol-water gradient (2 mis per min).
The results from the first preliminary run of these experiments 
differed from those of slightly modified, subsequent experiments. The first 
experiments using DNA from control rats contained such low levels of 
radioactivity that detection of bound benzo(a)pyrene adducts proved 
impossible. This may, in part, have been due to the enzymic hydrolysis 
because the preliminary results using DNA from 3-methylcholanthrene pre­
treated rats showed there to be four peaks of radioactivity. The largest 
of these peaks of radioactivity was thought to be associated with 
unhydrolysed DNA, the second with 7,8-dihydrodiol-9,10-epoxide-guanosine 
adduct and the remaining two, both small, were unidentified. However, 
repeat of this hydrolysis and analysis, with further samples from 3-methyl­
cholanthrene pretreated rats, showed only single peaks of radioactivity, 
which was identified as 7,8-dihydrodiol-9,10-epoxide-D-guanosine (anti- 
diol-epoxide adduct) (Figure 37). Each individual analysis showed there 
to be peaks of radioactivity of approximately 100-300 cpm (40% efficiency) 
associated with the diol-epoxide adduct (Figure 37). Since this is almost 
at the limit of resolution of the detection system, smaller amounts of 
adducts due to other benzo(a)pyrene metabolites cannot be precluded.
Repeat experiments with control rats were less satisfactory due to
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FIGURE 37. H.p.l.c. analysis of benzo(a)pyrene-DNA products after exhaustive 
enzymic hydrolysis with DNA-ase, snake venom, phosphodiesterase and alkaline 
phosphatase. DNA products were prepared by phenol extraction after incubation of 
[  ^ H7-benzo(a)pyrene with mouse embryo cells or perfusion through the lungs of 
control or induced (3-methylcholanthrene pretreated 20 mg/kg) . rats. H.p.l.c. 
was performed on a Water Associated 250 x 4.6 mm Partisil column with a 30-100% 
methanol-water gradient.
low levels of bound radioactivity. In this case, it was necessary to 
pool DNA from two lungs to obtain a single peak of radioactivity (100 
cpm) which did not precisely cochromatograph with the diol-epoxide adduct.
It was concluded from these results that’ the diol-epoxide' adducts 
produced in the lungs of the 3-methylcholanthrene induced rats is similar 
to that known to occur in many other tissues. The results obtained with 
control lungs is less satisfactory since a positive identification was 
not achieved, however, it seems most likely that the observed peak of 
radioactivity was associated with diol-epoxide adduct. The result, however, 
is important as induction of lung mixed function oxygenase by 3-methylchol- 
anthlrene has been shown to readily induce induction of diol-epoxide adducts. 
Smoking has been shown to readily induce DNA binding during rat lung 
perfusion (Cohen et al, 1977b) and it is probable that this is due to 
increased binding of the diol-epoxide adduct. This is of high significance 
when one considers human smokers which, in all likelihood, maintain induced 
mixed function oxidase in respiratory tissues over a long period of time.
Recent investigations .using microsomes from 3-methylcholanthrene pre­
treated rats have shown there to be a high degree of stereospecificity 
in benzo(a)pyrene metabolism (Yang et al, 1977e;Thakker et al, 1977) which 
is, however, less marked with non-induced microsomes (Thakker et al, 1977). 
It is not probable that the 3-methylcholanthrene induced rat lung 
metabolises benzo(a)pyrene more stereospecifically than its non-induced 
counterpart. It is possible that the peak of radioactivity from the control 
lungs did not precisely cochromatograph because it was associated with syn 
diol-epoxide adduct (7a 83-dihydrodoxy-9a, 10a-epoxy-7,8,9,10-tetrahydro- 
benzo(a)pyrene) rather than the anti isomer.
Experiments to confirm and further these results would have been 
desirable but were not performed due to insufficient time.
Overall, this experiment has indicated that the binding of 
benzo(a)pyrene to the DNA of rat lung is similar to that observed with 
other species and tissues. Perhaps surprisingly is the rapidity with 
which the formation of adducts occurs, in this case over 45-55 minute 
periods. The amount of benzo(a)pyrene in each of these experiments, 
approximately 6 yg, is equivalent to approximately 200 cigarettes. If 
the disposition of benzo(a)pyrene is similar on its inhalation into 
human lung as observed in these isolated perfused rat lungs, it is not 
difficult to envisage the formation of diol-epoxide adducts in the lungs 
of cigarette smokers continually exposed to the inducing effects of 
smoke and its constituent, benzo(a)pyrene.
Summary
Rapid developments in polycyclic hydrocarbon carcinogenesis have 
taken place over the past decade. Metabolism studies have shown that 
many tissues, including many thought to be metabolically inert, do indeed 
convert polycyclic hydrocarbons to many metabolites. Carcinogenesis in 
respiratory and other tissues has been explained by the formation of 
diol-epoxides which are known to interact with the genetic material.
However all the many advances have not elucidated a mechanism of cancer.
Many points remain to be investigated before this complex process will 
be understood.
Respiratory tissues, because of their susceptibility to polycyclic 
hydrocarbons, will probably feature heavily in future research. Recent 
improvements in methodology will enable the biochemical pharmacology and 
the mutagenic and carcinogenic processes in these tissues to be investigated 
with greater ease. Hsu et al (1978) have recently extended the use of 
bronchial explant cultures by. using them as a source of metabolism in a 
mammalian cell mutation system. This simple screening test is most 
appropriate for the analysis of inhaled materials and will undoubtedly 
be of value to those concerned with screening the environment (Mon.tesa.no 
et al, 1976). The use of tracheal microsomes (Mass and Kaufman, 1978) may 
also find value in this field.
Another welcome technique is that of Nettesheim and coworkers (Pal 
et al, 1978) who have recently developed a novel cancer test by using 
hamster tracheae grafted into syngeneic hosts; this enables the study of 
the tumorigenic process under conditions of continuous and regulated 
carcinogen exposure. Benzo(a)pyrene, 7,12-dimethylbenzo(a)anthracene, 
phenol esters and N-nitroso-N-methyl urea have all been shown to.have
carcinogenic effects in such a system (Pal et al, 1978; Yarita et al,
1978). Nettesheim’s technique may well supercede previous methods 
because it allows the development of large tumours which are unlikely 
to kill the host directly, a feature of previous methods. This will be 
a great advantage in the study of therapeutic agents.
These types of methods are likely to provide, in themselves, 
information as' to the mechanism of carcinogenesis and as long as cigarette 
smoking is a popular habit, their usage is assured. However, detailed 
molecular studies will be required to completely elucidate the carcinogenic 
mechanisms. Very little is known of the interrelationships between DNA 
damage, mutagenicity and carcinogenicity. Of these, the most investigated 
relationship is that between mutagenicity and DNA damage, and, for 
example, it is known that certain compounds can cause certain types of 
mutations (Ames et al, 1972). If we are ever to understand carcinogenesis 
we must have much more information along these lines and relate these 
specific mutations in some way to carcinogenesis. There are many further 
questions to be asked:- Are specific mutations required for carcinogenesis 
Are certain genes involved? Is there a certain sequence of mutations or 
damage that must take place? What is the role of viruses? All these 
questions must be considered with the known factors of chemical carcino­
genesis. Protective mechanisms such as DNA repair and immunosurveillance 
must also be considered. Investigations will be long and varied but are 
already well under way with benzo(a)pyrene diol-epoxides. Their effects 
on DNA repair, DNA template activity and viruses have already been 
published (Heflich et al, 1977; Hsu et al, 1977; Leffler et al, 1977; 
Shooter et al, 1977).
Events in chemical carcinogenesis will probably as always follow
those of biology. Great promise must be held for future research 
into the genome and the powerful technique of recombinant DNA will 
not only be of ultimate importance to the biochemical geneticist but 
also to the oncologist.
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Appendix
A Summary of Spectrofluoresoence Data
APPENDIX
Fluorescence excitation and emission spectra of benzo(a)pyrene and benzo(a) 
pyrene metabolites. Spectra were recorded in 96% ethanol solutions using 
a Perkin-Elmer LPF-3 spectrofluorimeter with 5 nm slit widths.
Wavelengths are in nm.
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